The role of CFTR in normal human lung microvascular endothelial cells by Khalaf, Maha Mohsin
 The role of CFTR in normal human lung 
microvascular endothelial cells  
 
By  
Maha Mohsin Khalaf 
 School of Pharmacy and Biomedical Sciences 
University of Portsmouth 
White Swan Road 
Portsmouth, United Kingdom 
 
February 2019 
The thesis is submitted in partial fulfilment of the requirement for the award of the 
degree of Doctor of Philosophy of the University of Portsmouth 
 
I 
 
Abstract:  
Cystic fibrosis is the most common hereditary lethal disease in the Western world, 
resulting from defects in the expression or function of cystic fibrosis transmembrane 
conductance regulator (CFTR), a chloride ion channel that controls the movement of salt 
and water through epithelial cells in multiple organs including airway, intestine and 
genitourinary system, and has anti-inflammatory and antioxidant properties. 
The hypothesis tested in this research is that CFTR expressed in normal human lung 
microvascular endothelial cells protects the cells from inflammatory changes and 
oxidative stress. 
A low level of stable CFTR, which was down-regulated by CFTR activity was found. 
Pharmacological inhibition of CFTR in endothelial cells results in a rapid increase in 
production of reactive oxygen species and a decrease in the abundance of the 
transcriptional factor Nrf2, both of which are characteristic of oxidative stress. An 
increase in production of vascular endothelial growth factor was a consequence of this 
oxidative stress. Furthermore, CFTR inhibition in endothelial cells results in an increase in 
IL-8 production through activation of the activator protein-1 pathway, which is mediated 
through activation of the epidermal growth factor receptor. Also inhibition of CFTR in 
neutrophils increased the expression of neutrophil elastase activity on the cells surface in 
response to opsonized zymosan, indicating a mechanism for the observation that 
neutrophil surface elastase activity correlates with decline in lung function in patients 
with CF. 
Exposing endothelial cells to shear stress significantly enhanced the production of nitric 
oxide and reduced endothelin-1 release from vascular endothelia cells, and the responses 
were not influenced by CFTR function. In addition, CFTR inhibition increased F-actin 
polymerisation and influenced the distribution of F-actin, preventing the alignment of 
cells with the direction of shear flow.  
Treatment of endothelial cells with antioxidant decreases both oxidative and 
inflammatory changes after CFTR inhibition by reducing reactive oxygen species 
production and reduced IL-8 production. The data indicates that endothelial CFTR may be 
a target for oral systemic potentiators and correctors that are in development for CF. 
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Chapter One 
General Introduction 
 
The aim of this chapter is to highlight the important role that human lung microvascular 
endothelial cells (HLMVECs) play in the regulation of normal vascular function in the 
human body, and to describe disturbances in the physiology of the endothelium such as 
those due to inflammation or oxidative stress.  
1.1 Human Lung Microvascular Endothelial cells: 
HLMVECs are a highly specialized multifunctional monolayer of cells that line the 
microvascular blood vessels in the lung. They act as a selective physical barrier between 
the blood and the underlying cells, allowing the movement of chemicals, nutrient, and 
inflammatory cells. HLMVECs are also responsible for maintaining the physiologically 
normal environment in the blood vessels.  
 
Figure 1. 1 Endothelial cell functions: 
Regulatory factors secreted by endothelial cells (Sumpio et al., 2002). 
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They control vascular tone, regulate primary haemostasis and participate in the early 
response to inflammation, as well as influencing the growth and differentiation of cells in 
the blood vessels, as a source of multiple factors that work in harmony (Figure 1.1) 
1.1.1 Vascular endothelium role in regulating vascular tone: 
HLMVECs are the main source of numerous vasoactive factors that relax or constrict the 
blood vessels affecting pulmonary blood pressure. The relaxant factors include nitric 
oxide, prostaglandin and endothelium-derived hyperpolarizing factor (EDHF). 
Nitric oxide (NO) is produced by the endothelial cell, nitric oxide synthases NOS III 
(constitutive expression) and NOS II (inducible expression). Nitric oxide is an important 
vasodilator, and numerous vasodilator agonists produce their effect indirectly through 
inducing NO production, for example acetylcholine (Furchgott & Zawadzki, 1980), 
histamine, substance P. NO is not only important in controlling the vascular tone, but it 
also inhibits the adhesion of platelets to the endothelium. Also evidence indicates that 
NO inhibits inflammation through inhibition of P- selectin expression (Armstead et al., 
1997). 
 Prostacyclin (PGI₂) like NO, is a potent vasodilator, and an inhibitor of platelet 
aggregation. The enzyme responsible for the main step of prostacyclin formation is cyclo-
oxygenase (COX), which has two isoforms COX-1 and COX -2, COX 1 is constitutively 
expressed, but COX-2 is inducible. These enzymes, via oxygenase and peroxidase activity 
form prostacyclin H₂ after which the prostacyclin synthase enzyme synthesises 
prostacyclin from its precursor prostaglandin H₂ (Needlemen et al., 1976). Both COX1 and 
prostacyclin synthase enzymes are highly expressed by the vascular endothelial cell, 
which make it rich in PGI₂ (Mitchell et al., 2008). 
NO and PGI₂, the vasodilators substances released from ECs are also antithrombotic and 
decrease the aggregation of platelets via increased intracellular cGMP of the platelets, 
thus decreasing its adhesion to the endothelium (Mitchell et al., 2007). 
Endothelium derived hyperpolarization factor (EDHF) causes the relaxation of blood 
vessels through the activation of potassium channels (K⁺), and the inhibition of calcium 
channels (Ca²⁺) (Jackson, 2000). 
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The endothelins are vasoconstrictor factors: Endothelin is a potent vasoconstrictor, which 
has multiple isoform (ET-1, ET-2, ET-3). The vascular endothelium produces Endothelin-1 
(ET-1).Via preproET-1, which is transformed to pro-ET-1 with the help of signal peptidase, 
then furin transforms it to big-ET-1, and finally big-ET-1 converted to ET-1 by endothelin-
converting enzyme in the endothelial cells. ET-1 signals through two types of receptors, 
endothelin receptor A (ETᴀ) and endothelin receptor B (ETв)(Yanagisawa et al., 1988, Blais 
et al., 2002, Houde et al., 2016). 
1.1.2 Vascular endothelium role in regulating haemostasis: 
HLMVECs, depending on specific triggers, may be antithrombotic or prothrombotic.  
As antithrombotic, HLMVECs maintain the fluidity of blood and inhibit the aggregation of 
platelets on the vascular endothelium (when the ECs are not activated or injured), by the 
presence of heparan sulfate (and related glycosaminoglycans) (Weitz, 2003). These 
chemicals bind and inhibit thrombin which is the serine protease that convert fibrinogen 
into fibrin and forms blood clots, and also activates platelets, and activate vascular 
endothelial cells via proteinase-activated receptor (Bogatcheva et al., 2002). Also 
HLMVECs express thrombomodulin, which binds to thrombin, and reverses it is action 
from procoagulant to anti-coagulant. The thrombin-thrombomodulin complex activates 
anticoagulant protein C, which in turn activates cofactor protein S. Protein S inactivates 
several factors that is important in the coagulation cascade (factor V and VIII). Thrombin-
thrombomodulin complex can also inactivate plasminogen activator inhibitor 1 (PAI-1). 
Furthermore, HLMVECs express tissue factor pathway inhibitor, which also bind and 
inhibit two factors in the coagulation cascade, TF-factor VIIa (TF-FVIIa) and factor Xa (FXa), 
and inhibit the coagulation process (Wood et al., 2014). 
HLMVECs not only inhibit the aggregation of platelets, but synthesis two important 
enzymes, tissue type plasminogen activator (tPA), and urokinase –type plasminogen 
activator (uPA), both of which promote the conversion of  plasminogen to plasmin, and 
lysis of the thrombus. The cells synthesise PAI-1, to limit the activity of tPA and u-PA 
(Loskutoff et al., 1983). 
The vascular endothelium switches to the prothrombotic role when it is perturbed by 
various triggers, chemical or mechanical, which lead to exposure of sub-endothelial layers 
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that express tissue factor (TF) to initiate extrinsic coagulation. TF is also expressed by 
activated endothelial cells. TF binds to factor VII and activate it to form a complex, which 
activates several downstream steps, ending in transformation of prothrombin to 
thrombin (Lopez-Bezerra & Filler, 2003). Thrombin eventually cleaves fibrinogen into 
fibrin and the clot starts to establish. In addition thrombin activates platelets to aggregate 
at the site of the blood vessel insult. This is one of multiple mechanisms that control the 
regulation of coagulation to prevent blood loss (Yau et al., 2015). 
More endothelium-specific functions that appear when the cells are injured or stimulated 
is release of the stored von Willbrand factor (vWF), from Weibel-Palade body. This factor 
is a marker for vascular endothelium, and it is constitutively released by the endothelium 
but in case of stimulation the release of it increases. When the sub-endothelium is 
exposed, vWF has two roles, one is to stimulate platelet aggregation and binding to the 
exposed collagen resulting from blood vessel damage, and the second role is that vWF is a 
stabilizer of coagulation factor (VIII) (Peyvandi et al., 2011). 
Lipid-mediator platelet activating factor (PAF) is synthesised and released by the 
endothelium after stimulation with thrombin or cytokines, and is a potent platelet 
aggregation activating factor (Zimmerman et al., 1990). 
1.1.3 Vascular endothelium role in inflammation: 
The vascular endothelium plays the gate-keeping role and is the first barrier, during 
inflammation. This role necessitates ECs to interact with leukocytes, that will include 
pathological changes in the endothelial cells to allow the leukocyte to marginate, adhere, 
and then migrate across the endothelium to the site of infection. This process of 
leukocyte extravasation consists of three main steps;  
First step: rolling and tethering of leukocyte on the luminal endothelium. This phase is 
mediated by specialised transmembrane selectin molecules. P-selectin is expressed by 
platelets and endothelial cells, E-selectin is expressed by endothelial cells, while L-selectin 
is expressed by leukocytes. Circulating pro inflammatory cytokines, e.g. tumor necrosis 
factor-α (TNF-α) or IL-1 activates ECs to increase synthesis of E-selectin, to start trapping 
the leukocyte by interacting with selectin ligands on leukocyte surface. This rolling and on 
and off attachment of leukocytes to the ECs surface helps to slow down the movement of 
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leukocytes, and promote sensing of the chemokine environment (Muller, 2013). Some 
chemokines produced by ECs following activation, such as IL-8 and it is added to the 
circulating pro-inflammatory pool of cytokines (Krishnaswamy et al., 1999). 
PAF synthesised by ECs as well promotes adhesion of platelets and neutrophils to the 
endothelium (Bussolino et al., 1990). 
The second step includes firm adhesion between leukocyte and the ECs mediated by 
intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecules (VCAM-
1), and their corresponding integrin on the surface of leukocyte. Once the integrins bind 
to their ligands leukocytes are arrested on the surface of the endothelium (Langer & 
Chavakis, 2009). 
In the last step, leukocytes migrate through the ECs to the surrounding tissues 
(extravasation), which is either through the junction between adjacent cells (Figure 1.2) 
the paracellular route used by most leukocytes to migrate to the site of inflammation, or 
the transcellular route through the endothelial cells, and usually few of leukocyte follow 
this pathway. This phase include heterophilic and homophilic adhesion between 
molecules on the surface of the leukocyte and the ECs (Muller, 2013). Platelet-endothelial 
cell adhesion molecule-1 (PECAM-1) was the first molecule to discover to have a major 
role in leukocyte transmigration. PECAM-1 is expressed on leukocyte, platelets and 
endothelial cells. PECAM-1 has different function depending upon cell type that express 
it. For leukocyte and platelets, PECAM-1 is inhibitor receptor and it reduces cellular 
activation responses. For vascular endothelial cells, PECAM-1 play a major role in 
maintaining endothelial cells permeability integrity (Lertkiatmongkol et al., 2016). 
6 
 
 
Figure 1. 2: Neutrophil extravasation through the vascular endothelium: 
(Schmidt et al., 2011). 
 
1.1.4 Vascular endothelium role in regulating angiogenesis: 
Vascular endothelial growth factors (VEGFs) are a group of signalling proteins that 
promote angiogenesis, in which new vasculature is formed from pre-existing blood 
vessels. This process is important for tissue formation and regeneration. But it also 
contributes to the development of tumors and metastasis as well as many other 
pathological changes, mediated primarily through the effect of VEGF on vascular 
endothelial cells stimulating those specific cells to proliferate, migrate, and differentiate.  
VEGFs consist of five main subfamilies, VEGF A, VEGD B, VEGF C, VEGF D, and placenta 
growth factor (PIGF). Within the VEGFA there are four isoforms, VEGFA121, VEGFA165, 
VEGFA189, and VEGFA 205, reflecting the number of amino acids in the protein.  
VEGFs stimulate angiogenesis by binding to their receptors which is of three types, 
VEGFR1, VEGFR2, and VEGFR3, which are receptors tyrosine kinases (RTKs). 
For the vascular endothelium, the main signalling receptor is VEGFR2, and its ligand is 
VEGFA. Binding of the ligand to its receptor trigger angiogenesis by promoting 
endothelium mitogenesis, migration, and tube formation. The process starts when VEGF 
binds to its receptor and increases cellular permeability, leading to DNA synthesis in the 
endothelial cells.  
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VEGFs also have the ability to stimulate nitric oxide production from endothelial cells 
(Reinders et al., 2003, Lahm et al., 2007, Tuder & Yun, 2008, Shibuya, 2011, Voelkel & 
Gomez-Arroyo, 2014). 
1.1.5 Vascular endothelium response to shear stress:  
Shear stress is the force that arises from the normal blood flow in the vasculature. This 
force is measured in dyne units, which is the power required to move one gram of mass 
for one centimetre in one second. The normal values of shear stress depend on whether 
blood vessel is in venous vasculature (1-6 dyne/cm2) or in arterial vasculature system (10-
70 dyne/cm2) (Malek et al., 1999). Usually this force affects the apical surface of the 
endothelium, causing deformation of cells and changes of the cytoskeleton. Vascular 
endothelial cells translate the changes in the fluid movement on the surface to 
intracellular signals, eventually affects the function of these cells. Increase in blood flow 
affects the production of vasoactive mediators such as increase in nitric oxide production 
through increase the expression of eNOS mRNA (Chistiakov et al., 2017), and increase in 
production of prostacyclin (Hanada et al., 2000), and decrease in endothelin-1 production 
(Vossi et al., 2014).  
The effect of shear stress on transcriptional factors is connected to the onset of applying 
shear stress, for example, after a few (1-30) minutes of starting shear stress there is a 
rapid transient translocation of nuclear transcription factor-k NFkB to nuclei (Hay et al., 
2003). Shear stress also activates the phosphorylation of c-jun, and results in an increase 
of nuclear protein binding to the AP-1 binding DNA site (Miyagi et al., 2005), stable 
sustain shear stress then down regulate c-Fos, c-jun activation. 
ICAM-1, and VECAM-1 expression on the ECs surface are also influenced by shear stress, 
ICAM-1 is upregulated, while VCAM-1 is down regulated (Li et al., 2005). 
The effect of shear stress on ECs intracellular signalling begins a few seconds after the 
shear stress is applied, and lasts for hours, maybe days, before ECs starts to adapt.  
The movement of fluid is sensed by vascular endothelial growth factor receptor (VEGFR2), 
integrin (α and β) and its interaction with focal adhesion kinase (FAK), G protein coupled, 
platelets endothelial cell adhesion molecule-1 (PECAM-1), and potassium channels. 
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Activation of α and β integrin is considered one of the primary important steps leading to 
auto phosphorylation of FAK. Recruitment of Scr increases the phosphorylation of FAK 
and phosphorylation of paxillin. Participation of GBR2 adaptor in this step explains the 
following activation of mitogen activated protein kinase (MAPK). In addition, the 
activation of VEGFR2 activates phosphatidyl-inositol kinase (PI3K). Furthermore, shear 
stress has been shown to transiently activate Rho family GTPases and downstream signals 
activate JNK and AP-1 (Li et al., 2005). 
Multiple pathways cross paths with each other, and the outcome changes at the 
transcriptional level, or even on immediate function of the cells, for example NADPH 
oxidase is inhibited directly after the beginning of shear stress resulting in decrease in the 
superoxide free radicals, and other changes will depend on several factor: the onset of 
shear stress, time, rate of the blood flow.  
1.1.6 Vascular endothelium and oxidative stress: 
The vascular endothelium is an organ sensitive to oxidative stress. Oxidative stress occurs 
when the balance between the reactive oxygen species and reactive nitrogen species 
become more than the capacity of anti-oxidative mechanisms, for example during 
inflammation or bacterial infection.  The anti-oxidative mechanisms of the vascular 
endothelium include several antioxidant molecules and enzymes that work as scavengers 
for the free radicals, e.g. superoxide dismutase (SOD I, SOD II, SOD III), catalase, reduced 
glutathione, thioredoxins, and peroxiredoxins. All of the previously mentioned 
antioxidants control the ROS produced by the vascular endothelium as part of metabolic 
by products of normal cellular function. In the vascular endothelium most of the ROS 
comes from Nicotinamide adenine dinucleotide phosphate-oxidase (NADPH-oxidase), 
especially from NOX4. In addition to other sources of ROS such as the mitochondrial 
electron transport chain and uncoupled NO synthase.  
Oxidative stress is a feature of all the important diseases that affect the lung tissue, 
chronic obstructive pulmonary diseases, cystic fibrosis, asthma, idiopathic pulmonary 
fibrosis.  
The endothelium is the only source of nitric oxide, which works primarily to relax the 
vascular smooth muscle, NO has several other functions that indirectly help to reduce 
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oxidative stress, such as inhibition of platelet aggregation and neutrophil adhesion. NO 
has a direct antioxidative effect on the vascular endothelium via a chain breaking 
antioxidant effect to prevent the oxidation of membrane lipid (Hummel et al., 2006). 
1.2 Role of CFTR in cystic fibrosis: 
The lung is the main organ affected in cystic fibrosis, a fatal genetic disorder that affects 
the respiratory, digestive, and the reproductive system. However, the high mortality rate 
results from respiratory failure.  
Cystic fibrosis is a multi-organ disease autosomal recessive genetic disorder, which affect 
mainly the white Caucasian population, around 10,400 registered patients in the UK (CF 
trust). That is 1 in every 2500 child is born in the UK with cystic fibrosis, and one out 25 
people in the UK carry one copy of the mutated CFTR gene. 
Cystic fibrosis results from a defect in cystic fibrosis transmembrane conductance 
regulator (CFTR) gene on chromosome 7 that encodes the 1480 amino acid CFTR protein. 
Newly synthesised CFTR protein is cotranslationally inserted in the endoplasmic reticulum 
membrane where it is N-linked to glycosyl groups, which increase the molecular weight of 
unglycosylated protein from 130 kDa to 150 kDa. Chaperone molecules such as calnexin 
and Hsp70 help the CFTR protein to fold in the correct way and become protease 
resistant. At this stage the CFTR moves to the Golgi-stacks, where it is further glycosylated 
and the molecular weight of the mature protein increases to 170 kDa (Vankeerberghen et 
al., 2002),( Farinha et al., 2013), prior to insertion in the plasma membrane. 
CFTR is a cAMP dependent Clˉ channel present on the apical membrane of epithelial cells, 
in the respiratory system, gastrointestinal tract, pancreas and sweat glands. This protein 
belongs to the family of ATP-binding cassette (ABC) transporters, with one structural 
difference being the presence of the regulatory hydrophilic domain (Cant et al., 2014). 
CFTR consists of two membrane spanning domains (MSD1, MSD2), and two nucleotide 
binding domains (NBD1, NBD2), and a central regulatory (R) domain (Sheppard & Welsh, 
1999). R domain phosphorylation is the first step in the opening of the CFTR channel 
modulated by cAMP-dependent protein kinase A. After the partial phosphorylation of the 
R domain, ATP (adenosine triphosphate) binds to NBD1 and allows a partial opening of 
the channel, but when the R domain is fully phosphorylated, ATP binds to the second 
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NBD2, resulting in long opening of the channel with anion, usually Cl⁻, conductance, 
although HCO₃⁻ may also be conducted. After the hydrolysis of ATP into ADP (adenosine 
diphosphate) and inorganic phosphate at NBDs the channel closes (Vankeerberghen et 
al., 2002). 
 
Figure 1. 3: The structure and functional domains of CFTR. 
(Oxford University Gene Medicine, 2012) 
 
CFTR also regulates the movement of Na⁺ ions through the inhibitory effect of CFTR 
activity on the epithelial sodium channels (ENaC) and water uptake. Subsequently CFTR 
regulates the viscosity of the mucous lining epithelia in various organs, but especially the 
airway.  
1.2.1 The irregularity in CFTR protein expression and function in CF  
There are more than 2000 different mutations in the CFTR gene that can cause the 
disease (Cystic fibrosis mutation database). These mutations have been divided into 6 
major classes; Class I is a defect in the translation of the protein from mRNA by stop 
codons, class II is a misfolded protein trafficking defect, class III and IV are defects in the 
conductance of the CFTR channel, class V is a small number of expressed CFTR channels 
and finally VI refers to the short life time of CFTR (Quintana-Gallego et al., 2014). 
However more than 70% of CF patients express the ∆F508 mutation, a deletion in 
phenylalanine at amino acid position 508, that belongs to class II (Collins, 1992)(Welsh & 
Smith, 1993). The symptoms are gastrointestinal and respiratory symptoms, such as 
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chronic respiratory infections especially with pseudomonas aeruginosa, male infertility 
and a high mortality rate due to respiratory failure.  
In the CF lung, pathological changes include mucus obstruction of the large airways, 
destruction of the tissue matrix, and massive accumulation of activated neutrophils. 
Neutrophilic inflammation is a consequence of over-expression of IL-8 by airway 
epithelium, which has been shown to be a direct consequence of dysfunctional epithelial 
CFTR (Perez et al., 2006). Dysfunctional CFTR is responsible for excessive uptake of water 
across the bronchial epithelium, and the subsequent dehydration of airway secretions.  
Reduced mucociliary clearance results in repeated cycles of bacterial infection, further 
neutrophil inflammation, and accumulation of high levels of neutrophil elastase activity 
which stimulates further mucus secretion and damages extracellular matrix proteins, 
including collagen and elastin, leading to bronchiectasis, respiratory failure and death 
(Cantin et al., 2015). 
In addition to these inflammatory changes, oxidative stress is a further characteristic of CF 
airways, with excessive amount of reactive oxygen and nitrogen species that contributes 
to the pathological changes in the airways. As a consequence antioxidant 
supplementation showed an improvement in the lung function (Wood et al., 2003).      
This oxidative stress occurs after the antioxidant defence mechanism of the airway is 
overwhelmed by the oxidants from respiration of inflammatory cells neutrophils and 
macrophages, and the structural cells such as epithelial and endothelial cells (Rab et al., 
2013). 
1.2.2 Cystic fibrosis therapies 
Current therapeutic options are limited in CF. Antibiotics are given systemically, by 
inhalation, or intravenously, to control infection in the respiratory system. Nebulized 
Pulmozyme (DNase) and hypertonic saline are mucolytics that aid mucus clearance.  CFTR 
correctors, correctors and potentiators are currently in development (Rowe & Verkman, 
2013) (Elborn, 2012), but till now these new drugs, such as Ivacaftor, can only treat 4-5% 
of CF patients , because it only corrects the G551D mutation (Yu et al., 2012). 
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1.2.3 Hypothesis, aims and objectives: 
The hypothesis of this study is that CFTR is expressed in normal human lung microvascular 
vascular endothelial cells and has an important anti-inflammatory role in protecting these 
cells from oxidative stress. 
In view of the important role that the microvascular endothelial cells play, and the 
primary evidence that cystic fibrosis patients have dysfunctional vascular endothelium 
(Poore et al., 2013), with not a lot of research done in this area, it was decided to 
investigate the role of these cells in pulmonary dysfunction especially in cystic fibrosis. 
Most of the research in CF to date has been focused on the role of CFTR in the epithelium, 
in which CFTR regulates the movement of ions and thus controls the water movement 
and hydration of mucus. However, endothelial cells regulate another side of the disease, 
which is the trafficking of the neutrophils from the circulation into lung tissue. Therefore 
pathophysiological changes due to defective CFTR in HLMVECs are hypothesised to 
contribute to the severity of lung disease in CF. 
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Chapter Two 
Materials and Methods 
 
2.1 Human Lung Microvascular Endothelial cells:  
Human lung microvascular endothelial cells (HLMVEC) were used in this study from 
passage 3-9. Cells were purchased from Lonza (catalogue number CC-2527). Table 2.1 
contains information of endothelial cells donors provided by the supplier. Cells were 
grown in full growth medium (FGM) Lonza EGM-2 MV (Lonza-CC3202), which consists of 
basal medium Lonza CC-3156 and supplement EGM -2 MV (CC-4147). Supplements 
consist of (final concentration) 5% (v/v) FBS, 0.4% (v/v) hydrocortisone, 4% (v/v) human 
fibroblast growth factor (hFGF-B), 1% (v/v) vascular endothelial growth factor (VEGF), 1% 
(v/v) insulin-like growth factor (Rᶟ-IGF-1), 1% (v/v) ascorbic acid, 1% (v/v) human 
epidermal growth factor (hEGF), 1% (v/v) gentamycin and amphotericin B (GA-1000). 
Table 2. 1 Endothelial cells donors’ information: 
Data from Lonza were supplied with each batch of HLMVECs. This data describes the 
donor age, sex, smoking status and race, plus information about endothelial cell culturing.  
Donor 
Batch 
number  
Age Sex Smoke Race Seeding 
efficiency 
% 
Viability 
% 
Total 
cell 
count  
366560 6 Y Male No Black 35 % 75 % 772000 
408029 57 Y Female No Caucasian  42 % 83 % 1035000 
485964 38 Y Male No Caucasian 84 % 94 % 1095000 
489936 2 Y Female No Black  49 % 93 % 802500 
531583 44 Y Male  No Caucasian  22 % 91 % 699000 
547317 57 Y Male No Hispanic 45 % 95 % 913000 
580578 57 Y Male  No Hispanic 70 % 90 % 745500 
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2.1.1 Seeding HLMVECs: 
HLMVEC were stored in liquid nitrogen. Twenty minutes before starting seeding the cells 
10 ml of FGM were added to the flasks and kept in the incubator to reach (370 C) and pH 
(7.4). The new vial of cells was thawed in a water bath at 37°C for 1- 2 minute, then 
seeded in the density of 5X10ᶟ cells/cm² in 75 cm² flasks (Fisher Brand), FGM was changed 
after 24 hour following cell adhesion, and every 48 hours after that. Cells were 
maintained to 90% confluence in incubator with 37 °C and CO₂ 5%.  
2.1.2 Passaging HLMVECs: 
After removing the medium, the confluent cells in 75 cm² flasks were washed with 5 ml of 
warm 1X PBS (-Ca/Mg) (10X DPBS Gibco) twice, just to make sure to remove all excess 
medium that contains serum which deactivates trypsin. Then 5 ml of 1X trypsin-EDTA 
(Sigma) prepared in PBS (-Ca/Mg) were added to each flask and incubated for 2-3 
minutes. Meanwhile the flask was tapped against the hand palm to make sure all the cells 
were detached. During this step the cells were checked every 30 seconds under the 
microscope. When 90% of the cells were detached then 2ml of FBS (Sigma) were added. 
The cell suspension was transferred to 15 ml Falcon tube and centrifuged 1150 RCF for 5 
minutes. The clear supernatant was removed carefully and the pellet re-suspended gently 
in 1 ml of FGM. To count the cells 10 µl of the suspension was added to 90 µl of trypan 
blue (0.4%, Sigma), re-suspended gently and 10 µl of cell suspension was loaded into a 
haemocytometer chamber. The cells were counted according to the following equation: 
Cell count/ flask = Number of cells after averaging two counts in 25 squared grid (N) X 10 
(dilution factor) X 104 (factor)  
2.1.3 Subculturing HLMVEC: 
To subculture HLMVEC into flasks, plates, and chamber slides, FGM was added 20 
minutes and incubated before seeding the cells. 
The number of cells seeded in each type of cell culture dishes, and the volume to FGM 
depends on the seeding surface area in square centimetre. For example, a 75 cm² flask 
required 375 X 10ᶟcells/ flask, because every cm² should be seeded with 5X 10ᶟ cells. This 
number of cells (375 X 10ᶟcells) was counted from the total number of cells that was 
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obtained from the equation above. From 1 ml of cell suspension the volume was 
calculated that contains 375 X 10ᶟcells, and the cells were then transferred in this volume 
to the new flask containing warm medium.  
Table 2. 2: Number of confluent HLMVECs and volume of FGM required for flasks, 
slides, plates 
Type of seeding   No of cells each  FGM volume in ml  
75 cm2 Flask 2 X 10⁶ cell/flask 10-15 ml 
25 cm2 Flask 65 X 10⁴ cell/flask 4-5 ml 
6 well plate  25 X 104 cell/well 2 ml  
24 well plate 5 X 10⁴ cell/well 0.3 ml 
8 well chamber slide 2 X 10⁴ cell/well 0.25 ml 
96 well plate 8 X 10 ³ cell/well 0.1 ml 
35 mM petri dish 25 X 104 cell /dish 2 ml 
 
2.1.4 Cryopreservation of cells: 
HLMVEC were lifted from 75 cm² flasks using the same steps as in passaging. After 
counting the cells in 1 ml FGM they were centrifuged again and re-suspended in freezing 
medium which consists of : 80% (v/v) FGM, 10% (v/v) FBS, 10% (v/v) DMSO (Sigma). The 
cells were stored as 1X10⁶ cells/ 1 ml of freezing medium/vial. The information recorded 
on the cryovials (Sigma) were cell type, passage number, cells count/ml/vial, the date of 
freezing. These cryovials were kept in -80 in Mr Frosty (ThermoFisher) overnight, then 
transferred to liquid nitrogen the next day. 
2.2 Coating plates and chamber slides with collagen IV: 
Each of the plates (6, 24, 96), and chamber slides (8 well), were coated with collagen IV 
(Sigma) (human placenta collagen) before seeding the cells into it.   
Collagen IV (Sigma) was prepared by dissolving 5 mg in 1 ml of 3% acetic acid for 1 hour at 
room temperature, then diluted to 50 ml in 3% acetic acid to give a final concentration of 
0.1 mg/ml.  
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Collagen IV were poured into plates at volume shown in Table 2.2 below , left there for 2 
hours at room temperature (RT), then the excess were removed and kept in 4°C fridge, to 
be used two more times (total of three times). The plates were left to dry for 1 hour at RT 
(200C). After that the plates were washed with basal medium (RPMI or MEM) that contain 
phenol red, three times, just to ensure all the acid was removed from the plates. 
Following a fourth wash with 70% ethanol to sterilise the plates, they were dried 
completely, and stored in sterile bags in 4°C fridge. 
Table 2. 3: The required volume of collagen IV (0.1 mg/ml) to coat plates.    
Type of plate  Collagen IV and washes volume  
 6 well plate  2 ml /well 
24 well plate  0.5 ml /well 
96 well plate  0.1 ml /well 
8 well camber slide  0.25 ml / chamber  
35 mM petri dish  2 ml 
 
2.3 Processing samples: 
2.3.1 Supernatant:  
After cells were treated, the supernatants were collected, centrifuged 1500 RCF at 4 °C 
for 10 minutes, and then transferred into a new labelled set of tubes, stored in -80 until 
they were analysed. All the steps were carried out on ice.  
2.3.2 Cells: 
2.3.2.1 Processing samples for ELISA: 
If the cells were used for ELISA, they were lysed directly after removing the supernatant, 
with hypo-osmotic lysis buffer that consisted of (20 mM NaCl, 1% Triton -100, and 20 mM 
Tris-base, pH to 7.4), to which was added complete protease inhibitor tablets (Roche), 
and protease inhibitor cocktail stock (Calbiochem), 1 tablet in 10 ml of each. The cells 
were washed with ice cold PBS (-Ca/Mg), then cold lysis buffer was added to the wells, 
the cells were lysed for 10 minutes, then the lysates were transferred to tubes, 
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centrifuged at 5000 RCF for 10 minutes, at 4 °C then finally the samples were transferred 
to a new set of tubes and stored in -80 °C freezer.  
2.3.2.2 Processing samples for Western blot: 
Cells were lysed for Western blot directly with (35 µl/ well for 24 well plate, and 75 µl/ 
well for 6 well plates) of 1 X sample buffer prepared from 2 X reduced sample buffer (15% 
(v/v) glycerol, 100 mM Tris- Base, 4% (w/v) sodium dodecyl sulfate, 200 mM DL-
Dithiothreitol, 0.02% (w/v) bromophenol blue, 4 mM MgCl₂, 0.1% (v/v) benzonase 
nuclease (Sigma), 2X protease inhibitor (Calbiochem), PhosSTOP (Roch). The cells were 
washed twice with ice-cold PBS (-Ca/Mg) while they were placed on ice through the 
whole process, after that the lysis buffer were added to the wells, and the cells were 
incubated with it for 10 minutes, the cells were scraped, transferred into labelled tubes. 
Then 1 µl of 0.25 M EDTA were added to each well of cell lysate to chelate calcium and 
magnesium, and inhibit protease and DNase  activities which depend on these ions as 
cofactors. The samples then were placed in a water bath, the time and the temperature 
depended on the protein. 
2.4 Western blotting: 
2.4.1 Electrophoresis:  
After the gels were prepared (Table 2.4), 35 µl of the cell lysate were loaded into each 
lane, in addition to 5 µl of molecular weight ladder (Sigma) molecular range (8-220 kDa) 
and Bio-Rad molecular range ( 10-250 kDa). Then 1X running buffer (25 mM Tris, 0.192 M 
Glycine, 0.1% SDS) were added to the electrophoresis reservoir, the samples were left to 
run on low voltage (50 V) through the stacking gel, and the voltage was increased to 140V 
through the resolving gel.  
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Table 2. 4: Western blot gels preparation 
 Volume (ml) required for a 
 7.5 % gel 10% gel 12 % gel 
ddH2O 4.8 3.97 3.3 
Resolving gel buffer 2.5 2.5 2.5 
10% SDS * 0.1 0.1 0.1 
Acrylamide solution ** 2.5 3.33 4 
10% APS *** 0.08 0.08 0.08 
TEMED **** 0.008 0.008 0.008 
TOTAL 10 10 10 
* SDS: Sodium dodecyl sulfate (Fisher Scientific) 
** Acrylamide solution: 30% Acrylamide/ Bis solution 29:1 (BIO-RAD) 
*** APS: Ammonium persulfate (Fisher Scientific) 
**** TEMED: (Sigma). 
 
2.4.2 Protein Transfer:  
The nitrocellulose membrane, the gel, and the blotting paper pads were soaked with 
transfer buffer (80% (v/v) running buffer, 20% (v/v) methanol). The transferred proteins 
were blotted to 0.45 µM nitrocellulose membrane (Bio-Rad), using semidry apparatus, 
and 22V for 45 minutes for 2 blots. 
The blots were washed with appropriate buffers, incubated with blocking buffer, then 
loaded with primary antibody, followed by secondary antibody, between each step, the 
membranes were washed three times with buffers containing 0.1% Tween-20. Details of 
primary and secondary antibodies and blocking buffers are given in table 2.5: 
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Table 2. 5 : Western blot staining- antibody details: 
Antibody Type Against  Species 10 Working 
concen. 
Blocking 
buffer 
Secondary 
antibody 
20 Working 
concen. 
Mr Pink Polyclonal CFTR  Rabbit 2 µg/ ml 3 % 
MPBS-T 
*. 
Goat anti-
rabbit-
HRP 
0.05 µg/ ml 
Nrf2 Polyclonal Nrf2 Rabbit 1 µg/ ml 5% 
MPBS-T. 
Goat anti-
rabbit-
HRP 
0.125 µg/ 
ml 
P-c-jun Polyclonal  p-c-jun Rabbit 0.2 µg/ ml 3 % 
MTBS-T. 
** 
Goat anti-
rabbit-
HRP 
0.125 µg/ 
ml 
 
After the blots were prepared they were incubated with chemiluminescent substrate 
(Promega) for 5 minutes with no direct light, to allow HRP to oxidise luminol and produce 
light, this light was captured ChemiDoc BioRad imager. Images of the bands were taken 
then calculated with Image-J software, and the bands were normalised to B actin after 
removing the antibodies and restaining the blot for B actin.  
2.4.3 β- Actin staining: 
After the blots were imaged for the protein of interest, the blots were washed with PBS 
(without Ca/Mg) for 3 times 5 minutes each time, followed by 3 times with PBS (without 
Ca/Mg) with 0.1% Tween-20, 5 minutes each time. Then the blots were incubated in 
Western blot stripping buffer (Thermo) for 10-15 minutes. The blots were rewashed with 
3 times with PBS (without Ca/Mg) with 0.1% Tween-20, and 3 time with PBS (without 
Ca/Mg), incubated with 5% skimmed milk blocking buffer  prepared in PBS ( without 
Ca/Mg) with 0.1% Tween-20, for overnight at 4⁰C. The next day the blot were incubated 
with β- Actin primary antibody (Sigma—Aldrich) with 1:1000 dilution to the working 
concentration (0.4-0.8 µg/ml) in in the same blocking buffer (5% skimmed milk in 1% 
Tween in PBS), the blots were incubated with the primary antibody for 1 hour at room 
temperature, washed 3 times in 1% Tween-20 in PBS (without Ca/Mg), followed by 1 hour 
incubation at room temperature with the secondary antibody goat anti rabbit HRP 
(DAKO), diluted 5000 time in 1% Tween-20 in PBS (without Ca/Mg) to working 
concentration (0.05 µg/ml). The blots were washed 3 times with 1% Tween-20 in PBS 
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(without Ca/Mg), followed by 3 times in PBS (without Ca/Mg), then incubated with 
Chemiluminescent, and visualised with BioRad imager.  
2.5 HLMVEC immunocytochemistry: 
The cells were seeded in 8-well glass chamber slide (Thermo Scientific), pre-coated with 
collagen IV (as described above) and the cells were left to attach overnight. The following 
day the medium was changed and treatments started. After all the appropriate 
incubation time, the cells were washed twice with PBS (+ Ca/Mg) 500 µl/ well, fixed with 
ice cooled freshly prepared 4% (w/v) paraformaldehyde (Sigma) dissolved in PBS (- 
Ca/Mg) for 30 minutes 200 µl/ well. The cells were then washed once for 5 minutes with 
PBS (- Ca/Mg) 400 µl/ well. Then 0.1 M glycine prepared in PBS (-Ca/Mg) 300 µl was 
added to the wells for 10 minutes to bind free aldehyde groups preventing them from 
binding primary and secondary antibodies, followed by 3 washes in PBS. The cells then 
were permeabilized with 200 µl of 0.1 % of Triton-X 100 (Sigma) prepared in PBS (-Ca/Mg) 
for 10 minutes. The wells then were washed three times with PBS (-Ca/Mg). All the 
previous steps were performed at RT.  
After preparing the slides, they were incubated with blocking buffer containing serum 
from the same species of the secondary antibody prepared in PBS (-Ca/Mg) (Table 2.6), 
overnight at 4°C. Next day the primary antibody prepared in blocking buffer (the 
concentration varied from one antibody to the other) were added to the cells for 1 hour 
at 4°C for polyclonal antibodies (200 µl/well), then after the slides were washed three 
times with 400µl of PBS (-Ca/Mg), the fluorescent secondary antibody were added to the 
wells after dilution in blocking buffer, 200 µl/well. There was no direct light from this step 
further, to prevent the bleaching out of the fluorescent secondary antibody.  
The slides then were co-stained with Hoechst 33342 (Molecular Probes), prepared in PBS 
(-Ca/Mg), diluted 2000 fold to (5µg/ml) final concentration, 250 µl was loaded each well, 
Incubated with the cells for no longer than 10 minutes. Finally the cells were washed with 
500 µl of PBS (-Ca/Mg). The slides were mounted with Fluor Preserved reagent 
(Calbiochem), and covered with a cover slip. The slides were imaged using a Zeiss LSM 
710 confocal microscopy.     
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Table 2. 6: Immunocytochemistry – antibody details: 
Antibody Type Against  Species  10 
Working 
concen.  
Blocking 
buffer  
Secondary 
antibody 
20 
Working 
concen.  
Nrf2 Polyclonal Nrf2 Rabbit 5 µg/ ml 5% goat 
serum 
in PBS 
goat anti-
rabbit IgG-
Alexa Fluor 
555 
2 µg/ ml 
P-c-jun  Polyclonal P-c-jun Rabbit  0.8 µg/ ml 5% goat 
serum 
in PBS 
goat anti-
rabbit IgG-
Alexa Fluor 
555 
2 µg/ ml 
NF-kB Monoclonal NF-kB 
p65 
Mouse 4 µg/ ml 5 % 
rabbit 
serum 
in PBS 
rabbit anti-
mouse 
Alex Fluor-
488 
2 µg/ ml 
 
2.6 Statistical analysis: 
Statistical analyses were performed on data using Graphpad Prism (V 8.0.0). Data were 
expressed as an average ± standard error of the mean. One- way ANOVA and post hoc 
tests were performed on the data, such as Tukey`s or Dunnett`s for multiple comparisons. 
The tests were considered significant when the p value was less than 0.05. 
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Chapter Three 
Cystic fibrosis transmembrane conductance regulator expression 
in human lung microvascular endothelial cells 
 
3.1 Cystic fibrosis transmembrane conductance regulator: 
Cystic fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane 
glycoprotein and a cAMP-dependent chloride channel that belongs to the family of ATP-
binding cassette (ABC) transporters. CFTR is encoded by the CFTR gene on chromosome 
seven (Guggion & Stanton, 2006). CFTR is expressed in multiple functionally different 
organs such as lung, intestine, pancreas, kidney, heart, vas difference and sweat glands 
(Guo et al., 2009). Mutations in the gene encoding for CFTR is linked to life threatening 
cystic fibrosis disease, with a high prevalence of 1 in 2500 in Caucasian people (Rommens 
et al., 1989). There are nearly 2000 different mutations in the CFTR gene, and 280 of 
these mutations causes cystic fibrosis (Sosnay et al., 2013). 
3.1.1 CFTR structure: 
CFTR consists of two membrane spanning domains (MSD1, MSD2) consists of six 
transmembrane alpha helices. Two cytoplasmic nucleotide binding domains (NBDs), and a 
regulatory domain (R) which distinguishes CFTR from other ABC transporters. The PDZ 
domain of the COOH terminal facilitates binding of CFTR to cytoskeleton proteins (Figure 
3.1).  
As described by Zhang and Chen (2016) from studying CFTR atomic structure using 
electron cryo-microscopy from zebrafish, followed by analysis of human CFTR 3D 
structure (Liu et al., 2017). The CFTR channel consists of a large cytosolic vestibule for 
anion conduction, a thin transmembrane tunnel, with one extracellular gate, and the R 
domain which connects the two parts of CFTR. The R domain prevents dimerization 
between these two halves when the R domain is dephosphorylated.  
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Figure 3. 1: CFTR structure: 
Human CFTR structure which consist of two membrane spanning domains MSDs, each 
MSD consist of six transmembrane helices (TM) and four intracellular loops (ICL). Two 
nucleotide binding domains (NBDs), and one regulatory domain (R domain) (Moran, 
2017). 
 
For CFTR to function as a chloride channel, it requires dimerization of NBD1 with NBD2. 
This dimerization take place when the R domain is phosphorylated by cAMP-dependent 
protein kinase A (PKA) and PKC. When cAMP is elevated intracellularly, it activates PKA, 
which in turn phosphorylates the R domain at several serine residues (Gadsby & Nairn, 
1999). In addition, protein kinase C (PKC) phosphorylation of CFTR at different positions is 
required for full PKA-dependent CFTR channel activation (Chappe et al., 2003, 
Seavilleklein et al., 2008). Phosphorylation of the R domain facilitates binding of ATP to 
each NBD, forming a heterodimer consisting of NBD1, NBD2 and 2 ATPs (Zoghbi & 
Altenberg, 2014). The formation of dimer allows the opening of the CFTR gate and 
subsequently transport of Cl-. After ATP is hydrolysed by NBD enzymic activity, and ADP is 
released, the channel closes (Muallem & Vergani, 2009). 
3.1.2 CFTR channel function: 
Normally CFTR controls anion movement across the airway epithelium through secreting 
Cl- and HCO3- (5 to 1 ratio) , as well as inhibition of epithelial sodium channel (ENaC) 
activity, decreasing Na+ absorption (Mall et al., 2004). Regulation of salt movement 
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results in control of the movement of water across airways epithelium (Figure 3.2). Thus 
CFTR defects in cystic fibrosis result in increased Na+ uptake through ENaC and a decrease 
in airway surface liquid (ASL) volume and dehydrated mucus (Saint-Crip & Gray, 2017, 
Castellani & Assael, 2017). 
 
Figure 3. 2: CFTR chloride channel in lung epithelial cells 
 (A) Normal CFTR chloride channel in airway epithelial cells maintain hydration of airway 
surface liquid, (B) defective CFTR in CF epithelial cells increase thickness of mucus, and 
dehydration of airway surface liquid (ASL) (Cystic Fibrosis Medicine, 2008). 
 
Functional CFTR inhibits ENaC channel activity (Stutts et al., 1995). Mall et al. (2004) 
demonstrated that CFTR inhibition of ENaC is mediated through the effect of extracellular 
ATP acting on CF and non-CF nasal epithelial cells to increase intracellular Ca+ ion.  In 
another study conducted on Xenopus laevis oocytes (Rauh et al., 2016) expression of 
CFTR decreased membrane surface expression of ENaC, in addition to decreasing ENaC 
channel open frequency. 
A 
    B 
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Under normal conditions, CFTR in the bronchial epithelium secretes Cl- and HCO3- ions. Cl- 
is important for salt and fluid movement and airway hydration, while HCO3- is important 
for regulation of ASL pH. Defective CFTR in CF results in acidic ASL which results in 
impairment of ASL antimicrobial activity in a porcine model of cystic fibrosis lung (Pezzulo 
et al., 2012). Furthermore, HCO3- was found important for MUC2 mucin unfolding and 
expansion in volume in mouse small intestinal epithelial cells. HCO3- chelates Ca+ ions 
when mucin is released from goblet cell granules forming CaCO3, and this step at pH 7.4 
results in normal mucin thickness (Gustafsson et al., 2012). 
Normally, Cl- secretion from epithelial cells consists of two steps. The first step includes 
the accumulation of Cl- intracellularly through active transport via NKCC1 cotransporter in 
the basolateral membrane of epithelial cells. The intracellular accumulated Cl- is then 
secreted from airway epithelial cells in the second step, primarily via CFTR channel down 
the electrochemical gradient. In addition, other Cl- transporting channels, such as calcium 
activated chloride channel (CaCC) and solute carrier (SLC) may be involved (Saint-Criq & 
Gray, 2017). 
Although CFTR functions as a Cl- and HCO3- channel, and regulates Na+ absorption, CFTR 
was found to regulate several other Cl- channels, such as the solute channel (SLC26) 
family. SLC26A9 is an anion exchanger that transports Cl- in human bronchial epithelial 
cells (HBEs), although there are controversial studies regarding the relation between CFTR 
and SLC26A9. One of the studies demonstrated that mutation in CFTR prevent SLC26A9 
activity in transporting Cl- (Bertrand et al., 2009). Another study reported that the CFTR 
regulatory domain inhibits SLC26A9 anion transporter (Chang et al., 2009). These two 
studies indicates there is a regulatory role of CFTR on SLC26A9 that requires more 
clarification. 
Furthermore, CFTR was found to affect Ca+ activated Cl- channel (CaCC) in human 
bronchial epithelial cells (16HBE). Activation of CFTR with forskolin or IBMX in 16HBE14o- 
led to inhibition of TMEM16A which is a CaCC channel, and when CFTR was expressed and 
activated in CFBE cells, CaCC activity was inhibited (Ousingsawat et al., 2011). 
26 
 
Another Cl- channel which was found to be activated by CFTR is outward rectifying Cl- 
channels (ORCC). In a study on nasal epithelial cells from CFTR knockout mice, ORCC 
channels did not respond to protein kinase A activation (Gabriel et al., 1993). 
CFTR was also found to interfere with paracellular transport which influences the 
movement of water across tissue. This effect is mediated through interaction of CFTR 
with epithelial cells cytoskeleton F-actin. Comparing trans-epithelial resistance and 
permeability to (14C) mannitol in wtCFTR (16HBE 14o- ) and del508-CFTR(CFBE41o-) 
showed that cells with defective CFTR (del508-CFTR(CFBE41o-) exhibited less 
electroresistance and greater permeability, that was mediated through myosin II a 
component of stress fibres that include F-actin and α-catenin (Weiser et al., 2011). 
Inhibition of CFTR in primary rat lung microvascular endothelial cells by either CFTRinh172 
or GlyH-101 resulted in redistribution of F-actin from subcortical plasma membrane and 
increase stress fibre formation. This redistribution results in retraction of endothelial 
cells, and increase in the paracellular gaps between adjacent cells (Brown et al., 2014). 
In addition to interaction with paracellular transport, CFTR was found to interfere with 
water transport through airway epithelial cells (transcellular transport) through 
interfering with the function of the aquaporin 3 water channel. Activation of CFTR by 
cAMP resulted in increase in glycerol uptake as an indicator of water movement in normal 
airway epithelial cells, but not in CFTR mutant cells. It appeared that aquaporin 3 is 
responsible for changes in glycerol and water uptake that are dependent on CFTR 
(Schreiber et al., 1999). 
3.1.3 CFTR expression and instability in epithelial cells: 
CFTR biogenesis consists of translation, co-folding and post-folding of CFTR domains 
individually which starts on the endoplasmic reticulum membrane. CFTR synthesis starts 
with MSD1 (membrane spanning domain consisting of 6 transmembrane helices) which is 
the first synthesised CFTR domain. After translation of TM1 by ribosome, it is recognised 
by the signal recognition particles located in translocon, these particles anchors CFTR to 
the ER membrane, this step is followed by emerging of TM2 as complementary signal in 
order to strength the connection. The same sequenced steps take place with TM3 and 
TM4 until all TMs of MSD1 are translated and linked as sequenced structure. Then NDB1 
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and R domain are translated and folded in the cytoplasm and linked to MBD1. This step is 
followed by co-translation folding of MSD2, which starts from TM7 translation till TM12 
translation and folding. And final step of CFTR biogenesis is cytosolic translation of NDB2 
which is connect to MSD2. All of the domains are then post-translationally folded to form 
immature CFTR (Molecular weight of 130 kDa).  
The translation accompanied by the folding steps in CFTR synthesis is to prevent 
proteolysis of CFTR intracellularly (Farinha & Canato, 2017). All previously mentioned 
steps are monitored by an endoplasmic quality control system; such as chaperones and 
co-chaperones (Hsp70 and co-chaperone Hsp40), any abnormalities in newly synthetised  
immature CFTR results in targeting of the immature CFTR by chaperones for 
ubiquitination and subsequently degradation by 26S proteasome (Kim & Skach, 2012). 
The newly synthesised immature CFTR is then core glycosylated in the endoplasmic 
reticulum to form band B immature CFTR (Molecular weight 150 kDa), then exported to 
Golgi apparatus inside coat protein-II coated vehicles (COPII). Finally, in COP1 of the Golgi 
apparatus complex, CFTR is further glycosylated, and complex sugars are added to CFTR, 
that increase CFTR molecular weight to 170- 180 kDa and results in band C fully matured 
CFTR (Amaral et al., 2016).  
Post-Golgi CFTR is translocated into plasma membrane, where the abundance of CFTR 
channel protein on plasma membrane is determined by recycling and degradation by 
endocytosis (Farinha et al., 2017) 
After CFTR is localised in the apical plasma membrane, CFTR stability and anchoring to 
plasma membrane depends on CFTR interaction with different proteins, specifically PDZ 
containing proteins, such as NHERF 1 and 3, which link CFTR to actin cytoskeleton 
(explained in details in Chapter 6). 
CFTR is then exposed to endocytosis through clathrin-coated vesicles, where usually half 
of wt-CFTR is usually recycled to the cells membrane, a process controlled by small 
GTPase Rab family. More specifically, CFTR recycling depends on Rab4, while and the 
remaining of non-recycled CFTR are either degraded by endosomes, or enter another 
recycling cycle regulated by Rab 11 (Gentzsch et al., 2004). 
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CFTR translation and translocation to cell membrane is multistep process that is 
controlled by cellular quality control at many steps of CFTR biogenesis, this results under 
normal condition only 25% of the translated proteins arriving at the cell membrane (Ward 
& Kopito, 1994). 
Also another upstream step that controls CFTR expression is CFTR mRNA stability, which 
was found to be highly susceptible to oxidative stress (Cantin et al., 2006). 
3.2 Endothelial cell CFTR: 
CFTR protein expressed in epithelial cells (Quinton, 1990) (Poulsen et al., 1994) as well as 
in endothelial cells (Tousson et al., 1998). The vast majority of the previous studies of 
CFTR expression and function were in epithelial cells (Engelhardt et al., 1992), where CFTR 
regulate the movement of salt and water, and subsequently regulation of ASL volume 
(Song et al., 2003). Thickening and dehydration of airway mucus cripples airway defence 
mechanisms against pathogens. Chronic respiratory infections especially with 
Pseudomonas aeruginosa, in addition to the CFTR defect stimulates uncontrolled 
recruitment of inflammatory cells which damages lung tissue. Eventually, 80-95 % of 
cystic fibrosis patients die from respiratory failure (Lyczak et al., 2002). 
In endothelial cells CFTR expression and intracellular regulation of CFTR expression was 
not extensively studied. However, CFTR function was found to play important roles in 
endothelial cell physiology. Endothelial cell activation and perturbation in CF patients 
were indicated through increase in tissue-plasminogen activator (t-PA) and von 
Willebrand factor (vWF) in serum of CF patients (Romano et al., 2001). vWF and t-PA are 
constitutively and inducibly synthetised and released from vascular endothelial cells. In 
another study (Nowak et al., 2017) soluble VCAM-1 was found elevated in serum of cystic 
fibrosis patients, which reflect increase in interaction between vascular endothelial cells 
and leukocytes. Evidence of dysfunctional in microvascular (Rodriguez-Miguelez et al., 
2016) and vascular endothelium through clinical study on cystic fibrosis patients (Poore et 
al., 2013) were reported in cystic fibrosis patients. 
CFTR was found to regulate the endothelial glycocalyx in bovine aorta endothelial cells 
(GM7373) (Peters et al., 2015). The glycocalyx is a network of glycoprotein and 
proteoglycans bound to the endothelial cell membrane and line the vascular lumen. 
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Damage to this layer is linked to endothelial dysfunction which results in increase in 
endothelial permeability and inflammatory cells adhesion (Sieve et al., 2018). Activation 
of GM7373 cells with polyphenols (resveratrol) induced glycocalyx swelling, and reduced 
glycocalyx stiffness. The effect of polyphenol was mediated through activation of CFTR, 
and when GM7373 cells were treated with CFTR inhibitor (CFTRinh172) before polyphenol, 
glycocalyx swelling was inhibited. The activation of CFTR in regulating glycocalyx thickness 
was through phenol-induced decrease in actin polymerisation. The effect of endothelial 
CFTR on actin polymerisation was investigated in primary endothelial microvascular 
pulmonary rat and human cells. When CFTR was inhibited with CFTR inhibitors CFTRinh172 
and GlyH-101, the permeability of these cells increased, with an increase in formation of 
stress fibres and redistribution from the subcortical position (Brown et al., 2014). 
CFTR function as a chloride channel was also investigated in HUVECs and human 
pulmonary artery endothelial cells (PAEC). cAMP induced chloride currents in both cells, 
and treating the cells with the CFTR inhibitor CFTR172 inh blocked the cAMP effect. In the 
same study PAEC were tested for transendothelial electrical resistance and permeability 
after CFTR inhibition. CFTR172 inh increased ECs permeability and decreased resistance, 
these results were compared with cystic fibrosis pulmonary artery endothelial cells (CF2-
PAEC), CF2-PAEC permeability was higher than PAEC and the resistance was lower (Totani 
et al., 2017). 
3.3 CFTR inhibition and GlyH-101: 
 
Figure 3. 3: GlyH-101 structure (Verkman et al., 2013). 
The CFTR inhibitor GlyH-101 is a glycine hydrazide [N-(2-naphthalenyl)-((3,5-dibromo-2,4-
dihydroxyphenyl)methylene)glycine hydrazide] (Figure 3.3). GlyH-101 is a potent, 
reversible, rapid, pharmacological CFTR channel inhibitor, which closes CFTR channel from 
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the external side of the cell membrane. GlyH-101 reduces CFTR channel opening time 
from 264 ms to 13 ms at 5 µM concentration (Muanprasat et al., 2004).  
GlyH-101 and CFTR172inh are selective and potent pharmacological inhibitors of CFTR 
channel function at low concentration. GlyH-101 had good water solubility, and low IC50. 
Synthesizing CFTR inhibitors was partially to mimic cystic fibrosis by closing CFTR channels 
to study and investigate the pathogenesis of CF disease, and in attempts to produce non-
absorbable externally acting CFTR inhibitors that can be used to treat secretory diarrhoea 
and developing treatments to polycystic kidney disease (Verkman et al., 2013). 
3.4 Aims and objectives: 
The aim of the experiments described in this chapter is to investigate CFTR expression in 
human lung microvascular endothelial cells. The objective was to use Western blotting to 
investigate the expression and stability of CFTR in HLMVECs. 
 
3.5 Materials and Methods: 
3.5.1 CFTR Western Blotting: 
HLMVECs were seeded in collagen IV coated 6-well plates (2.5 X 105 Cells/ well) in full 
growth medium (Chapter 2, section 2.2). Cells were left to attach overnight and next day 
the medium was refreshed to remove the dead cells. The cells were treated with CFTR 
inhibitor GlyH-101 20 µM for 16 hour (duplicate wells for each condition), and results 
were compared with 0.1% DMSO as the control vehicle. After the treatment, the 
supernatants were collected, centrifuged at 1500 Xg for 10 minutes at 4oC, and the clear 
supernatant stored in -80o C for further analysis. HLMVECs were washed twice with ice 
cold PBS (without Ca/Mg). The cells from duplicate wells were lysed directly in a total of 
75 µl of 2 X reducing sample buffer with protease inhibitors (Chapter 2, section 2.3.2.2). 
The cells were scraped and collected and 1 µl 0.25M of EDTA was added to each sample, 
and the samples in the tubes were incubated in a water bath at 50oC for 20 minutes. 
Finally, samples were stored at -80oC till the day of analysis.  
On the day of analysis 7.5% SDS-PAGE gels (Chapter 2, table 2.3) were prepared. The 
samples were loaded (35 µl), and electrophoresis started at 50V until the samples entered 
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the resolving gel, then voltage was increased to 140V. When electrophoresis was finished, 
the gels were blotted onto 45 µm nitrocellulose paper. The blots were incubated 
overnight at 4oC with rolling in blocking buffer of 3% skimmed powdered milk (Marvel) 
prepared in PBS (without Ca/Mg) containing 0.1 % Tween 20 (PBS-T). Next day the blots 
were washed three times with 20 ml PBS-T for 5 minutes with rocking (70 rpm) through 
the three washes. Then the blots were incubated with Mr Pink primary antibody (kindly 
provided by Prof Ineke Braakman, Utrecht University through the CFTR Folding 
Consortium, USA) (polyclonal antibody raised in rabbit against NBD1 domain of human 
CFTR) (1 mg/ml), at a working concentration of 2 µg/ml diluted in PBS-T. The blots were 
incubated with antibody for 1 hour at room temperature, followed by repeating the three 
wash steps. Finally the blots were incubated with the secondary antibody goat anti-rabbit 
HRP (Dako, P0448, 0.25 g/l), working dilution 1/5000 (0.05 µg mlˉ¹) for 1 hour, the blots 
were washed with 20 ml PBS (without Ca/Mg) for 5 minutes containing 0.1% Tween-20, 
for three times, then with 20 ml PBS (without Ca/Mg) for 5 minutes for 3 times.  
Bands were visualised after incubation for 5 minutes in the dark with chemiluminescence 
substrate (Promega; W1015), allowing HRP to oxidise luminol to emit light, followed by 
detection of the bands with the Bio-Rad ChemDoc western blot imager.  
The bands were normalised to β- actin staining (Chapter 2, Section 2.4), and compared 
with the control.  
The staining was quantified using Image J software, and data from band C and B of CFTR 
were pooled together and normalised to β-actin. 
3.5.2 MTT assay: 
In order to investigate whether CFTR inhibitor had an effect on HLMVECs metabolic 
activity, the MTT assay was conducted with a range of CFTR inhibitor concentrations (5, 
10 and 20 µM), after 16, 24 and 48 hours of incubation with GlyH-101. Results were 
compared with DMSO vehicle at the same concentration used with GlyH-101. 
MTT is yellow 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide compound, 
and it is reduced by mitochondrial succinate dehydrogenase into insoluble dark purple 
formazan product.  
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HLMVECs were seeded at a density of 1 X 104 cells/well/100 µl of FGM in collagen IV 
coated 96-well plates. Cells were left to adhere overnight at 370C and 5 % CO2. Next day 
the cells were treated with GlyH-101 and DMSO (0.1 %). The treatments (GlyH-101 and 
DMSO) were added to the cells with full growth medium for 16, 24 and 48 hours. In order 
to eliminate the effect of ascorbic acid (in FGM) on MTT colour changes, the medium was 
replaced with 100 µl phenol red free medium (MEM) contained 0.3% of FBS to each well, 
followed by adding 10 µl of MTT solution ( 5 mg/ml of PBS without Ca/Mg, protected 
from light) were added to each well. After adding MTT with phenol-free medium the 
HLMVECS were incubated at 370 C and 5 % CO2 for 4 hours to allow the formation of 
formazan purple crystals. Then 100 µl of MTT solvent (10 % SDS in 0.01 M HCL) was added 
to each well and were gently resuspended. Plates were incubated overnight at RT in a 
humidified sealed container, thus allowing crystals to dissolve. Content were re-
suspended once more, the plates were then read at 570 nm using the Spectramax i3x 
plate reader. 
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3.6 Results:  
3.6.1: CFTR expression in endothelial cells: 
CFTR expression in HLMVECs was examined with Western blotting, HLMVECs were lysed 
directly with 4X reduced sample buffer with protease inhibitors.  CFTR was detected as 
mature ≈ 180 kDa band (Figure 3.4), but there was degradation in the protein as band at ≈ 
85 kDa. As shown in figure 3.4 of blot stained with antibody against CFTR.  
 
 
 
Figure 3. 4: CFTR expression in HLMVECs cells lysate 
CFTR is expressed as fully mature (180 kDa band), but there was degradation and 
instability of CFTR protein in HLMVECs. 
 
3.6.2 Effect of proteasome inhibitor (MG132) and calpain I (ALLN) and II (ALLM) 
inhibitors on CFTR expression in HLMVECs: 
HLMVECs (25 X 104 cells/ well/ 2ml of FGM) seeded in collagen IV coated 6-well plates. 
Following cells adhesion to plates, cells were treated with MG132 (10 µM) for 16 hour 
and compared with control cells without treatments (Figure 3.5), HLMVECs were then 
lysed in reduced sample buffer, and blots were stained for CFTR, β- actin. There was 
reduction in β-actin after MG132 treatment, indicating that HLMVECs were sensitive to 
MG132 treatment, and the cells appeared abnormal after treatment (data not shown).  
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Figure 3. 5: Effect of MG132 on CFTR expression in HLMVECs 
MG132 did not decrease degradation of CFTR on Western blot results.   
 
In figure 3.6, ALLN at 20 µM concentration was added to HLMVECs 4 hours before lysing 
the cells in reduced sample buffer, and after the cells were treated with GlyH-101 (20 µM) 
for 16 hour, and DMSO (0.1%) vehicle control. As well as N-acetyl cysteine (5 mM) added 
for 1 hour before GlyH-101 (total of 17 hour) as an antioxidant to protect CFTR (Figure 
3.6) to increase the stability of CFTR by decreasing oxidative stress in HLMVECs.  
Degradation of CFTR continued, and the expression of band B (140 kDA) decreased when 
HLMVECS were treated with ALLN. However, β- actin was increased in this experiment, 
although the number of cells, the volume of reduced sample buffer, and the volume 
loaded to SDS-gel were equal in this experiment.  
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Figure 3. 6: Effect of ALLN on CFTR expression in HLMVECS 
No effect on CFTR expression after treating the cells with ALLN as an inhibitor of CFTR 
degradation, as well as NAC antioxidant on expression and stability of endothelia CFTR. 
 
To test the effect of ALLM, HLMVECs (25 X 104 cells/well/ 2ml of FGM) were seeded in 
collagen IV coated 6-well plates, and the next day the cells were treated with ALLM (2 
µM) for 24 hour, with and without CFTR inhibitor GlyH-101 (20 µM) and vehicle inhibitor 
DMSO 0.1% both for 16 hours.   
Western blot results in figure 3.7 show 140 kDa bands of CFTR in addition to 35 kDa bands 
detected by Mr Pink antibody indicating that CFTR fragmentation continued and there 
was no effect of ALLM on CFTR expression. 
 
Ladder              control          DMSO          Gly ALLN NAC          Gly                ALLN              
250 kDa 
150 kDa  
100 kDa  
75 kDa  
50 kDa 
37 kDa 
β- Actin 
140 kDa CFTR (Band B) 
85 kDa CFTR  
35 kDa NBD1 CFTR fragments  
36 
 
 
 
 
Figure 3. 7: Effect of ALLM on CFTR expression in HLMVECs: 
Cells were treated with ALLM (2µM) for 4 hours with and without GlyH-101 (20 µM) for 
16 hour, in addition to treating HLMVECs with DMSO (0.1%) as vehicle treatment of GlyH-
101. 
 
3.6.3: The effect of GlyH-101 on CFTR expression: 
CFTR was detected as two high molecular weight bands in HLMVECs cells lysate. Partially 
glycosylated band B (140 kDa), and fully mature band C (170 kDa). The abundance of CFTR 
in cell treated with 16 hour of GlyH-101 (20 µM) was higher than cell treated with DMSO 
(0.1 %) vehicle control (Figure 3.8). Because each experiment was conducted on HLMVECs 
obtained from two different donors, there was a difference in CFTR band expression due 
to genetic factors and individual variation.  
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Figure 3. 8: CFTR expression in HLMVECs cell lysate: 
CFTR expression in HLMVECs cell lysate by Western blot after 16 hour incubation with 
GlyH-101 (20 µM) and DMSO (0.1 %) vehicle control. Data were normalised to β-actin, 
numbers expressed as average of 3 independent experiments.  
 
3.6.4: MTT assay of CFTR inhibitor GlyH-101: 
The effect of the CFTR inhibitor on metabolic activity of HLMVECs was detected using the 
MTT assay. GlyH-101 concentrations in the concentration range between 5- 20 µM were 
tested at 16, 24 and 48 hours incubation. The MTT assay shows that the CFTR inhibitor 
had an effect on reducing metabolic activity at 48 hours, but only at the highest 
concentration tested (20 µM). This effect appeared to be due to a significant reduction in 
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the number of adherent cells by 34.1 ± 1.7 % after 48 hours incubation with CFTR 
inhibitor as measured using the crystal violet staining (Chapter 6). This reduction in 
number of cells resulted in significant reduction in MTT assay by 40.1 ± 1.6 % (Figure 3.9).  
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Figure 3. 9: MTT assay 
HLMVECs were treated for 16, 24 and 48 hour with CFTR inhibitor GlyH-101 at 5, 10 and 
20 µM concentration. Results were compared with DMSO vehicle (0.1%). Data were 
expressed as mean ± SEM (**p value ˂ 0.01 comparing GlyH-101 (20 µM) to DMSO (0.1%) 
at 48 hour, n=3). Data were analysed with 2 way ANOVA and Tukey`s multiple comparison 
test.   
 
3.7 Summary of results: 
• CFTR expression in HLMVECs is low. 
• Degradation of CFTR continued even after treating the cells with proteasome and 
protease inhibitors.  
• Pharmacological inhibition of CFTR activity with 20 µM of GlyH-101 in HLMVECs 
increased CFTR expression. 
• CFTR inhibition did not affect cell viability or metabolic activity over 24 hours. 
 
3.8 Discussion:  
In the current study, CFTR expression in HLMVECs was examined using Western blot. 
Initial experiments indicated a low level of intact mature protein, and several low 
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molecular weight bands. And although cells were lysed directly in buffers containing a 
cocktail of protease inhibitors, the degradation reflects endogenous unstability and 
turnover of CFTR in endothelial cells. Inhibiting of proteasomal protease including 
calpains with MG132, ALLN and ALLM did not increase the expression of intact CFTR in 
ECs. HLMVECs treatment with GlyH-101 CFTR inhibitor (20 µM) increase CFTR expression. 
Only the highest concentration of GlyH-101 (20 µM) over 48 hours inhibited metabolic 
activity. All subsequent experiments investigating the effect of CFTR on inflammation and 
oxidative stress were carried out using 20 µM GlyH-101 over 16-24 hour or less. 
Although clinical studies referred a systemic complication includes vascular dysfunction in 
CF (Poore et al., 2013, Rodriguez-Miguelez et al., 2016), the role of CFTR in regulating 
microvascular endothelial cells is poorly defined. Expression of CFTR by HUVECs and 
HLMVECs was previously reported by Tousson et al. (1998), and evidence using 
immunocytochemistry against the R domain, NBD1 and C terminus of CFTR, in addition to 
RT-PCR and immunoprecipitation for CFTR expression. Patch clamp technique and Cl- 
efflux assay were used to analyse CFTR function, and endothelial CFTR function was 
inhibited when HLMVECs and HUVECs were treated with glibenclamide (a selective CFTR 
inhibitor). Recently Totani et al., (2017) studied CFTR expression and function in HUVECs 
as well as in pulmonary artery endothelial cells (PAEC) from normal and CF patients. In 
both HUVECs and PAEC, inhibition of CFTR with CFTR inhibitor 172 resulted in increased 
permeability of both cells types, and decreased trans-endothelial electrical resistance 
(TEER). TEER was found lower in PAEC from CF patients than from normal individuals.  
The current study found that HLMVECs expresse CFTR band B and C. Inhibition of CFTR 
with GlyH-101 at 20 µM concentration for 16 hour increased CFTR expression. There are 
two possible explanations for the effect of GlyH-101 on CFTR expression. The first 
explanation is that inhibition of CFTR with GlyH-101 results in decrease in Nrf2 
transcriptional factor in HLMVECs, Nrf2 was found to have suppressor effect on CFTR 
transcription in human bronchial epithelial cells (Rene´ et al., 2009) that was mediated 
through cooperation with transcriptional repressor factor (YY1), both YY1 and Nrf2 bind 
and repress CFTR transcription. Therefore, reduced Nrf2 in HLMVECs following CFTR 
inhibition as seen in the current study, resulted in increase in CFTR expression.  
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The explanation of effect of Nrf2 decrease on increase of CFTR expression in HLMVECs 
differs from Mutolo et al. (2018) finding in Calu-3 cells, where they demonstrate that Nrf2 
increases the expression of CFTR by displacing repressive transcriptional factors from 
CFTR promoters, thus inducing expression of CFTR.  
The second possible explanation is that active CFTR has an inhibitory effect on TRADD 
(tumor necrosis factor receptor type 1-associated DEATH domain protein) through 
sending TRADD to be degraded by lysosomes. When CFTR was inhibited by the CFTR 
inhibitor 172 in bronchial epithelia cells, the inhibitory effect of CFTR on TRADD 
disappeared, leading to increased activity of TRADD. Increased TRADD feedback to 
elevate levels of CFTR and expression of CFTR at the cells surface, and further activate NF-
kB signalling (Wang et al., 2016).   
The CFTR channel blocker GlyH-101 is a selective CFTR blocker, which closes the channel 
by binding to the pore of the channel extracellularly (Muanprasat et al., 2004). GlyH-101 
was used extensively to block CFTR channel pharmacologically in epithelial cells such as 
Calu-3 (MacVinish et al., 2007). Melis et al. (2013) reported that GlyH-101 non-selectively 
blocks other Cl- channels such as calcium activated chloride channel (CaCC). However, but 
CaCC is inhibited by CFTR in bovine pulmonary artery endothelium, so inhibition of CFTR 
by GlyH-101 should increase the activity of CaCC (Wei et al., 1999). In addition, Melis et 
al. (2013) reported that CFTR inhibitor GlyH-101 non-selectively inhibits volume sensitive 
outwardly rectifying Cl− (VSORC) channel, but inhibition of this channel results in 
decrease in intracellular ROS levels (Shen et al., 2014), while in the current study CFTR 
inhibitor GlyH-101 induced increase in intracellular ROS of HLMVECs (Chapter 4).  
The effect of GlyH-101 on HLMVECs are therefore likely mediated through CFTR. 
In this study, HLMVEC CFTR was detected with Mr Pink antibody, which is a polyclonal 
antibody for detection of multiple epitopes on the NDB1 domain of CFTR. CFTR is a 
membrane protein with low cellular expression that is correlated to the availability of 
cellular membrane, and high turnover rate. Even under normal conditions only 25 % of 
synthesized protein reach the epithelial cell membrane (Ward & Kopito, 1994). And 
although CFTR in this study was detected as band B and C (depending on the cell passage 
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and the donor), there were other smaller molecular weight bands detected by Mr. Pink 
indicating that CFTR is fragmented. 
CFTR fragmentation that was not an artefact of cell lysis or cell type was reported 
previously by Tosoni et al. (2013). Two cell types, baby hamster kidney (BHK), and human 
bronchial epithelia cells (HBE) were tested for CFTR fragmentation with several antibodies 
against NBD1, NBD2 and R domains. Both cell types had in addition to fully matured band 
C CFTR (160-170 kDa), fragments of CFTR consisting of two asymmetrical halves of the 
protein, derived from C and N terminus each linked to the neighbouring NBDs were 
detected, indicating that CFTR is fragmented at the R domain region, in addition to 
numerous smaller fragments (≈30 and 60-80 kDa). 
CFTR fragmentation to small bands was also reported by Du et al. (2004). CFTR from baby 
hamster kidney cells was detected with Western blot, and fragmentation of CFTR was due 
to the effect of trypsin on CFTR. Trypsinolysis of BHK resulted in fragmentation of both 
NBD1 and NBD2 into small molecular weight fragments (30-39 kDa). In the current study, 
an abundance of CFTR fragments were observed as low molecular band (≈ 36 kDa), and 
although the cells were lysed directly in reduced sample buffer without trypsinization, 
human vascular endothelia cells express trypsin significantly (Koshikawa et al., 1997).  
Other researchers had reported CFTR fragmentation especially at 100 and 150 kDa, and 
bands were rescued to full mature 170 kDa by treating Fisher rat thyroid cell (over 
expressing CFTR) and human leukocyte T-cells and with C.I.2 (calpain inhibitor 2), as CFTR 
is highly susceptible to be degraded by calpain (Averna et al., 2010) to restore the full 
mature CFTR. In the current study, although HLMVECs were treated with MG132 
(carbobenzoxy-Leu-Leu-leucinal) which is a potent proteasome inhibitor, MG132 did not 
rescued CFTR from degradation. In addition HLMVECS appeared abnormal and unhealthy 
(data not shown) after treatment with MG132. ALLN (N-Acetyl-Leu-Leu-Nle-CHO) which is 
a calpain 1 and 2 and cathepsin K and L inhibitor were used to rescue CFTR from 
degradation, but there was no effect of CFTR expression through increasing the 170 kDa, 
or reducing the smaller molecular weight bands. Finally, ALLM (N-Acetyl-L-leucyl-L-leucyl-
L-methioninal), which is calpain 2 inhibitor were also tested on the effect on CFTR 
degradation, and as for the previously mentioned protease inhibitors, did not decrease 
the degradation of CFTR.  
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Although all the recommendations for solubilisation, isolation and purification of CFTR 
were followed, such as replacement of 2-mercaptoethanol by DTT to enhance CFTR 
solubility and lysing the cells directly in reduced sample buffer, avoiding the use of trypsin 
during cell lysis, the fragmentation of CFTR was still observed. 
The data clearly indicate the low expression and unstable nature of CFTR in HLMVECs. 
Nevertheless, subsequent experiments show that low levels are sufficient to maintain an 
anti-inflammatory, anti-oxidative endothelial phenotype.  
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Chapter Four 
HLMVEC and oxidative stress 
4.1 Introduction:  
4.1.1 Reactive oxygen species and endothelial cell function: 
Reactive oxygen species (ROS), for example hydroxyl radicals (OH•ˉ), superoxide (O₂•ˉ) 
and hydrogen peroxide (H₂O₂), are produced by the vascular endothelium as part of 
normal cellular metabolism. Although these cells depend largely on anaerobic glycolysis 
as a source of energy (Culic et al., 1997), still ROS are produced via the mitochondrial 
electron transport chain in considerable amounts that can affect redox balance.  
When ROS levels are within the normal range in healthy tissues their specific functions in 
endothelial cells are termed redox biology. For example, when epidermal growth factor 
(EGF) and platelet-derived growth factor (PDGF) bind to their specific receptors tyrosine 
kinase activity induces autophosphorylation of the receptor and activates it. ROS 
production increases through activation of NADPH oxidases (NOX) and inactivation of cell 
membrane associated peroxiredoxins 1. This increase in ROS, more specifically H₂O₂, 
reversibly inhibits protein tyrosine phosphatases (PTPs) and phosphatase and tensin 
homolog (PTEN) prolonging activation of the EGF and PDGF receptors. These two 
phosphatases also have an inhibitory effect on phosphatidylinositol 3-kinase (PI3K)-AKT 
and RAS-MEK-ERK MAP kinase activity, which is the sequence pathway of EGF-R and 
PDGF-R activation (Schieber & Chandel, 2014). When the phosphatases are inhibited by 
H₂O₂, both EGF and PDGF intracellular signals propagate to promote cell growth and 
proliferation.  
As well acting as a second messenger, H₂O₂ is also an essential molecule for 
cyclooxygenase activation in the process of prostaglandin synthesis (Martin & Williams, 
1980). In addition, ROS have an active role in endothelial proliferation, and angiogenesis 
that is mediated primarily in the vascular endothelium by an increase in vascular 
endothelial growth factor (VEGF) expression (Maulik & Das, 2002).   Furthermore, 
oxidative stress was found to increase vascular endothelial cells programmed death 
44 
 
(anoikis), through the activation of c-jun n-terminal kinase (JNK) and intracellular caspase 
(Li et al., 1999).     
However, when ROS overwhelm antioxidant defence mechanisms in the cells oxidative 
stress occurs, which is either due to increase in the production of ROS, or due to 
impairment of anti-oxidative mechanisms. 
Oxidative stress is an important manifestation in many diseases, and affects the normal 
function of ECs. In addition to the damaging effect resulting from oxidation and alteration 
of cellular lipids, protein, and DNA, oxidative stress interferes with the abundance of nitric 
oxide (NO), because excessive superoxide (O₂ˉ•) interacts with NO to produce highly 
reactive peroxynitrite (ONOOˉ)(Beckman, 1996). This product has a harmful effect on the 
vascular endothelium, and decreased NO levels result in a decrease in its vasodilator 
effect, while reversing the inhibitory effect of NO on platelets adhesion, leukocyte 
adhesion (Kubes et al., 1991), vascular permeability and increase in the expression of P-
Selectin (Armstead et al., 1997). 
4.1.2 Sources of intracellular ROS in vascular endothelium: 
Reactive oxygen species can be divided into two groups, free radical and non-radical 
groups. Free radicals contain one or more free unpaired electrons in their molecular 
structure like superoxide O₂ˉ•, hydroxyl OH•, while the non-radical group are molecules 
that share their free unpaired electron e.g. hydrogen peroxide H₂O₂. The first group are 
highly reactive molecules with more harmful effects on intracellular compartments, while 
the second group are more stable, have longer duration of action and diffuse rapidly 
through the cellular membrane, exerting effect more widely than the first group which 
usually work locally (Aldosari et al., 2018).  
ROS are produced intracellularly as part of cellular respiration and ATP production by the 
mitochondria, as well as being produced as a by-product during metabolism of 
compounds or toxins e.g. cytochrome P450. There are several intracellular ROS producing 
enzymes including NADPH oxidases, xanthine oxidase, lipoxygenase, and cyclooxygenase 
(Szocs, 2004). Additionally ROS could come from extracellular sources during the 
accumulation of inflammatory cells at site of inflammation e.g. leukocytes, macrophages.  
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The main source of intracellular ROS in the vascular endothelium: 
4.1.2.1 NADPH oxidases (nicotinamide adenine dinucleotide phosphate-dependent 
oxidase): these are a family of membrane associated and cytosolic enzymes, and the 
main source of ROS in the vascular endothelium.  
The NADPH oxidase family consists of seven isoforms (NOX1, NOX2, NOX3, NOX4, NOX5, 
DUOX1, and DUOX2), but only NOX 1, 2, 4, and 5 are found in vascular endothelium. They 
differ in structure and number of assembling units to be activated. For example, NOX2 
which was the most extensively studied isoform, consists of membrane associated 
protein gp91ᴾʰᵒˣ, and its partner P22ᴾʰᵒˣ. These two membrane proteins together form 
flavocytochrome b ₅₅₈ (cyt b 558). For NOX2 to be activated it requires another three 
multidomain cytosolic proteins, P40ᴾʰᵒˣ, P47ᴾʰᵒˣ, and P67ᴾʰᵒˣ to be phosphorylated and 
translocated to bind cyt b 558 and form the activated complex. This activated complex 
demand another two proteins, Rac 2 and Rap1 to function properly (Panday et al., 2015). 
On the other hand NOX4 structure and activation needs only P22ᴾʰᵒˣ and polymerase δ-
interacting protein 2 (Poldip2) (Lyle et al., 2009) (figure 4.1). 
Vascular endothelium expresses four isoforms NOX1, NOX2, NOX4, and NOX5, although 
the predominant isoforms are NOX4 and NOX2. 
Figure 4. 1: NADPH oxidase and their isoforms subunits that are expressed in vascular 
endothelium. (Drummond & Sobey, 2014). 
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All enzymes in this family use NADPH as the electron donor to reduce oxygen O₂ to 
superoxide O₂˙⁻. The superoxide anion is transformed to H₂O₂ in a reaction that is 
spontaneous or catalysed by superoxide dismutase (SOD). However, NOX4 produces 
hydrogen peroxide directly due to the E-loop in its structure that contains highly 
conserved histidine which acts as a proton donor to readily dismutate superoxide to H₂O₂, 
such that NOX4 produces H₂O₂ without the O₂˙⁻ intermediate (Takac et al., 2012).  
NOXs have a specific function depending on their intracellular localisation. NOX2 is 
predominantly in the perinuclear space, cytoplasm and plasma membrane. NOX2 
activation is important for P38 MAP-Kinase-mediated ECs proliferation, and for vascular 
endothelium migration induced by VEGF. Also superoxide produced by NOX2 affects the 
bioavailability of NO, and increase the expression of ICAM and VCAM in the vascular 
endothelial cells (Konior et al., 2014). 
NOX4 is located in the endoplasmic reticulum, plasma membrane and perinuclear regions 
(Van Buul et al., 2005, Pendyala et al., 2009). Its activation will mediate the activation of 
p38MAPK, as well as Ras/ERK pathway, JNK and Akt (Lassegue & Griendling, 2010). NOX4 
has a role in promoting ECs angiogenesis through the activation of eNOS (Abid et al, 2000, 
Petry et al., 2006, Craige et al., 2011, Manuneedhi Cholan et al., 2017).   
NADPH oxidases can be activated by different triggers, such as cytokines tumor necrsis 
factor-α (TNF-α), transforming growth factor-β (TGF-β), and agonists like thrombin and 
angiotensin II (Ray & Shah, 2005). 
4.1.2.2 Xanthine oxidase:  
Xanthine oxidase is a superoxide and hydrogen peroxide producing enzyme. Xanthine 
oxidase belong to the xanthine oxidoreductase family, including xanthine oxidase and 
xanthine dehydrogenase. Xanthine oxidase enzyme produces ROS during the conversion 
of hypoxanthine to uric acid. These enzymes also need NADPH as their electron donor to 
oxidise oxygen. (Munzel & Gori, 2012). 
4.1.2.3 Mitochondrial electron transport chain: 
The main function of mitochondria is normally to yield energy through the formation of 
adenosine triphosphate (ATP). However, because of the low energy requirements of the 
endothelium, which depends mainly on glycolysis as a source of energy, mitochondrial 
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oxidative phosphorylation is not the main source of energy for these cells. Instead, 
mitochondria act more as signaling regulatory organelles that orchestrate intracellular 
haemostatic function through the production of ROS, which changes according to 
intracellular and extracellular environmental factors. Under normal condition nitric oxide 
has an inhibitory effect on mitochondrial ROS production, but when intracellular ROS 
increase this will lead to scavenging of NO by formation of peroxynitrite (Kojda & 
Harrison, 1999), and diminish the inhibitory effect of NO on mitochondria, resulting in 
increase in mitochondrial ROS.  
There is increasing evidence of the regulatory effect of mitochondrial ROS on the 
concentration of intracellular calcium through mitofusin-1 that links the calcium depot 
(endoplasmic reticulum) to mitochondria (Kaufman & Malhorta, 2014). Also increase in 
mitochondrial ROS increases the abundance of cytochrome c, the pro-apoptotic protein 
which results in activation of caspase and triggers apoptosis (Cai et al., 1998, Ott et al., 
2007). 
Mitochondria forms ATP in a process called oxidative phosphorylation, which uses either 
NADH (nicotinamide adenine dinucleotide) or FADH₂ (flavin adenine dinucleotide) as 
electron donors. During this process electrons leak from the mitochondrial electron 
transport chain that is formed from five complexes I, II, III, IV, V, and particularly from 
complex I  (NADH Coenzyme Q oxidoreductase), and complex III (cytochrome bc₁ 
complex) and bind oxygen to form superoxide. This superoxide is transformed to 
hydrogen peroxide with the help of mitochondrial superoxide dismutase (SOD-2) Mn-SOD 
(Han et al., 2001, Kadlec et al., 2016). H2O2 is highly diffusible and difusses from 
mitochondria to cytosol.  
In cystic fibrosis (Valdivieso & Santa-Coloma, 2013), epithelial CFTR defect occurs with 
abnormalities in mitochondrial structure and function. CFTR regulates mitochondrial 
genes CISD1 (Taminelli et al., 2008), and MT-ND4 (Valdivieso et al., 2007). Both of these 
genes are important for mitochondrial complex 1 subunit synthesis. Defects in CFTR or 
inhibition of CFTR channel activity down-regulated these genes. Also defects in 
mitochondrial Ca+ buffering to regulate Ca+ function was reported in CF cells (Antigny et 
al., 2009).  
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4.1.2.4 Uncoupled endothelial nitric oxide synthesis (eNOS): 
Although eNOS is responsible for the production of NO in the vascular endothelium, any 
disturbance in the cofactors or substrate that contribute to this process results in the 
formation of superoxide by eNOS instead of NO. In several pathological conditions this 
uncoupled eNOS is due to an abnormality in either oxidised or shortage of the 
tetrahydrobiopterin (BH4) cofactor, which stabilises the NOS isoform, leading to unstable 
eNOS and eventually production of superoxide. This malfunction of eNOS enzyme may 
also be due to a decrease in the L-arginine substrate for eNOS production of NO (Luo S et 
al., 2014). Both or any of those two defects ends in increase in oxidative stress due to 
increase production of superoxide. (Moens & Kass, 2006). 
There are additional ROS sources in the vascular endothelium, such as cytochrome p450 
monooxygenases and lipoxygenases (Guzik & Harrison, 2006). However, NADPH oxidase, 
xanthine oxidase, mitochondrial electron transport chain and uncoupled eNOS are the 
main sources. 
 
4.1.3 Anti-oxidative defence mechanisms in vascular endothelium  
In healthy, non-perturbed, vascular endothelial cells ROS are usually eliminated by 
different enzymatic and non-enzymatic mechanisms (Figure 4.2). Enzymatically, 
superoxide dismutase (SOD) activity converts superoxide to hydrogen peroxide, which is 
converted into water either by catalase or glutathione peroxidase. Alternatively, the free 
radical activity will be eliminated non-enzymatically through interaction with substrates 
such as glutathione. 
These mechanisms transform ROS from highly reactive free radicals into a lesser active 
one, reducing the harmful effect of ROS on the vascular intracellular compartment and 
prevent vascular endothelium dysfunction. 
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Figure 4. 2: Main sources of ROS in vascular endothelium: 
NOXs, mitochondria, eNOS. All the sources produce O₂˙⁻ with one exception of NOX4 that 
produces H2O2 directly. Free radicals are processed intracellularly by different enzymatic 
and non-enzymatic antioxidant defences which transform it finally to H2O2 under normal 
conditions. Extracellular superoxide dismutase (EcSOD), reduced glutathione (GSH), 
oxidized glutathione (GSSG), glutathione peroxidase (GPx-1), preoxiredoxin Prx (Lubos et 
al., 2011). 
 
4.1.3.1 Enzymatic antioxidants:  
4.1.3.1.1 Superoxide dismutase (SOD):  
SODs are the main enzymatic defence mechanism against superoxide. The enzyme is 
coded by gene 21, and it is upregulated when there is oxidative stress in the vascular 
endothelium. This enzyme has three isoforms, SOD1, SOD2, and SOD3. Both SOD1 and 3 
requires zinc and copper, while SOD2 requires manganese to be activated. These three 
isoforms differ in their distribution in the cells, SOD 1 is normally in the cytoplasm, SOD2 
in expressed mainly in the mitochondria and it scavenge the ROS that is generated from 
the oxidative phosphorylation, and finally SOD3 which works extracellularly.  
All three enzymes are expressed in vascular endothelium, and convert superoxide radicals 
O₂˙⁻ into hydrogen peroxide H₂O₂ (Equation 4.1).  
Equation 4.1: 
Enzymeₒₓ + O₂ˉ→Enzymered + O₂ 
Enzymered + O₂ˉ + 2H+ → Enzymeₒₓ +H₂O₂ 
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4.1.3.1.2 Catalase: 
This enzyme is ubiquitous intracellularly, where it can be found abundantly in 
peroxisomes. This enzyme is composed of four polypeptide chain, each chain contains a 
heme subunit in its structure (Chelikani et al., 2004). This enzyme uses NADPH as cofactor 
to prevent the deactivation of catalase by denaturation (Kirkman et al., 1987).  
Catalase decomposes hydrogen peroxide into water and oxygen (Equation 4.2). Usually 
catalase cooperates with glutathione reductase in turning hydrogen peroxide into water, 
each of these enzymes turn over 50% of the existing hydrogen peroxide (Gaetani et al., 
1994). The activity of catalase prevent H₂O₂ from entering the Haber-Weiss reaction 
(Equation 4.3) or Fenton reaction (Equation 4.4), if iron ions are available, and thus 
preventing the formation of highly toxic hydroxyl radicals.  
Equation 4.2:                                 2H₂O₂ + Catalase →2H₂O + O₂ 
Equation 4.3:                               H₂O₂ + Oˉ₂→ O₂ + OHˉ + OH• 
Equation 4.4:                              H₂O₂ + Mn+ → M(n+1) + OHˉ + OH• 
4.1.3.1.3 Glutathione peroxidase (GPx): 
Glutathione peroxidase is one of the tertiary structured antioxidant enzymes that have 
several isoforms (GPx1-8). The predominant isoform in the vascular endothelial cells is 
GPx-1. This isoform contains the selenocysteine amino acid residue in each of the four 
subunits. GPx-1 is highly expressed intracellularly, and is localised in the mitochondria, 
nucleus, and cytoplasm (Margis et al., 2008). GPx-1 uses glutathione to reduce hydrogen 
peroxide and lipid peroxides to corresponding alcohols (Equation 4.5) (Flohe, 1988, 
Arthur, 2000, Galasso et al., 2006). GPx-1 depends on glutathione for activity, 
subsequently it depends on glutathione reductase for supplying glutathione through 
conversion of oxidised glutathione to reduced glutathione.  
Equation 4.5:          H₂O₂ + 2GSH → GS-SG + 2H₂O. 
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4.1.3.1.4 Glutathione reductase (GR): 
Glutathione reductase is a homodimer enzyme which functions to supply reduced 
glutathione (GSH) from the oxidised glutathione (GSSG). This enzyme is present in the 
mitochondria and in the cytosol. GR function depends on two factors, NADPH+ cofactor 
and FAD prosthetic group. NADPH+ reduces FAD to FADH₂, then FADH₂ reduces oxidised 
GSSG to GSH (Couto et al., 2016). 
In addition to the previously mentioned major enzymes, there are several other effective 
anti-oxidative enzymes that are expressed by the vascular endothelium to help maintain 
the balance between oxidants and antioxidants, e.g. thioredoxins reductase and 
peroxiredoxins.  
4.1.3.2 Non-enzymatic antioxidants: 
Non enzymatic antioxidants include compounds that prevent the oxidative damage of 
protein, lipids and DNA. The major antioxidant molecules are: 
4.1.3.2.1 Glutathione: 
The tripeptide γ-glutamylcysteinylglycine (GSH), is a sulfhydryl containing thiol. It consists 
of glutamyl, cysteine and glycine (Figure 4.3). 
 
Figure 4. 3: Glutathione structure, (Van Haaften et al., 2003). 
GSH synthesis is controlled by glutamate cysteine ligase and GSH synthetase. GSH is a 
ubiquitous intracellular antioxidant that decreases pro-inflammatory cytokine production 
by lung endothelial cells through inhibition of activation of NF-kB by hydrogen peroxide 
(H₂O₂) (Antonicelli et al., 2002). GSH exist in two forms, either the thiol reduced form 
(GSH), or the oxidised glutathione disulfide (GSSG) form. In normal healthy cells, the 
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Glutathione reductase  
predominant form is the reduced form compromising almost 99% of total GSH (Akerboom 
et al., 1982). The ratio between the reduced and oxidised glutathione is used as a 
parameter for measuring oxidative stress in cells (Asensi et al., 1999) (Forman 
&Dickinson, 2003).  
GSH functions as an antioxidant through scavenging hydrogen peroxide, with the help of 
glutathione peroxidase (Equation 4.5). In this step GSSG is formed, and then GSSG can be 
reduced back to GSH through the action of glutathione reductase (Equation 4.6). In this 
GSH restoration step NADPH acts as an electron donor (Saydam et al., 1997). Glutathione 
also functions as a substrate for glutathione peroxidase (GPx) or peroxidases (Rhee et al., 
1999) to turn hydrogen peroxide and oxidised lipid to corresponding alcohol.  
Glutathione-s-transferase, has several isoforms, whose function is to catalyse the 
interaction between GSH and endogenous or xenobiotic electrophiles, usually epoxide of 
aromatic and aliphatic organic compounds in order to be eliminated (Hayes & Pulfrod, 
1995).  
Due to the role that NADPH plays in re-reducing GSH from the oxidised GSSG form, it can 
be considered to indirectly act as antioxidant that works as hydrogen anion donor to 
GSSG (Kirsch & De Groot , 2001)  
Equation 4.6: 
                          NADPH+                    NADP  
GSH (reduced)                                               GSSG (oxidised) 
               
4.1.4 Anti-oxidative role of transcriptional factors: 
4.1.4.1 Nuclear factor (erythroid-derived 2) related factor 2 (Nrf2): 
Nrf2 is a factor sensitive to oxidative stress in the vascular endothelium. Nrf2 increases 
expression of antioxidant phase 2 enzymes (Table 4.1) in response to oxidative stress 
(Baryn et al., 2013), and inhibits redox-sensitive inflammatory gene expression (Chen et 
al., 2005). 
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Nrf2 triggers the transcription of cytoprotective genes that coordinate the production of 
several antioxidant protein and detoxifying enzymes, and is the most extensively studied 
transcriptional factor from the Cap-N-Collar (CNC) subfamily of basic leucine zipper 
transcription factors. The CNC family consist of NEF2 (Nuclear factor-erythroid derived 2), 
and NEF2 related factors Nrf1, Nrf2, and Nrf3. Nrf2 is encoded by the NFE2L2 gene (Moi 
et al., 1994).  
Human Nrf2 consists of 605 amino acids, which form seven domains (Neh 1-7). One of 
these domains (Neh2) is for Keap-1 binding. Under normal conditions Nrf2 remains in the 
cytoplasm attached to its repressor molecule keap-1 (Kelch ECH associated protein 1) or 
what is called INrf2, as keap-1-Nrf2 complex (Figure 4.4), this attachment maintains low 
levels of Nrf2, which is regulated through the attachment of Keap-1 to Clu3 to form 
Culline-Ring E3 ligase complex that targets Nrf2 for ubiquitin dependent degradation by 
26S proteasome (Kobayashi et al., 2004, Kaspar et al., 2009, Canning et al., 2015). 
 
Figure 4. 4: Keap-1 suppressor effect on Nrf2: 
Under normal conditions Keap-1 directs Nrf2 to degradation by proteasomes after 
ubiquitination, while under oxidative stress conditions, Nrf2 is released from Keap-1 and 
translocated to the nuclei to increase the expression of antioxidant enzymes (Epinosa- 
Diez et al., 2015). 
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Neh2 is a basic leucine zipper Nrf2 domain though which Nrf2 forms heterodimer with 
small musculo-aponeurotic fibrosarcoma (Maf), (Itoh et al., 1997), sMaf facilitates Nrf2 
binding to antioxidant response element on the DNA in the nucleus and regulate the 
production of cytoprotective genes, detoxifying and antioxidant enzymes (Table 4.1)  
Table 4. 1: Nrf2/ARE regulated genes,  (Chen & Kunsch, 2004). 
 Genes 
Phase II detoxification 
enzymes  
NQO1, NQO2, GST-Ya, GST-pi, GST-theta 2, GST-mu (1, 2, 
3), Microsomal GST 3, γ-GCS, catalytic, γ-GCS, regulatory, 
Microsomal epoxide hydrolase, UDP—Glucuronosy 
Itransferase, Transaldolase, Transketolase, Drug-
metabolizing enzyme,  
Antioxidant  HO-1, Ferritin (L), Glutathion reductase, Glutathion 
peroxidase, Ferritin (H), Metallothionein I, Thioredoxin, 
Thioredoxin reductase, Peroxiredoxin MSP23, Cu/Zn 
superoxide dismutase, Catalase. 
NADPH generating 
system  
Malic enzyme, UDP-Glucose dehydrogenase, Malate 
oxidoredutase, Glucose-6-phosphate dehydrogenase 
Transcriptional factors  Nrf2  
 
Translocation of Nrf2 to the nucleus is activated by oxidative stress that induces 
phosphorylation of Nrf2 Ser 40 by protein kinase C ( PKCσ), and release of Nrf2 from 
Keap-1, followed by translocation of Nrf2 to the nucleus (Huang et al., 2002). 
Alternatively, phosphorylation of Nrf2 at serine 550 by AMPK leads to accumulation of 
Nrf2 in the nucleus (Joo et al., 2016). After the binding of Nrf2 to the antioxidant response 
element (ARE), Nrf2 exports from the nucleus due to phosphorylation of tyrosine 568 of 
Nrf2 by tyrosine kinase Fyn (Jain & Jaiswal, 2007). Another mechanism that lead to the 
determination of Nrf2 binding to ARE is through competition with Bach-1 that forms a 
heterodimer with small Maf to bind ARE at the same Nrf2 binding sites 
(Dhakshinamoorthy et al., 2005). 
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Keap-1 is enriched with cysteine residues of which Cys273, and Cys288 (Yamamoto T et 
al., 2008), are highly sensitive to oxidation, leading to change in the conformation of 
Keap-1 when there is oxidative stress in the cells. This conformational change frees Nrf2 
binding with Keap-1, Nrf2 is stabilised by phosphorylation and translocated to the 
nucleus.  
There are therefore multiple mechanisms involved in the activation of the Nrf2/ARE 
pathway and all of those pathway are triggered by changes in the redox status 
intracellularly. 
In the nuclei Nrf2 forms a heterodimer with small Maf (Li et al., 2008), this heterodimer 
binds to specific cis-acting enhancer called antioxidant response element (ARE), and it 
controls both constitutive and inducible gene expression (Nguyen et al., 2005), eg. 
Glutathione-s-transferase, NAD(p)H quinone oxidoreductase both 1 and 2 (NQO1, NQO2) 
(Rushmore et al., 1991, Joseph & Jaiswal, 1994) and others listed in table 4.1. 
Nrf2 therefore has an important role in protecting the lung from oxidative stress that is 
associated with lung inflammation, chronic obstructive pulmonary disease, and cystic 
fibrosis (Cho & Kleeberger . 2009) which is the focus in this study. 
4.1.5 Oxidative stress in CF and role of Nrf2 in protecting lung tissue from injury  
Oxidative stress causes lung damage in respiratory diseases, such as chronic obstructive 
pulmonary diseases, asthma, pneumonia and cystic fibrosis (Dworski, 2000, Cavailles et 
al., 2013, Kirkham & Barnes, 2013). In cystic fibrosis, oxidative stress due to inflammation 
and infection in the lung is augmented by additional malabsorption of antioxidants from 
the gastrointestinal tract, due to defects in CFTR in the pancreas and digestive system 
epithelium (Li & Somerset, 2014). However oxidative stress in CF lung epithelial cells was 
decreased after treatment with antioxidants, N-acetyl cysteine or selenium (Chen et al., 
2008). As well as clinical studies that showed that oral antioxidant supplementation (β-
carotene, CoQ10, ƴ-tocopherol, lutein) decreased systemic inflammation as well as 
lowered risk of first pulmonary exacerbation (Sagel et al., 2018). 
Oxidative stress in cystic fibrosis lung tissue has been widely investigated, not just 
because of the effect of free radicals on damaging important intracellular compartments, 
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but because oxidative stress down-regulates CFTR gene transcription and decreases CFTR 
protein expression (Cantin et al., 2006). 
Inflammatory cells (predominantly neutrophils) which are recruited in response to the 
elevated pro-inflammatory chemokines secreted from the CF epithelial cells and activated 
macrophages (Conese et al., 2003), are not just a source of numerous additional pro-
inflammatory cytokines, but also a source of ROS for their bactericidal function (Fruhwirth 
et al., 1998). 
In addition, epithelial CFTR mutations trigger increase of ROS in the airway through 
multiple pathways (Thomas et al., 2010). One of those is proposed to be defective CFTR-
mediated transport of GSH into the epithelial lining fluid, explaining the shortage of 
reduced GSH in epithelial lining fluid in CF patient. In addition a reduction in plasma level 
of reduced GSH is reported in CF patients (Roum et al., 1993, Gao et al., 1999, Hudson, 
2001). Also, CFTR defects resulted in decrease in intracellular concentration of 
thiocyanate, which removes hydrogen peroxide, because CFTR mediates transmembrane 
transport of thiocyanate (Pedemonte et al., 2007). 
 Defects in mitochondrial function correlated with defects in the CFTR ion channel in CF 
epithelial cells, especially in complex I, lead to increased production of ROS (Valdivieso et 
al., 2012, Valdivieso & Santa-Coloma, 2013). An increase in mitochondrial SOD2  in CF 
epithelial cells results in accumulation of hydrogen peroxide that originated from an 
increase in superoxide produced by mitochondria and NADPH oxidase (Pongnimitpraser 
et al., 2008, Pongnimitpraser et al., 2012), concomitant with decrease in catalase that 
usually converts hydrogen peroxide to H₂O (Chen et al., 2008) (Figure 4.5). 
The increase in mitochondrial SOD2, and decrease in catalase enzyme, led researchers to 
investigate the role of antioxidant response elements ARE and Nrf2 in CF epithelial cells. 
(Chen et al., 2008). 
Nrf2 is significantly (70%) downregulated in CF epithelial cells, resulting in a decrease in 
cellular antioxidant defence mechanism such as thioredoxins 1, and increase in oxidant 
burden in CF lung (Cantin et al., 2006, Chen et al., 2008). 
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Conversely, Nrf2 inhibits CFTR gene expression at the level of the CFTR gene promotors. 
Nrf2 has repressor effect on CFTR promotor mediated through YY1 (transcriptional 
repressor protein). Nrf2 induces YY1 nuclear translocation, and binding to CFTR promoter, 
which resulted in repression in CFTR transcription (Rene et al., 2010).  
Dysfunction of CFTR induces feedback increase cAMP intermediate signaling affecting the 
balance between NF-kB and Nrf2, with a decrease in Nrf2 activity and increase in NF-kB 
activity, shifting the cells dynamic balance from anti-inflammatory to pro-inflammatory, 
increase in cytokines and decrease in antioxidants (Zaidy et al., 2012).  
 
 
Figure 4.5: Dysfunctional CFTR in epithelial cells 
Dysfunctional CFTR disturbs the redox balance intracellularly resulting in an increase in 
hydrogen peroxide, and sequential increase in inflammatory cytokines (Chen et al., 2008). 
 
4.1.6 Vascular endothelial growth factor in cystic fibrosis: 
Vascular endothelial growth factors (VEGF) are a family of polypeptide growth factors, 
with main function to promote vascular angiogenesis and endothelial permeability in 
both normal and pathological conditions. The effect of VEGF is mediated through the 
activation of its transmembrane tyrosine kinase receptors, VEGFR1 (Flt-1), VEGFR2 (Flk-
1/KDR), and neuropilin-1/2 (Ferrera et al., 2003). Each of these receptors had specific 
function when activated by VEGF, the most important receptor responsible for 
angiogenesis is VEGFR2.  
Elevated VEGF is one of the features of cystic fibrosis, and is higher in CF serum than 
normal (McColley et al., 2000). VEGF promotes lung remodelling through peribronchial 
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angiogenesis resulting in increased incidence of lung haemorrhage in CF patients’, as well 
as haemoptysis (Flume et al., 2005). Through these newly formed blood vessels more 
inflammatory cells recruits, resulting in more cytokine production and reduction in lung 
functional capacity. 
The two main triggers of increased VEGF expression in CF are hypoxia via increased HIF-
1α expression (Gerber et al.,1997), and the increase in pro-inflammatory cytokines, such 
as IL-6, IL-8, TNF-α and TGF-α and β (Maloney & Gao, 2015). Hypoxia and induced 
inflammatory cytokine expression are two factors which are associated with the defect in 
CFTR (Martin et al., 2013). Hypoxia is associated with oxidative stress, a factor that 
increases VEGF expression in alveolar epithelial cells (Pham et al., 2002).  
In the vascular endothelial cells angiogenesis is controlled by ROS (Figure 4.6) primarily 
produced by NOX-4 and NOX2. Silencing of NOX2, NOX4, or overexpressing of 
mitochondrial catalase in endothelial cells inhibited VEGF mediated dimerization and 
autophosphorylation of VEGFR2 receptor (Kim & Byzova, 2014). Thus, indicating a role for 
H2O2. Treating endothelial cells with antioxidants (N-acetylcysteine) inhibited 
angiogenesis (Caiet al., 1999).  
ROS induces angiogenesis is strongly associated with ROS ability to increase VEGF 
expression in ECs (Chua et al., 1998). And increased VEGF stimulates production of more 
ROS through the activation of NOX2, NOX4 and mitochondrial ROS. Increased ROS in 
endothelial cells intermediate the action of VEGF on VEGFR2 receptor (Kim et al., 2017). 
VEGF activate VEGF-R receptor through autophosphorylation of tyrosine kinase, ROS is 
essential for the autophosphorylation of VEGF-R receptor. Furthermore increased 
intracellular ROS activates hypoxia induced factors-1 (HIF-1). This factor (HIF-1) activates 
the expression of VEGF (Ushio-Fukai, 2006), and stimulate angiogenesis after stimulation 
of VEGFR2 receptor (Figure 4.6). 
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Figure 4.6: ROS induce angiogenesis through multiple pathways 
Either directly through VEGF, or VEGF independent pathways through oxidation of lipids 
(Kim & Byzova, 2014) 
 
4.2 Aims and objectives: 
The aim of the experiments described in this chapter are to investigate the effect of CFTR 
channel function on endothelial oxidative stress. The objective was to use 
pharmacological inhibition of CFTR channel activity to examine free radical (ROS and 
H2O2) production, changes in anti-oxidant enzymes and changes in Nrf2 transcriptional 
factor expression. A further objective was to examine the role of CFTR and ROS in the 
regulation of VEGF protein expression using ELISA to quantify VEGF. 
 
4.3 Materials and methods: 
4.3.1 HLMVECs Intracellular ROS detection  
Intracellular ROS in HLMVECs were measured by changes in ROS levels at fixed time 
points (5, 10, 30 minutes) in cells seeded in 96-well plates, and also by detecting ROS with 
live cell imaging. 
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The probe which was used for both methods was 5-(and -6)-carboxy-2′, 7′- 
difluorodihydrofluorescein diacetate (carboxy-H2DFFDA) 10 µM prepared freshly in HBSS 
(+Ca/Mg) with each experiment. Cells were incubated with this probe for 30 minutes, 
washed with HBSS (+Ca/Mg), then incubated with FGM for 30 minutes to allow the 
esterase activity in the cells to remove the acetate group from H₂DFFDA, this made the 
probe more functionally stable intracellularly, washed again with HBSS (+Ca/Mg), then 
stimulated with GlyH (20 µM) and TNF-α (10 ng/ml) for up to 30 minutes  in the absence 
and presence of NAC, CuT, followed by oxidation of the reduced probe by intracellular 
ROS.  
 
4.3.2 Live cell images for ROS detection: 
HLMVECs (25 X 104 cells/dish) were seeded in 35 mM petri dish coated with collagen (IV), 
in 2 ml of FGM. The cells were left to attach overnight, washed with HBSS (+ Ca/Mg) once, 
then incubated for 30 minutes at 37⁰C and 5% CO₂ with Carboxy H₂DFFDA 10 µM 
dissolved in HBSS (+Ca/Mg), washed again with HBSS (+Ca/Mg), then the washing buffer 
was replaced with FGM for 30 minutes, meanwhile the cells were challenged with GlyH 
101 (20 µM), the images was recorded using 5.10 ZEISS microscope with immersion 
objectives, and stage with temperature controlled (37 °C). Cells were kept on this stage 
for 30 minutes without 5% CO₂. This experiment was repeated once to determine 
optimum time course to detect ROS. 
4.3.3 96-well plate ROS detection: 
HLMVECs (8X 10³ cells/well/100 µl of FGM) were seeded in 96-well plate (Thermo Nunc, 
Cat: 165305), coated with collagen IV (Sigma C-5533), and cells were left to attach 
overnight. Next morning antioxidant treatments (NAC, CuT) were added for three hours in 
FGM. After removing the medium with the treatments the cells were washed, and the 
detector Carboxy H₂DFFDA (5-(and-6)-carboxy-2′,7′-difluorodihydrofluorescein diacetate) 
(Invitrogen C13293), dissolved in HBSS (+Ca/Mg) was added to the concentration 10 µM. 
H₂DFFDA was incubated with the cells for 30 minutes in no direct light. The cells were 
washed again with HBSS (+ Ca/Mg), the washing buffer then was replaced with FGM. 
Depending on the plan, antioxidant treatment were refreshed, and the cells were 
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challenged with GlyH-101 (20 µM), and TNF-α (10 ng/ml) for 5, 10 and 30 minutes. All of 
the treatments and the washes were 100 µl volume. The plates were read in temperature 
controlled (37 °C), CO₂ 5% supplied plate Polar Star Optima plate reader. The excitation 
was 485 and the emission 520. 
HLMVECs used in these experiments were from three different donors (all were provided 
by Lonza), and different passages (7-9), each experimental condition was tested in 
triplicate and experiments repeated 6 times. The results of fluorescent intensity changes 
were expressed as percentage of changes as the baseline of each experiment is different.  
4.3.4 Hydrogen Peroxide detection: 
H2O2 detection was based on the method of Chen et al. (2008). In this experiment, 
HLMVECS were seeded in 24-well plates (5 X 104 cell/well/ 300 µl FGM) (Chapter 2, 
section 2.1.3). 
The cells were left to attach overnight, and next day medium was refreshed. Wells were 
loaded with medium with and without diphenyleneiodonium chloride (DPI) (Sigma, 
D2926) at a working concentration of 10 µM for one hour, then the cells were challenged 
with CFTR inhibitor GlyH-101 (20 µM) and its control DMSO (0.1 %) which was added for 
(5, 10, 30 minutes). H2O2 was measured in both supernatant, and cell lysate. Cells in each 
well were lysed in 125 µl of hypotonic lysis buffer (20 mM NaCl, 1% Triton X-100, 20 mM 
Tris-base, and pH to 7.4) with protease inhibitors (Calbiochem), phosphatase inhibitors 
(PhosSTOP, Roche, 04906845001), and sodium azide (0.1% w/v) to inhibit catalase and 
peroxidase activity in cell lysate.    
Standard, supernatant and cell lysate (50 µl each) were loaded in duplicate in to 96-well 
plate. Then 50 µl of 100 µM of Amplex Red reagent (Invitrogen) containing 0.2 U/ml of 
horseradish peroxidase (HRP) diluted in PBS without Ca/Mg, was added to the wells. 
The plates were incubated at 370 C for 30 minutes, with no direct light. The absorbance 
was measured at 550 nm. Optical density results were converted to H2O2 concentration 
by the mean of standard curve that ranged from (3.125- 200 µM). 
62 
 
4.3.5 SOD2 detection: 
SOD2 levels were measured in cell lysates (Chapter 2 section2.3.2.1) after HLMVECs were 
challenged with GlyH-101 (20 µM) for 6, 16, 24 hour and DMSO (0.1% v/v) control. CuT 
was tested with 24 hour challenge with GlyH-101 at concentration of 1µM, CuT was 
added 3 hours before GlyH-101, and was refreshed when GlyH-101 were added to the 
cells (a total of 27 hour for incubation with CuT). After the treatment was finished, cells 
were lysed with hypotonic lysis buffer (Chapter 2), samples were stored at -80 ᵒC till 
analysis of SOD2 by Human SOD2 ELISA Kit (Abcam, ab119694) according to 
manufacturer’s instructions.  
SOD2 was measured in HLMVECs lysate neat, the concentration were obtained after 
calculation of the absorption in comparison with standard curve prepared in range (7.8-
500 ng/ml). Experimental conditions were carried out in triplicate, and each experiment 
repeated 3 times. 
4.3.6 Catalase detection: 
Catalase was measured in HLMVECs cell lysate (Chapter 2 section 2.3.2.1) using catalase 
ELISA kit (Abcam, ab123456-Catalase Human ELISA Kit). HLMVECs were challenged with 
GlyH-101 (20 µM) for 6, 16, 24 hour. And the results were compared with DMSO (0.1% 
v/v). The standard curve was prepared between (7.8 and 500 ng/ml). The samples were 
measured neat, and the protocol for this kit was provided by the manufacture. 
Experimental conditions were carried out in triplicate, and each experiment repeated 3 
times. 
4.3.7 VEGF detection: 
VEGF was measured in HLMVECs supernatant by ELISA kit (Human VEGF DY293B R & D 
Systems). The cells were incubated in 24-well plates to investigate the concentration 
response curve of GlyH-101, and in 6-well plate to test the effect of antioxidants on VEGF 
levels. Both of the seeding surfaces were pre-coated with collagen (IV). The cells were left 
to attach overnight. The next morning, for the concentration response curve, cells were 
treated with GlyH-101 (5, 10, 20 µM), in the absence and presence of TNF-α (10 ng mlˉ¹).  
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In separated experiments, cells were treated with NAC (5mM), CuT (1µM) and the EGFR 
inhibitor AG-1478 (10µM) for 3 hours, followed by incubation with GlyH-101 (20 µM) 
alone, and with TNF-α (10 ng mlˉ¹) for 16 and 24 hour.  
After the treatments were finished the supernatants were collected and processed 
(Chapter 2). Samples were diluted 1:2 in reagent diluent (1%BSA in PBS without Ca/Mg), 
to allow detection of VEGF within the range of standard (31.22- 2000 pg/ml). Samples 
were measured following the instructions provided by the manufacturer. 
4.3.8 Nrf2 detection  
4.3.8.1 Nrf2 Immunocytochemistry: 
HLMVECs were seeded in 8-well chamber slides (Thermo scientific: 177402), 2 X 10⁴ 
cell/well in 0.25 ml of FGM. Slides were pre-coated with collagen (IV). The cells were left 
to attach overnight. The next day, medium was refreshed and the cells were challenged 
with GlyH-101 (20µM) and DMSO (0.1% v/v) control for 16 hour. After the treatment was 
finished the slides were fixed in 4% (w/v) paraformaldehyde and permeabilized in 0.1 % 
of Triton-X 100 (Chapter 2, section 2.5). 5% goat serum blocking buffer (Sigma, G 9023) 
was incubated with the cells overnight at 4°C. The primary antibody to Nrf2 (rabbit 
polyclonal anti-Nrf2, 200 µg ml ⁻¹, Santa Cruz) was diluted 1/50 to the concentration of 4 
µg ml⁻¹, and prepared in blocking buffer (200 µl/well). The cells were incubated with the 
primary antibody for one hour at 4°C, and one well from each slide was incubated with no 
primary antibody as a control. The cells were washed with 400 µl/well for three times 
with PBS (without Ca/Mg). Then the fluorescent secondary antibody, Alex Fluor 555 goat 
anti rabbit IgG (2 mg ml⁻¹; Molecular Probes, A21430), was diluted (1/1000) in PBS 
(without Ca/Mg) containing 5% goat serum to the concentration 2 µg ml⁻¹and 200 µl was 
added to each well, incubated with the cells for one hour at RT. After washing step in 400 
µl of PBS (without Ca/Mg) for three times, the slides were visualised as described in 
chapter 2 section 2.5. 
4.3.8.2 Nrf2 Western blotting: 
HLMVECs were seeded in 24-well plates (5 X 10⁴ cell/well) in 0.3 ml of FGM, coated with 
collagen (IV).  After the treatments of the cells, the supernatants were collected 
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centrifuged for 10 minutes at 1500 g at 4⁰ C, and kept in -80 ⁰C. The cells were washed 
with 0.5 ml of PBS (-Ca/Mg), followed by the addition of 2X reducing sample buffer 
(Chapter 2 Sec 2.3.2.2) was added (35 µl /well). The plates were placed on ice, and the 
cells were scraped. The cell lysates were collected, transferred to Eppendorf tubes, and 
heated in a water bath for 20 minutes at 50 °C.  
The samples were analysed on 10% SDS-PAGE (Chapter two, section 2.4), and transferred 
onto 0.45µm nitrocellulose membrane Bio-Rad; 1620115). The membrane was blocked 
with 5 % (w/v) skimmed milk powder dissolved in PBS (-Ca/Mg) with 0.1% Tween-20, 
overnight at 4°C on a roller mixer. The next day the membrane was stained with the 
primary Nrf2 antibody (rabbit polyclonal anti-Nrf2, 200 µg ml ⁻¹, Santa Cruz, Sc-722) 
diluted 200 fold (1 µg ml⁻¹ working concentration) in 4 ml of 5% blocking buffer with 0.1% 
Tween-20 for one hour at RT rolling in 50 ml tubes. After washing the blots with PBS-T 
(without Ca/Mg), the membrane was incubated with the secondary antibody, goat anti-
rabbit-HRP (Dako, P0448, 0.25 g/l), working dilution 1/2000 (0.125 µg mlˉ¹) for one hour 
ar RT, the blots were washed with PBS (without Ca/Mg) containing 0.1% Tween-20, for 
three times, then with PBS (without Ca/Mg) for 3 times.  
Blots were incubated for 5 minutes in the dark with chemiluminescente substrate 
(Promega; W1015), allowing HRP to oxidise luminol to emit light, followed by detection of 
the bands with Bio-Rad ChemDoc western blot imager.  
The bands were normalised to β-actin (Chapter 2 Section 2.4), and compared with the 
control.  
4.3.9 Copper tobramycin synthesis: 
Copper tobramycin was prepared to use as a novel antioxidant (Gziut et al., 2013). 
Tobramycin sulphate (Sigma), (0.25 mmols, 0.1169 g) was dissolved in 5 ml of ultrahigh 
quality water, and copper sulphate (Sigma) (0.25 mmols- 0.0624 g) added and mixed 
overnight at RT.  
Next day ethanol (3.3 ml) was added to reach 40 % final concentration, to remove free, 
uncomplexed tobramycin from the solution. Ethanol precipitated copper- tobramycin as a 
blue solid. The precipitant was recovered by centrifuging the suspension at 3000 rpm for 
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10 minutes at 10 °C, and the supernatant was discarded. The blue pellet was washed with 
5 ml of 100% ethanol, mixed vigorously to break it up, then the tube was placed on the 
roller mixer for three hours. The precipitate was recovered by centrifugation with the 
same condition. The washing was repeated for the second time for three hours, followed 
by centrifugation at 3000 rpm for 10 minutes, the supernatant was discarded and the 
pellet was dried under vacuum for one hour at 30 °C.  
4.4 Results: 
This section presents the results for the effect of CFTR inhibition using GlyH101 on 
intracellular ROS, Nrf2, and VEGF production by HLMVECs.  
4.4.1 Detection of ROS by live cell imaging: 
ROS was imaged in HLMVECs after the cells were incubated with carboxy H2-DFFDA (10 
µM) for 30 minutes. GlyH-101 (20 µM) was added with the medium, and changes in ROS 
levels were recorded as images taken while ROS was being generated intracellularly. 
Images were taken at zero time, and after 10, and 30 minutes of adding GlyH 101 (20µM).  
Low level of ROS were observed at time zero (A), and after 10 and 30 minute increasing 
ROS level (B and C). The staining pattern was punctate, indicating predominately a 
mitochondrial source of ROS (Figure 4.7 C)  
A:   0 minute                             B: 10 minutes                            C: 30 minute 
Figure 4.7: Increase in intracellular ROS in HLMVECs after adding GlyH 101 (20µM) 
Intracellular ROS in HLMVECs was detected by carboxy H2-DFFDA 10µM, incubated with the cells 
for 30 minutes in HBSS (+Ca/Mg), then GlyH 101 (20 µM) was added and the fluorescence was 
detected at (A: 0, B: 10, C: 30 min) following adding GlyH 101. Scale bar 50 µM. images 
representative of one experiment at each time point. 
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4.4.2 Effect of CFTR inhibition on intracellular ROS levels in HLMVECs: 
To test the effect of CFTR inhibition on intracellular ROS production, HLMVECs in 96-well 
plates were treated with CFTR inhibitor GlyH-101 (20 µM). Changes in fluorescent 
intensity detected with DFFDA were compared with GlyH 101 vehicle (DMSO 0.1% v/v). 
TNF-α (10 ng/ml) was used as positive control and compared to media alone (FGM).  
Changes in fluorescent intensity were recorded after 5, 10 and 30 minutes of treating 
HLMVECs with GlyH-101 (20 µM) and TNF-α (10 ng/ml). A significant increase was seen as 
early as 5 minutes after adding both of these reagents (Figure 4.8). For TNF, ROS levels 
were elevated to 165.18 ±35.13 % in comparison with control cells in FGM, and GlyH-101 
gave 170 ±11.5 % increase in ROS in comparison with cells that were incubated with 
DMSO. There was no significant difference in the magnitude of the effect between the 
stimuli at this time point.  
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Figure 4. 8: Intracellular ROS in activated endothelial cells: 
HLMVECs were incubated for 5-30 minutes in the absence and presence of GlyH 101 20 µM, and 
TNF-α (10 ng/ml). ROS were detected by intracellular DFFDA. The experiments were conducted in 
triplicate, n=6 independent experiments for GlyH-101, and n=3 for TNF-α. Data points represent 
the mean ± SEM. Results were analysed with two-way ANOVA, then with Tukey’s multiple 
comparisons test. (**** P value ≤0.0001, *** P value ≤0.001) comparing GlyH to control and (** P 
value≤ 0.01) comparing TNF to control, (††P value ≤0.01) comparing between TNF-α and GlyH, († 
P value ≤ 0.05) comparing GlyH and TNF-α. 
 
 
The effect for GlyH-101 continued over 10-30 minutes and ROS fluorescence was 164.45 ± 
9.9 %, of control at 10 minutes. The effect of GlyH-101 was significantly different to 
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control (p ≤ 0.0001), and significantly different to TNF-α (p ≤ 0.01), at this time point, 
while the TNF effect on ROS had disappeared by 10 minutes. 
The effect of GlyH-101 lasted for 30 minutes, and was still elevated above control. ROS 
fluorescent intensity was 128.1 ±7.6 % at this time point, and was significantly higher 
compared to the effect of TNF-α, which had returned to control levels. 
4.4.3.  The effect of HLMVECs treatment with antioxidant on intracellular ROS:  
In view of the increase in ROS with GlyH-101, the effect of the known antioxidant (NAC, 
10 mM), and the novel antioxidant (CuT, 0.5 and 1 µM) were tested on the cells at 5, 10, 
and 30 minutes of incubation with GlyH-101 (20 µM).  Early experiments indicated no 
effect of either antioxidant NAC and CuT at 5 minutes (not shown) or 10 minutes (Table 
4.2). 
However, at 30 minutes incubation with GlyH-101, both NAC (10 mM) and CuT (1 µM) 
significantly reduced intracellular ROS (Figure 4.9). GlyH-101 (20 µM) for 30 minutes 
increased fluorescent intensity to 128.1 ±7.6 % compared to DMSO. The cells which were 
treated with CuT (0.5 µM) reduced ROS intensity to 88.3 ± 11.7 %, and with higher 
concentration of CuT (1 µM) ROS was significantly lowered from 128.1 ±7.6 %  for 30 
minutes GlyH-101 to 53.4 ± 23.1 % fluorescent intensity (P <0.05) in comparison to the 
effect of 30 minutes GlyH 101. NAC (10 mM) significantly reduced the level of (** P value 
<0.01), compared with cells challenged with GlyH-101 for 30 minutes without treatment 
with antioxidants. NAC not only reversed the effect of GlyH-101 on ROS level, but even 
significantly reduced baseline level of ROS in HLMVECs to 42.8 ± 28.1 % fluorescent 
intensity.  
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Figure 4.9: The effect of antioxidant treatment on elevated ROS due to CFTR inhibition: 
HLMVECs ROS levels expressed as percentage to DMSO (0.1%) vehicle. The results of the 
effect of ROS levels were analysed with one way ANOVA and Tukey’s multiple 
comparisons test. Date point represent the mean ± SEM.  (* P value ≤ 0.05) comparing of 
CuT (1µM) + GlyH treatment to GlyH, (** P value ≤ 0.01) comparing NAC (10 mM) +GlyH 
to GlyH, († P Value ≤ 0.05) comparing NAC (10 mM) +GlyH to DMSO control. (n=6). 
 
Table 4.2: Percentage ROS changes after activation of ECs and treatment with 
antioxidant. 
Percentage of changes in ROS levels in HLMVECs compared with the control DMSO. Table 
shows the changes in ROS after treating the cells after 10, and 30 minutes incubation with 
CFTR inhibitor. n.s.= non-significant.   
Condition  10 minutes 30 minutes P value  
Control DMSO (0.1%) 100 % 100 %  
GlyH-101 (20 µM) 164.5 ± 9.9 % **** 128.1 ± 7.6 % P < 0.0001 vs DMSO 
GlyH-101+ NAC (10 mM)  156.9 ± 50 %  42.8 ± 28.1 % ** P < 0.01 vs GlyH-101 
GlyH-101+ CuT (0.5 µM) 224.3 ± 44.7 % 88.3 ± 11.7 %  n.s. 
GlyH-101+ CuT (1 µM) 255.4 ± 92.4 % 53.4 ± 23.1 %* P < 0.05 vs GlyH-101 
GlyH-101+CuSo₄ (0.5 µM) 164.98 ±17.6 % 101.6 ± 24.4 % n.s. 
GlyH-101+ CuSo₄ (1 µM) 141.3 ± 13.8 % 85.5 ± 11.2 % n.s. 
GlyH-101+ Tob (0.5 µM) 259.6 ± 64.5 % 127.3 ± 22.2 % n.s. 
GlyH-101+ Tob (1 µM) 248.3 ± 54.7 % 115.6 ± 17.3 % n.s. 
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As a control for the effect of CuT on ROS levels, both copper sulphate CuSO₄ (0.5 and 1 
µM), and tobramycin (0.5 and 1 µM) were tested for their effect on ROS levels after GlyH-
101 (20 µM), the data in table 4.2 shows no effect of tobramycin or CuSO4 on intracellular 
ROS. (n=3) independent experiments, and each experiment was done in triplicate.  
 
4.4.4 Effect of CFTR inhibitor on hydrogen peroxide in HLMVECs lysate:  
H2O2 was measured in both HLMVECs supernatants and cell lysates, in the absence and 
presence of the NADPH oxidase inhibitor, diphenyleneiodonium (DPI), for one hour. H2O2 
levels in supernatant were undetectable. DPI did not influence H2O2 levels in cell lysate.  
H2O2 concentrations after 5 and 10 minutes of treating the cells with CFTR inhibitor GlyH-
101 was 12.6 ± 4.4 µM and 16.1 ± 1.6 µM, respectively, with no significant difference 
between GlyH-101 and its vehicle control (0.1% DMSO) at the  two time points. Whereas 
H2O2 concentration was 23.4 ± 3.7 µM and 12.5 ± 6.7 µM, respectively in control wells. 
 After 30 minutes of CFTR inhibition with GlyH-101, H2O2 significantly increased (36.1 ± 
2.7 µM) in comparison to 5 and 10 minutes treatments with GlyH-101, and significantly 
higher than 0.1% DMSO H2O2 concentrations at 30 minutes,  13.2 ± 2.5 µM (Figure 4.10).  
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Figure 4. 10: Effect of CFTR inhibitor GlyH-101 on H2O2 concentration in HLMVECS cell lysate: 
A significant increase in H2O2 concentration after 30 minutes of treating cells with GlyH-101 for 
30 minutes (* p value ˂ 0.05 in compare to 10 minutes glyH-101, **p values ˂ 0.01 in compare to 
5 minutes GlyH-101 treatment, n=4), data were analysed with two way ANOVA and Tukey`s 
multiple comparison test. († p value ˂ 0.01, in comparison to DMSO after 30 minutes, n=4), data 
were analysed with two way ANOVA and Sidak`s multiple comparison test. Data were expressed 
as average ± SEM. 
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4.4.5 The effect of CFTR inhibitor on SOD2 levels in HLMVECs lysate: 
SOD2 was detected in HLMVECs lysate after treatment with GlyH-101 (20 µM) for 6, 16, 
24 hour, and the effect of CuT (1 µM) on SOD2 levels were analysed after 24 hour 
incubation with GlyH-101.   
GlyH-101 (20 µM) increased SOD2 in a time dependent manner from 81.1 ± 23.6 ng mlˉ¹ 
in control cells to 111.8 ± 3.1 ng mlˉ¹ after 6 hours of inhibition of CFTR. After 16 hour 
SOD2 levels increased significantly to 133.6 ± 13.3 ng mlˉ¹, and at 24 hour SOD2 in the cell 
lysate reached to 159.1 ± 5.2 ng mlˉ¹ which was significantly higher than control ( ** p 
value < 0.01). CuT significantly decreased SOD 2 level from 159.1 ± 5.2 ng mlˉ¹ with GlyH-
101 24 hour to 111.3 ± 7.7 ng/ml (Figure 4.11).  
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Figure 4. 11: Time dependent changes in SOD2 with CFTR inhibitor GlyH-101. Changes in 
SOD2 levels in HLMVECs cell lysate over time after CFTR inhibition with GlyH-101 (20 µM) 
were measured by ELISA, (**p value <0.01) compare with the control. Data were analysed 
with one way ANOVA, and Fisher test. n=3. (*, p < 0.05, **, p value <0.01 compare to 
control. †, p value <0.05 compare CuT (1µM +GlyH to GlyH101 alone at 24 hour) 
4.4.6 The effect of CFTR inhibition on catalase in HLMVECs lysate: 
Levels of catalase in the HLMVECS lysates were low and treatment with the CFTR inhibitor 
GlyH 101 (20 µM) for 6, 16, 24 hours did not significantly affect enzyme levels (Figure 
4.12) when compared to the 0.1% v/v DMSO control.  
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Figure 4. 12: Changes in Catalase in HLMVECs lysate after inhibition of CFTR at different 
time points Changes in catalase enzyme concentration in HLMVECs lysate after inhibition 
of endothelial CFTR by GlyH-101 (20 µM) over time were not significant. Experimental 
conditions were repeated in triplicate in each of three independent experiments. 
 
4.4.7 The effect of CFTR inhibition on Nrf2 protein level in HLMVECs: 
To investigate the effect of inhibition of CFTR on Nrf2 expression in HLMVECs. HLMVECs 
seeded in 8 well chamber slides coated with collagen IV were treated with GlyH-101 (20 
µM), CFTR inhibitor was incubated with the cells for 24 hours alone, and with CuT (1, 10 
µM) for 3 hours prior to adding GlyH-101. The cells were immunostained for Nrf2. The 
images (Figure 4.13) shows that Nrf2 was predominantly in the cytoplasm in control cells. 
There was a decrease in the intensity of cytoplasmic Nrf2 after 24 hours incubation with 
GlyH-101, compared with cells that were treated with DMSO (0.1%) as a control. Residual 
Nrf2 appears to be in nucleus the (arrow).Conversely, in the presence of the antioxidant 
CuT (1, or 10 µM), Nrf2 remained in the cytoplasm, and did not appear to be a decrease in 
expression at either concentration tested. Since 1 µM CuT was as effective as 10 µM CuT, 
1 µM was used in the quantitative analysis of NrF2 expression by Western blot. 
 
 
 
72 
 
 
 
 
Figure 4. 13: Nrf2 immunocytochemistry in HLMVECs treated with GlyH-101: 
Nrf2 immunocytochemistry, A: No primary antibody control, B: DMSO (0.1 % v/v) control, 
(C) The effect of CFTR inhibition by GlyH-101 (20 µM). D: E: the influence of the novel 
antioxidant CuT at 1, and 10 µM (D and E) in protecting Nrf2 against the effect of GlyH-
101 (20 µM). Arrows point nuclei shows the difference between GlyH-101, where NrF2 is 
in the nuclei, while in control and cells treated with CuT, Nrf2 was in cytoplasm. Scale bar 
50 µm. Images are representative of 2 independent experiments. 
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4.4.8 Quantitative analysis by Western blotting of the changes in Nrf2 protein 
expression in HLMVECs after inhibition of CFTR: 
Confluent HLMVECs grown in 24-well plates coated with collagen (IV), were treated with 
GlyH-101 (20 µM) as a model of CF endothelium. The effect of inhibition of CFTR on Nrf2 
expression was time-dependent over 6, 16 and 24 hour. The transcriptional factor Nrf2 
was detected as single band at ≈ 85 kDa (Figure 4.14). Inhibition of endothelial CFTR with 
GlyH-101 decreased the abundance of Nrf2 after 6 hours of treatment, and after 24 hour 
Nrf2 was significantly decreased by 70.8 ± 11.6 %. Treatment of HLMVECs with CuT (1 
µM) for three hours before adding GlyH-101 in the example shown, appeared to fully 
restore Nrf2 levels, However, on average CuT rescued 15.01 ± 8.9 % of Nrf2. The blot 
shown in figure 4.14 is representative of three independent experiment for HLMVECs 
from three different donors. Nrf2 levels were normalised to β- actin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 14: Nrf2 expression level after inhibition of CFTR in HLMVECs: 
Decrease in Nrf2 levels in HLMVECs cell lysate after treatment with GlyH-101 (20 µM) for 
6, 16, and 24 hour Bars indicate mean ± SEM (***p value <0.001) comparison of GlyH-101 
24 hour with control, n=3 independent experiments. 
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4.4.9 The effect of CFTR inhibition on VEGF levels in HLMVECs: 
Since oxidative stress follows CFTR inhibition using GlyH-101, and VEGF expression is 
increased by oxidative stress, the effect of GlyH on VEGF expression was analysed.  
VEGF levels were investigated after inhibition of CFTR with GlyH-101 in a concentration 
dependent manner 5, 10, and 20 µM for 16 hour. The concentration of VEGF in HLMVECs 
control supernatant (0.1% DMSO) was 78.0 ± 6.9 pg mlˉ¹. GlyH-101 at (5µM) 
concentration did not change VEGF concentration  77.14 ± 6.8 pg mlˉ¹, 10 µM of GlyH-101 
elevated VEGF to 111.2 ± 7.8 pg mlˉ¹, but a significant increase in VEGF levels were seen 
with 20 µM of GlyH-101 which gave a concentration of 168.8 ± 14.5 pg mlˉ¹ (Figure 4.15).  
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Figure 4.15: Concentration dependent changes in VEGF concentration in HLMVECs 
supernatant: 
VEGF levels after 16 hour CFTR inhibition with GlyH-101 increased in a concentration (5, 
10, 20 µM) dependent manner.  VEGF was measured by ELISA. VEGF concentrations were 
expressed as average ± SEM (*** p value < 0.001, n=3) comparing control with 24 hour 
GlyH-101.Data were analysed with one way ANOVA test and Dunnett’s multiple 
comparison test, n=3 independent experiments, each carried out in triplicate. 
 
VEGF concentration was also measured in HLMVECs supernatants after treating the cells 
with TNF (10 ng mlˉ¹) for 16 hour (Figure 4.16). Concomitantly the cells were treated with 
GlyH-101 in a concentration dependent manner (5, 10, 20 µM) to measure if there is 
additive effect of GlyH-101 to TNF in influencing VEGF concentration. TNF alone increased 
VEGF from 78.0 ± 6.9 pg mlˉ¹ at baseline to 204 ± 76.5 pg mlˉ¹ after 16 hour treatment 
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with TNF-α (10 ng mlˉ¹). GlyH-101 (5 µM) added with TNF-α increased VEGF to 278.4 ± 
88.9 pg mlˉ¹, and GlyH 101 (10 µM) increased VEGF to 305.1 ± 97.4 pg mlˉ¹. And GlyH-101 
(20 µM) added to TNF-α (10 ng mlˉ1) gave a significant increase to 401.2 ± 85.4 pg mlˉ¹ 
VEGF concentration in HLMVECs supernatant. That indicate that TNF-α enhanced the 
effect of GlyH-101 and increased VEGF from 168.8 ± 14.5 pg mlˉ¹ for GlyH-101 alone at 
(20 µM) (Figure 4.15), to 401.2 ± 85.4 pg mlˉ¹ VEGF concentration when the cells were 
treated with GlyH-101 (20 µM) and TNF-α (10 ng mlˉ¹). (Figure 4.16)  
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Figure 4.16: Concentration dependent additive effect of GlyH-101 to TNF-α on VEGF 
level in HLMVECs: 
 
VEGF concentrations in HLMVECs supernatants were measured by ELISA after treatment 
of endothelial cells with TNF-α (10 ng mlˉ¹), alone and with GlyH-101 with range of 
concentrations from (5 – 20 µM) for 16 hour. Concentrations were expressed as average ± 
SEM (*p value < 0.05) comparing TNF-α and GlyH-101 (20 µM) with control. n=3 
independent experiments, each carried out in triplicate. Data were analysed with one way 
ANOVA and Fisher post hoc test. 
 
4.4.10  The effect of CFTR inhibition and antioxidants on VEGF concentration: 
VEGF in HLMVECs supernatants increased after 16 hour incubation with CFTR inhibitor 
GlyH-101 (20 µM), and TNF-α (10 ng mlˉ¹). VEGF concentration in the medium was 55.5 ± 
27.7 pg mlˉ¹, and increased to 77.5 ± 25.5 pg mlˉ¹ with DMSO (0.1% v/v) as GlyH-101 
control. GlyH-101 elevated significantly VEGF to 235.3 ± 33.5 pg mlˉ¹ after 16 hour of 
treatments. In the presence of TNF-α (10 ng mlˉ¹) alone VEGF levels were 122.6 ± 27.4 pg 
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mlˉ¹. This concentration was significantly increased In the presence of GlyH-101 and TNF-
α 387.8 ± 73.3 pg mlˉ¹. Treating with CuT (1µM) before adding GlyH-101 and TNF-α did 
not change VEGF concentration 366.8 ± 62.7 pg mlˉ¹. However, NAC (5 mM) treatment 
significantly reduced VEGF to 105.6 ± 21.8 pg mlˉ¹. These results indicate that CFTR 
inhibition resulted in increase in VEGF in supernatant, that elevation was even higher 
than the effect of TNF-α alone on VEGF levels (Figure 4.17).  
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Figure 4.17: Effect of antioxidants on VEGF level in supernatant after stimulation with 
GlyH-101 (20µM) and TNF-α (10 ng mlˉ1) for 16 hour: 
Changes in VEGF in supernatant of HLMVECs after challenging the cells with (20µM) of 
GlyH-101, and TNF-α (10 ng mlˉ¹) for 16 hour. Bars show mean ± SEM value of 3 
independent experiments carried out in triplicate. Date were analysed with one way 
ANOVA and Tukey’s multiple comparison test. Cells were from three different donors, 3 
independent experiments carried out in triplicate (** p value <0.01, n=3).(* p value ˂ 
0.05, n=3). 
 
4.4.11 Effect of EGFR inhibition on VEGF concentration in CFTR inhibited 
HLMVECs supernatant  
Previous reports indicated that VEGF expression was trans-stimulated via EGFR (Goldman 
et al., 1993), and it was expected that EGFR inhibitor AG-1478 would decrease VEGF 
release into supernatant. CFTR inhibition with GlyH-101 (20µM) over 16 hour increased 
VEGF from 70.6 ± 25.1 pg mlˉ¹ (Figure 4.18) in supernatant of control cells treated with 
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DMSO (0.1 % v/v) to 235.3 ± 33.5 pg mlˉ¹. VEGF in supernatant of cells was significantly 
increased by EGFR inhibition by AG-1478 (10 µM) treatment for 3 hours before adding 
GlyH-101, in total of 19 hour, to reach 456 ± 95.4 pg mlˉ¹. For AG-1478 alone the VEGF 
concentration in supernatant were elevated after 19 hour incubation with HLMVECs 
above the control 312.785 ± 162.1 pg mlˉ¹. However, the effect was not significant 
because of the high SEM, but see figure 4.21 which shows the effect of AG-1478 was 
significant after 24 hour incubation. 
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Figure 4.18: Effect of EGFR inhibitor AG-1478 (10 µM) on VEGF concentration in 
HLMVECs supernatant. 
AG-1478 had increased VEGF concentration after treatment with CFTR inhibitor. AG was 
added for 3 hours before CFTR inhibition for 16 hour. (p value <0.0.01, n=3) comparing 
AG-1478 plus GlyH-101 to DMSO. Samples were analysed with one way ANOVA test and 
Dunnett’s multiple comparison test.   
4.4.12 Effect of EGFR inhibitor on VEGF in CFTR-inhibited HLMVECs supernatant 
in the presence of TNF-α: 
The effect of TNF-α and GlyH-101 were previously shown to be additive. Therefore, the 
effect of AG-1478 on VEGF in culture supernatant from cells incubated with both TNF-α 
and GlyH-101 were investigated. 
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AG-1478 (10 µM) was added 3 hours before GlyH-101 (20 µM), and TNF-α (10 ng ml ˉ¹), 
and then refreshed with GlyH-101 and TNF-α, for a further 16 hour incubation.  EGFR 
inhibition lead to further significant increase in VEGF concentration in HLMVECs 
supernatant that were already activated with GlyH-101 plus TNF-α (Figure 4.19). 
GlyH-101 plus TNF- α significantly elevated VEGF from 70.6 ± 25.1 pg mlˉ¹  in DMSO to 
387.8 ± 73.3 pg mlˉ¹  , the addition of AG-1478 made a further significant elevation in 
VEGF  to reach 663 ± 64.3 pg mlˉ¹ in the presence of GlyH -10 and TNF-α. (Figure 4.19).  
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Figure 4.19: Effect of AG-1478 was added to the stimulatory effect of both GlyH-101 and 
TNF-α at 16 hour incubation. 
Treating HLMVECs with GlyH-101 (20 µM) and TNF-α (10 ng mlˉ1) significantly increased 
VEGF, the addition of AG-1478 (10 µM) further increased VEGF in HLMVEC supernatants 
(* p value < 0.05, ** p value < 0.01, *** p value < 0.001, n=3). Samples were analysed 
with one way ANOVA and Tukey’s multiple comparison test. Samples were from three 
different donors. 
 
4.4.13 Effect of CFTR inhibition for 24 hour on VEGF concentration in HLMVECs 
supernatant: 
Measurements of VEGF in HLMVECs supernatants were still high (Figure 4.20), even after 
24 hour of incubation with GlyH-101 (20 µM), and TNF-α (10 ng mlˉ¹). In control cells 
incubated with FGM, VEGF at 24 hour was 8.8 ± 1.5 pg mlˉ¹, and with DMSO (0.1% v/v) 
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VEGF concentration was slightly higher to 13.5 ± 2.9 pg mlˉ¹. Following  CFTR inhibition in 
HLMVECs for 24 hour, VEGF concentration was 132.3 ± 31.8 pg mlˉ¹, and for the cells 
treated with TNF-α alone (10 ng mlˉ¹) alone VEGF was more than 5 fold increased 46.1 ± 
22.5 pg mlˉ¹ than the control. After the cells were challenged with both GlyH-101 plus 
TNF-α together to detect the additive or synergistic effect of the triggers, VEGF levels 
were significantly higher than both of the controls (DMSO control for GlyH-101, and FGM 
control for TNF-α), with a value of 168.5 ± 46.6 pg mlˉ¹. This elevation was reduced when 
the cells were pre-treated for 3 hours with NAC (5 mM) and VEGF was 93.2 ±34.3 pg mlˉ¹, 
but not with CuT (1 µM), and VEGF was 197.4 ± 50.4 pg mlˉ¹. Both effects of NAC and CuT 
on VEGF were not significant. 
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Figure 4. 20: VEGF in HLMVECs supernatant after 24 hour incubation with CFTR inhibitor 
GlyH-101 (20 µM) and TNF-α (10 ng mlˉ¹). 
VEGF were measured by ELISA. The samples were from 3 different donors. And it was 
analysed with one way ANOVA test and Tukey’s multiple comparison test. (*p value 
<0.05, n=3). 
 
4.4.14 Effect of EGFR inhibitor, AG-1478 on VEGF levels in CFTR inhibited 
HLMVECs supernatant: 
After 24 hour of inhibition of CFTR in HLMVECs with GlyH-101 (20 µM), VEGF 
concentration was significantly 10-fold elevated from 13.5 ± 2.9 pg mlˉ¹ in control cells, to 
132.3 ± 31.8 pg mlˉ¹ (Figure 4.21). When the cells were pre-incubated for 3 hours with 
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AG-1478 (10µM) followed by 24 hour exposure to GlyH-101 (20µM), VEGF was further 
signifncantly increased to (598.8 ± 63.6 pg mlˉ¹). AG-1478 on its own significantly 
increased VEGF in supernatant to (481.6 ± 59.2 pg mlˉ¹) after total of 27 hour of 
incubation with HLMVECs (an effect not seen at 16 hour).  
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Figure 4. 21: VEGF in HLMVECs supernatant after inhibition of CFTR by GlyH-101 (20 µM) 
for 24 hour and the effect of AG-1478 alone (10µM) and with Glyh-101 at 24 hour. 
(** p value <0.01. *** p value <0.001. **** p value < 0.0001, n=3), samples were 
analysed with one way ANOVA and Tukey’s multiple comparison test. 
 
4.4.15 Effect of TNF-α, CFTR inhibitor GlyH-101, and AG-1478 on VEGF 
concentration: 
Since the effect of GlyH-101 and TNF-α appear to be additive, the effect of AG-1478 was 
investigated in the presence of GlyH-101 plus TNF-α over 24 hour. 
CFTR inhibitor increased VEGF from 13.5 ± 2.9 pg mlˉ¹ in control cells to 132.3 ± 31.8 pg 
mlˉ¹. A significant increase in VEGF was seen when the cells were treated with TNF-α plus 
GlyH-101 for 24 hour, and the VEGF concentration reached 201.5 ± 46.6 pg mlˉ¹. Finally, 
inhibition of EGFR with AG-1478 for total of 27 hour (3 hours prior to adding GlyH-101 
plus TNF-α) led to a further significant increase in VEGF concentration to reach 643.1 ± 
25.6 pg mlˉ¹ (figure 4.22).  
81 
 
D M S O Gly T N F
 + Gly
A G +
T N F+  Gly
0
2 0 0
4 0 0
6 0 0
8 0 0
V
E
G
F
 p
g
/m
l
*
* * * *
* * * *
* * * *
 
Figure 4.22: Changes in VEGF concentration in the supernatant of HLMVECs after 
inhibition of CFTR, EGFR, and challenging the cells with TNF-α for 24 hour: 
Samples were analysed with one way ANOVA test and Tukey’s multiple comparison test. 
(*p value<0.05, ****p value <0.0001, n=3). 
   
4.5 Summary of results: 
• CFTR inhibition resulted in a rapid and significant increase in intracellular ROS,   in 
a pattern indicating a mitochondrial source. Treating HLMVECs with antioxidants 
decreased ROS generated intracellularly. 
• The increased ROS generated was predominately hydrogen peroxide, and was not 
dependent on NADPH oxidase activity. 
• The antioxidant enzyme SOD2 protein level increased significantly after CFTR 
inhibition. 
• Nrf2 transcriptional factor expression decreased significantly after CFTR inhibition. 
• VEGF expression increased with CFTR inhibition and was dependent on oxidative 
stress. 
• The EGFR inhibitor AG1478 increased VEGF expression in HLMVECs. 
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4.6 Discussion: 
The role of CFTR in protecting lung epithelium from oxidative stress and inflammatory 
changes was reported previously (Chen et al., 2008, Hunter et al., 2010). In Chen et al. 
study, CFTR inhibition with the CFTRinh 172 in human tracheal epithelia cells treated with 
either TNF-α or IL-1β resulted in significant increase in H2O2 production. Also other 
studies demonstrated that the defect in CFTR is accompanied by oxidative stress 
measured as increase in hydrogen peroxide and subsequent influence on inflammatory 
status measured as changes in pro-inflammatory cytokine IL-8 excreted from epithelial 
cells (Vij et al., 2009).  
In the current study, HLMVEC cells were treated with CFTR inhibitor GlyH-101 to produce 
a model of CF endothelium. The redox status of these cells was examined as the fast 
production of free radicals, and the effect of oxidative stress on the antioxidant, 
cytoprotective transcriptional factor expression (Nrf2). 
Carboxy-H2DFFDA was used to detect changes in ROS. This probe enters the cells as non-
fluorescent dye, intracellular esterase removes acetate group, converting the probe to a 
fluorescent ROS-sensitive compound for detecting hydroxyl radical and peroxynitrite, 
hydrogen peroxide but not superoxide anion (Tikekar et al., 2011). The reason for chosen 
this reagent was that O₂⁻ quickly and spontaneously mutates to H₂O₂, and NOX₄ produces 
H₂O₂ in O₂⁻ independent way.  
The increase in intracellular ROS after challenging the cells with CFTR inhibitor GlyH-101 
(20µM) was rapid and significantly increased by 5 minutes. The results were compared 
with the effect of TNF-α (10 ng mlˉ¹) which also significantly increased intracellular ROS 
within 5 minutes. However, the effect of GlyH-101 lasted longer that TNF-α, indicating 
two different pathways are activated by these stimuli in vascular endothelial cells. Also 
the difference in the duration of effect between GlyH 101 and TNF-α indicated an 
increase in H2O2 because hydrogen peroxide is more stable than other ROS. Alternatively. 
it might reflect a decrease in catalase activity, although catalase protein and not activity 
was measured.  
TNF-α was previously shown to increase intracellular ROS in vascular endothelium 
through activation of NADPH oxidases, TNF-α binding and activates its receptors, tumor 
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necrosis factor alpha receptor-associated factors (TRAFs), which phosphorylate P47ᴾʰᵒˣ 
(component  of NOX2 and NOX4) and initiate superoxide production, triggering the rapid 
activation (in 5 minutes) of ROS production by ECs (Li et al., 2005). TNF also activates 
mitochondria in ECs, especially complex (III) and triggers superoxide release (Chen Xet al., 
2008). The increase in intracellular ROS activated by GlyH-101 started as early as 5 
minutes, but it lasted up to 30 minutes, suggesting that the effect of GlyH-101 pathway is 
different from TNF-α. It was reported that mitochondria produce more ROS in CF 
epithelial cells than healthy cells, due to deficiency of mitochondrial glutathione levels 
and increase of mitochondrial oxidative stress in CF epithelial cells (Velsor et al., 2006). 
In the current study of ECs, the effect of CFTR inhibition on ROS levels using live cell 
imaging indicates that increased endothelial ROS was of mitochondrial origin, which 
lasted up to 30 minutes. This may explain the difference between GlyH-101 and TNF-α in 
terms of duration of the increase in intracellular ROS which was measured as H2O2 at 30 
minutes. Treating HLMVECs with DPI, an inhibitor of NADPH oxidase, which are the main 
source of ROS in the endothelial cells, especially NOX4, did not decrease H2O2. This may 
be due to several possible explanations. Firstly, the mitochondria are the source of ROS. 
Kleme et al. (2018) reported CFTR knockout in intestinal epithelial cells, resulted in an 
increase in mitochondrial ROS, in addition to a decrease in mitochondrial Nrf2. The other 
explanation is related to the DPI mechanism of action.  In a study conducted by Lambert 
et al. (2008) on rats’ skeletal muscle, DPI inhibited ROS from NOX and mitochondria, 
which indicates in the current study, ROS in endothelial cells had a different source, which 
might be lipoxygenase 4 (A4), for example, or cyclooxygenase..  
Furthermore, DPI was found to induce the production of ROS in concentration-dependent 
manner (Riganti et al., 2004) in glial cells. However, in the current study DPI did not add 
more ROS to the cells, when the cells were treated with CFTR inhibitor GlyH-101 plus DPI.  
Antioxidant treatments NAC and CuT were investigated with CFTR inhibitor, and both NAC 
and CuT significantly decreased ROS generated after 30 minute of challenging the cells 
with GlyH-101. NAC previously used as antioxidant in CF epithelial cells (Chen et al., 2008) 
and decreased H2O2 production from CF epithelial cells and epithelia cells with CFTR 
inhibited with CFTR inhibitor 172. Copper-tobramycin is a novel antioxidant that 
scavenges ROS due to SOD like activity (Gziut M, 2012).  
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Changes in SOD2 enzyme expression was previously reported in epithelial cells after CFTR 
inhibition with CFTR inhibitor 172 (Chen et al., 2008). In endothelial cells CFTR inhibition   
with GlyH-101 increased the expression of SOD2 in a time-dependent manner, and at 24 
hour was almost 1.96 fold increased. Such an effect would indicate an increase in 
superoxide dismutation to H2O2 in the mitochondria. This finding of the current study are 
consistent with those of Chen et al. (2008) who reported an increase in SOD2 after 24 
hour of CFTR inhibition (CFTRinh 172). 
In the current study, inhibition of CFTR in HLMVECs showed no significant change in 
catalase. This finding differ from the finding of Chen et al. (2008), where inhibition of 
CFTR was found to cause a reduction in catalase expression in epithelial cells after CFTR 
inhibition.  
Carboxy H₂-DFFDA in comparison with other ROS detectors (DCFDA) is consider more 
stable intracellularly. To further ensure that ROS signal are intracellular, live cells images 
showed that GlyH-101 elevated intracellular ROS signal which accumulated to a maximum 
of 30 minutes after incubation. Longer than 30 minutes incubation shows the start of 
decrease in ROS signal (Data not shown). 
The detection of oxidative stress usually consists of multiple stages, starting from the 
rapid increase in free radicals in the cells (minutes), which consequently affect antioxidant 
enzyme abundance (hours). So the effect of redox status of those cells after CFTR 
inhibition was examined at the ARE-transcriptional factor level i.e for Nrf2. 
Increase in oxidative stress might be expected to increase Nrf2 expression. However, 
CFTR inhibition decreased Nrf2 by 70 % at the protein level, the same percentage of Nrf2 
reduction observed in epithelial cells treated with CFTR inhibitor 172 (Chen et al., 2008). 
Immunocytochemistry images showed that Nrf2 in control was mainly in the cytoplasm, 
and after treatment with GlyH-101 Nrf2 was distributed mainly in the nucleus with 
substantial reduction in cytoplasmic Nrf2. Also, antioxidant treatment with CuT reduced 
the accumulation of Nrf2 in the nuclei. Oxidative stress resulting from CFTR inhibition in 
HLMVECs induced nuclear translocation of Nrf2, which resulted in increase in antioxidant 
enzyme SOD2 in endothelial cells. This response was previously reported in epithelial 
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cells. The overall effect of CFTR inhibition in epithelia cells was a decrease in Nrf2 
expression and activity (Chen et al., 2008). 
Inhibition of CFTR using GlyH-101 for 24 hour led to a 70% decrease in total Nrf2 
expression that was partially reversed when the cells were treated with CuT (1 µM).  
The changes in Nrf2 expression in these cells is likely to affect different cytoprotective 
enzyme pathway, resulting in dysfunctional endothelial cells. Previous studies revealed 
that CFTR and Nrf2, important regulators in the cells, influence expression of each other. 
Nrf2 surprisingly was found to down regulate CFTR protein expression (Rene, 2010). As a 
result, when ROS status in epithelial cells were increased due to inhibition of CFTR, Nrf2 
level were decreased (Chen et al., 2008). But because Nrf2 has an inhibitory effect on 
CFTR, a reduction in Nrf2 promotes CFTR expression (Rene, 2010) in CF epithelial cells. 
According to that, when Nrf2 decreases due to oxidative stress, CFTR protein expression 
increases, due to the disappearance of the suppresser role of Nrf2 on CFTR gene 
promoters, which leads to an increase in CFTR expression in endothelia cells as observed 
(Chapter 3). 
Another important manifestation of cystic fibrosis disease is the increase in VEGF in 
serum of CF patient (McColley et al., 2000), which contributes to haemoptysis in CF 
patients (Hurt & Simmonds, 2012). Increase in VEGF leads to continuous vasculature 
remodelling. VEGF activates endothelial cells proliferation, differentiation and migration 
to form new vessels. Due to the fragile nature of the newly established blood vessels 
surrounding the bronchioles in the lung, haemoptysis can develop in patient with CF, 
especially during infectious exacerbation.  
An increase in VEGF was seen following CFTR inhibition. This was associated with 
oxidative stress and further increased by inhibition of EGFR. The relation between EGFR 
and VEGF were studied extensively due to the important role of these two factors in 
cancer diseases, tumor growth and metastasis, and their inhibitors became part of 
different types of tumor therapy. The activation of EGFR receptor can activate VEGF 
production and VEGF up-regulation is resistant to EGFR inhibitors (Bianco et al., 2008) in 
cancer cells. The inhibition of EGFR receptor with AG-1478 in this study led to increase in 
VEGF. However, EGFR is an important factor that regulates Nrf2-Antiooxidant response 
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element transcriptional response, which downstream regulate antioxidant enzyme in 
endothelial cells, so in the current study inhibition of EGFR led to increase in oxidative 
stress, and increase in VEGF from endothelial cells, as reported previously in endothelial 
and epithelia cells that inhibition of EGFR with AG-1478 resulted in increase in oxidative 
stress (Papaiahgari et al., 2007). 
In this study CFTR inhibition at (20 µM) GlyH-101 concentration as a model of CF in 
endothelial cells led to a significant increase in VEGF in supernatant in a concentration-
dependent manner, and further increased the effect of TNF-α. Therefore, both defective 
CFTR and elevated TNF-α contribute to the pathological changes in CF endothelia cells. 
TNF-α is increased in serum of cystic fibrosis pateints (Levy et al., 1993), as well as in 
airway secretion (Mitola et al., 2008).   
This indicated that the inhibition of CFTR in HLMVECs with GlyH-101 lead to oxidative 
stress, this was measured in endothelial cells by increase in free radical production, and 
disturbance in antioxidative mechanism defence in HLMVECS, and as a result one of the 
important transcriptional factors that the cells uses against oxidative stress was 
decreased (Nrf2). This redox imbalance lead to an increase in the production of VEGF in 
the cells, which was reduced by the well-known antioxidant NAC.  
These results indicated that the CFTR defect in vascular endothelium leads to oxidative 
insult of the barrier between the blood and the microvascular wall, which interfered with 
the normal regulatory function of these highly specialised cells, leading to dysfunction in 
the protective role of these cells as well as the normal physiological regulatory role that 
those cells can influence. 
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Chapter Five 
Inflammation in cystic fibrosis lung disease 
5.1 Introduction:  
Cystic fibrosis (CF) is a genetic disorder which results from deficit or defects in the CFTR 
ion channel that affects primarily the lung, and to a lesser extent the digestive system and 
genitourinary tract. However, the morbidity and early mortality associated with CF is 
mainly due to progressive inflammatory lung tissue damage (Castellani & Assael, 2017).  
5.1.1 Initiation of inflammation in CF airways: 
Although pulmonary inflammation causes damage to lung tissue in CF patients, the 
initiation of this inflammation has not been resolved. However, there are three possible 
explanations.  
Inflammation in cystic fibrosis airways is initiated through defective or reduced CFTR 
expression, and recruitment of inflammatory cells prior to infection. In CF epithelial cells, 
the ΔF508 CFTR mutation, which represents more than 70% of mutant CFTR chromosome 
(Morral et al., 1994), results in misfolded and mistrafficked CFTR that accumulates in the 
endoplasmic reticulum. This triggers cell stress, and activates NF-kB, with increased 
expression of IL-8 (Weber et al., 2001). Other studies had confirmed that intact CFTR is a 
negative regulator of NF-kB, and overexpression of wild type CFTR inhibited baseline and 
IL-1β induced IL-8 production (Vij et al., 2009). In addition, it was found that normal CFTR 
inhibits EGFR-mediated IL-8 production in epithelial cells. Inhibition of CFTR using the 
CFTR inhibitor 172 resulted in increase of IL-1β binding to its receptor, IL-1R, that triggers 
multiple intracellular signals that stimulate EGFR and downstream signaling to produce IL-
8, Figure 5.1. 
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Figure 5. 1: Inhibition of epithelial CFTR leading to EGFR transactivation and IL-8 
synthesis 
CFTR inhibition increased IL-8 through activation of the EGFR receptor pathway (Kim et 
al., 2013). 
 
The second pathway that explains the initiation of inflammation in the CF lung also 
depends upon sterile inflammation. Initially, thickened mucus is due to a defect in CFTR 
that works as a channel for Clˉ as well as HCO3ˉ. HCO3ˉ was found to be very important 
to chelate both Ca2+ and H+ cations to allow mucus to expand 1000-fold after secretion. 
The defect in CFTR reduces HCO3- that result in viscous mucus (Quinton, 2008). Thickened 
mucus limits O2 diffusion and results in hypoxia and necrosis of epithelial cells 
(Johannesson et al., 2012, Zhou-Suckow et al., 2017, Montgomery et al., 2017). Necrotic 
cells stimulate inflammation through the activation of IL-1 receptor (Lukens et al., 2012), 
and downstream increase in IL-8 production and increase neutrophil accumulation. 
The absence or defect in airway CFTR results in thickening of mucus and hypoxia resulting 
in defective mucociliary clearance. In addition, defective CFTR induces changes in airway 
surface liquid pH to acidic that compromises the action of multiple antimicrobial 
pathways in CF lung (reviewed Berkebile & McCary, 2014). This reduces lung defence 
mechanism against infection, resulting in gram negative pathogens predominantly 
Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenza, to 
stimulate a vicious cycle of inflammation. Normally airway epithelial cells recognises LPS 
released from Pseudomonas aeruginosa through toll-like receptors-4 (TLR-4), in CF 
89 
 
bronchial epithelial cells expression of TLR4 was decreased, which impaired the innate 
immune responses (John et al., 2010).   
5.1.2 Cystic fibrosis cytokine profile: 
There are many pro-inflammatory cytokines found to be elevated in both bronchoalveolar 
lavage or sputum and plasma from CF patients, such as IL-1, IL-6, IL-8, TNF-α (Salva et al., 
1996, Courtney et al., 2004), indicating that local lung inflammation is reflected 
systemically. Other cytokines were found to increase either locally in lung, or systemically 
in plasma. Granulocyte-colony stimulating factor (G-CSF) was found elevated in CF serum 
(Jensen et al., 2006). Increase in this factor influences granulocyte-macrophages colony 
stimulating factor (GM-CSF) to G-CSF ratio (Moser et al., 2005), and when G-CSF is 
elevated this skews T-helper cells differentiation from Th-1 (IFN-ƴ producing, related to 
lower mortality and lesser lung inflammation) to Th2 (IL-4, IL-5 producing). Also, 
leukotriene B4 (LTB4) which stimulates neutrophil transendothelial migration, and 
activation was found elevated in epithelial lining fluid (Konstan et al., 1993). This 
leukotriene concentration is related to lower level of lipoxin A4 (LXA4) which counteract 
the effect of LTB4, particularly on neutrophil transmigration to lung (Colgan et al., 1993). 
The ratio of LXA4 to LTB4 was found reduced in the airway of cystic fibrosis patients 
(Ringholz et al., 2014).  
The action of IL-1 is to prime neutrophils and increase their adhesion to the endothelium, 
while IL-8, LTB4 both are potent neutrophil chemoattractants. In addition, IL-8 increases 
strength of neutrophil binding to adhesion molecules (sICAM-1) on vascular endothelial 
cells was found elevated in cystic fibrosis (De Rose et al., 1998, Nowak et al., 2017). IL-6 
and TNF-α had multiple effect in the inflammatory status of CF lung. IL-6 cytokine works 
as proinflammatory and anti-inflammatory. In cystic fibrosis, elevated IL-6 is correlated to 
decrease in bone marrow density in CF patients, and IL-6 increase the production of TNF-
α and IL-1β (Nixon et al., 1998). TNF-α increases the synthesis of IL-8 by airway epithelial 
cells and endothelial cells.  
Studies have revealed that the anti-inflammatory cytokine IL-10 is down regulated in 
cystic fibrosis (Bonfield et al., 1995-B). IL-10 inhibits secretion of TNF-α, IL-1β, IL-6, and IL-
8 produced by macrophages and increase the synthesis of I-kB that inhibits NF-kB (Barns & 
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Karin, 1997). Other counter-regulatory factors that attenuate the effect of elevated TNF-α 
is soluble TNF-α receptors (TNF-sR), which are of two types, type I and II. Both decrease 
TNF-α concentration by binding to it and inactivating it. IL-1 receptor antagonist (IRAP) 
prevents IL-1 α and β from binding to its receptor. Both TNF-sR and IRAP are slightly 
increased in bronchoalveolar lavage (BAL) (Bonfield et al., 1995-A) but their increase was 
not proportional to increase in proinflammatory cytokines. Other mediators of 
inflammation changes in cystic fibrosis are shown in figure 5.2. 
 
Figure 5. 2: Airway inflammation in cystic fibrosis lung: 
The figure indicates multiple cellular sources of neutrophil chemoattractant. In addition 
to airway epithelial cells, macrophages, T-cells. The accumulated neutrophils become a 
source for more IL-8, oxidant, and neutrophil elastase which damages lung tissue and 
trigger an uncontrolled cycle of inflammation (Nichols & Chmiel, 2015). 
 
5.1.3 Interleukin-8:  
IL-8 is the main neutrophil chemo-attractant produced by different cells including 
monocytes, macrophages, airway epithelial cells, airway smooth muscle cells and 
eosinophils (Chung, 2009), as well as endothelial cells (Utgaard et al., 1998). In cystic 
fibrosis, IL-8 is considered as a sputum biomarker of lung inflammation (Sagel et al., 
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2012), and its increase is characteristic for cystic fibrosis disease. IL-8 was found in early 
as well as in advanced stage of cystic fibrosis. 
IL-8 expression increases in CF epithelial cells in response to TNF-α, LPS from 
Pseudomonas aeruginosa that binds and stimulates TLR-4 on epithelial cells and 
upregulates IL-8 production (Roussel et al., 2011). In addition, neutrophil elastase 
released from accumulated neutrophils, and ROS, activate IL-8 production (Nakamura et 
al., 1992, Hoffmann et al., 2002).  
IL-8 expression is regulated by the CXCL8 gene. IL-8 expression is stimulated in response 
to binding of transcriptional factor to IL-8 promoters. These inducible transcriptional 
factors includes: NF-kB, NF-IL-6 (Hoffmann et al., 2002), AP-1 (Saadane et al., 2011), CHOP 
(Vij et al., 2008), and CREB (Kawaguchi et al., 2007). 
NF-kB is a ubiquitous transcriptional factor composed of dimeric hetero- and homodimer 
combination of 5 subunits: P50, P52, P65, C-Rel, Rel-B (Zheng et al., 2011). In non-
stimulated cells, NF-kB is retained in the cytoplasm, attached to its inhibitor either IkBα or 
IkBβ. Upon inflammatory stimulation, NF-kB dissociates from its inhibitor, due to 
phosphorylation, ubiquitination and degradation of IkB (Zhang et al., 2017) and 
translocate to nuclei where it induces production of IL-8 
The AP-1 transcriptional factor belongs to the basic leucine zipper transcription family. 
AP-1 activity is stimulated by various stimuli, such as cytokines, growth factors, and 
physical and chemical cell stresses. AP-1 is essential for cell proliferation, differentiation, 
and apoptosis. AP-1 comprises multiple subunits which bind to form hetero and 
homodimers of Jun (c-Jun, JunB, JunD, v-Jun), Fos (c-Fos, v-Fos, FosB, Fra-1, Fra2), ATF 
(ATF2, B-ATF, LRF1/ATF3), JDP (JDP1, JDP2), and Maf (c-Maf, MafA/L-Maf, MafB/Kmrl1, 
and Nrl) (Karin et al., 1997, Yang & Cvekl, 2007). Jun subunits form homodimers among 
themselves, and even stronger heterodimers with Fos and ATF family members (Angel & 
Karin 1991). The AP-1 protein is usually found normally in nuclei, and regulation of its 
activity is controlled by its abundance. AP-1 abundance increases by two pathways, either 
by increasing the transcription of its genes, or through stabilization or reduction of 
degradation. For c-Jun, both pathways are controlled by mitogen activating protein kinase 
(MAPK), more specifically by c-Jun terminal kinase (JNK). JNK phosphorylates c-Jun at 
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serines 63 and 73, this phosphorylation stimulates c-Jun transcription, in addition it 
protects c-Jun from degradation, thus increasing its abundance and activity (Karin et al., 
1997). While c-Fos synthesis is controlled by another type of MAPK, the extracellular-
regulated protein kinase (ERK) (Karin, 1995). 
The final step after activation of IL-8 transcription, either through NF-kB and AP-1, is 
stabilization of IL-8 mRNA by MAPKs in CF epithelial cells (Jundi & Greene, 2015). 
The functional effect of epithelial CFTR on IL-8 production was investigated using two 
approaches. The first utilised pharmacological CFTR inhibition in human tracheal epithelial 
cells (THE). Using the CFTR inhibitor CFTRinh -172, basal IL-8 production and in response to 
stimulation with pseudomonas aeruginosa bacteria, was significantly increased compared 
to normal cells. An increase in nuclear NF-kB translocation upon treating cells with TNF-α 
or IL-1β with CFTRinh -172 (Perez et al., 2006). The second approach used CF epithelial 
cells (CFBE41o-) transfected with wild type CFTR. CFBE41o- produce more IL-8 than non 
CF cells. Transfection of CFBE41o- with wild type CFTR resulted in decrease in basal and 
IL-1β induced IL-8 production (Vij et al., 2009).  
IL-8 binds to G protein coupled seven transmembrane receptors, CXCR1 and CXCR2, 
expressed on neutrophils, and stimulates neutrophil recruitment and degranulation 
(Baggiolini & Clark-Lewis, 1992). In cystic fibrosis CXCR1 which stimulate bacterial killing 
ability of neutrophils is cleaved by increased proteolytic activity, and the cleaved CXCR1 
fragments then stimulates bronchial epithelial cells to produce more IL-8 through the 
activation of TLR2 (Hartl et al., 2007). 
5.1.4 Neutrophil recruitment in cystic fibrosis lung: 
Elevated cytokines, IL-8 and TNF-α, in circulating blood of CF patients’ upregulate 
adhesion molecules (ICAM-1) expression on vascular endothelial cells. Neutrophils 
migrate to the lung as response to proinflammatory cytokines such as IL-8 (induced by 
TNF-α and IL-1β) expressed on endothelial cells.  
Transendothelial migration of neutrophils from blood to the lung tissue is either between 
adjacent endothelial cells (paracellular) or through them (transcellular). This process 
starts by the rolling of neutrophils on the endothelial cell surfaces which is facilitated by 
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the interaction between CD11/CD18 integrins expressed on neutrophils and selectins (P 
and E selectins) molecules expressed on endothelial cells. Intracellular adhesion 
molecule-1 (ICAM-1) helps the neutrophil to firmly attach to the endothelial cells, and 
finally transmigrates though the endothelial cells monolayer to the surrounding lung 
tissues (Downey et al., 2007). In healthy lung, neutrophil migration to sites of 
inflammation is the first innate immune system defence line to phagocytose, kill, and 
digest pathogens (Mollinedo et al., 1999). In cystic fibrosis neutrophil influx is 
exaggerated, and although neutrophils are required for antibacterial and antifungal 
defence, excessive recruitment of neutrophils produces damaging effects on parenchymal 
lung tissue, because these cells when activated produce high concentrations of 
superoxide, neutrophil protease, as well as DNA from dead neutrophils (Stoltz et al., 
2010). Several studies reported that neutrophils from cystic fibrosis act differently from 
neutrophils from healthy patients. Neutrophils isolated from CF patients release more 
neutrophil elastase in response to TNF-α and IL-8 stimuli than the ones isolated from 
healthy donors (Taggart et al., 2000). Other neutrophil abnormalities include: more ROS 
production, increased IL-8 production which leads to recruit more neutrophils. (Witko-
Sarsat et al., 1996, Corvol et al., 2003, Moriceau et al., 2010) 
Although neutrophils influx in massive numbers to the lung, these cells fail to eradicate CF 
pathogens P. aeruginosa and Staph. aureus, which indicates a defect in the bactericidal 
capability of CF neutrophils. This defect was found to be due to a defect in CFTR in 
neutrophils (Zhou et al., 2013). Neutrophils rely on the intracellular generation of toxic 
products such as hypochlorous acid (HOCl) to kill bacteria. HOCl formation requires 
hydrogen peroxide H₂O₂ produced by NADPH oxidase, and the azurophilic granule protein 
myeloperoxidase (MPO), as well as chloride Clˉ to produce HOCI (Equation 5.1): 
Equation 5.1: 
H₂O₂ + Clˉ+ H⁺   MPO     HOCl + H₂O 
Normally CFTR transports Cl- into phagosomes. In CF, the CFTR protein defect results in 
impairment of the transport of chloride to inside the phagosomes (Zhou et al., 2013), 
which results in a decrease in HOCl production.  
94 
 
5.1.5 Neutrophil elastase in cystic fibrosis: 
Neutrophil elastase (NE) is a serine protease included in azurophil granules and functions 
to digest bacterial protein in neutrophil phagosomes. Under normal conditions, there is a 
balance between NE and endogenous antiprotease in the lung, such as α1-antitrypsein, 
secretory leukocyte peptidase inhibitor (SLPI) and elafin (Stockley, 1999). But in CF lung, 
excessive NE activity overwhelms the antiprotease capacity, and NE inactivates elafin, and 
although SLPI is resistance to proteolytic activity of NE, SLPI is sensitive to cysteinyl 
cathepsins and MMPs, and both are upregulated by NE (Kelly et al., 2008, Sagel, 2012).  
The exaggerated activity of free NE and increase in the expression and activity of 
neutrophil surface bound NE in CF lung had multiple adverse effect, and recently the 
adverse effect of NE was found to be mediated primarily through surface bound NE, 
because the surface-bound NE can not be inhibited by α1-antitrypsein and SLPI (Dittrich 
et al., 2018), measurement of NE activity in CF sputum correlates adversely with lung 
function and is used as marker of disease severity (Sagel, 2012). In addition to stimulating 
epithelial cells to produce more IL-8, NE degrades C5 complement to produce the potent 
neutrophil chemoattractant C5a to recruit more neutrophils (Fick et al., 1986). NE causes 
damage to lung structure through degrading elastin, basement membrane collagen I-IV, 
fibronectin and proteoglycan (Janoff et al., 1979). NE was recently shown to both degrade 
CFTR through the activation of calpains in lung epithelial cells (Le Gars et al., 2012), and 
increase the viscosity of the mucus layer by proteolytic activation of ENaC channels on the 
epithelial cells, resulting in increased the absorption of Na⁺ ions, and further dehydration 
of airway surface liquid (Caldwell et al., 2005). NE attenuate immune system defence of 
the lung against pathogens through cleavage of epithelial antibacterial growth factor 
midkin. This antimicrobial factor is highly expressed in CF lung but with impaired 
bactericidal activity due to NE-mediated proteolysis (Nordin et al., 2013). NE further 
promotes pathogen infections through impairment of complement mediated 
phagocytosis of bacteria by cleaving C3b bound to opsonized bacteria, as well as cleavage 
of complement 1 receptor (CR1) on neutrophils (Tosi et al., 1990). 
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Furthers, NE also increases the production of multiple matrix metalloproteases (MMPs) 
(Geraghty et al., 2007), resulting in extensive airway remodelling and inflammation 
(Figure 5.3). 
 
  
 
Figure 5. 3: Effect of neutrophil elstase on lung tissue 
Multiple adverse effects of NE activity in the lung of cystic fibrosis patients resulted in 
lung tissue destruction and reduction of antimicrobial defence mechanisms against 
pathogens (Reeves et al., 2015). 
 
5.1.6 Oxidative stress and inflammation: 
Oxidative stress is one of the features of cystic fibrosis lung disease (Reverri et al., 2014), 
and contributes to chronic lung inflammation through stimulation of IL-8 production from 
CF epithelial cells. Oxidative stress, as discussed Chapter four, results from defective CFTR 
channel function with multiple intracellular signalling pathways that ends with increase in 
intracellular concentration of ROS (Chen et al., 2008). ROS increases the production of 
inflammatory mediators, for example through the activation of NF-kB by enhancement of 
IkB degradation (Rahman & Adcock, 2006) , or hydrogen peroxide which increases IL-8 
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gene expression through increase activation of activating protein-1 (AP-1) transcriptional 
activity to bind IL-8 promotors (Roebuck et al.,1999).  
Recently, antioxidant treatment had proven its efficiency in reducing inflammatory 
symptoms in CF lung after systemic administration of lutein, β-carotene, and ƴ-tocopherol 
as shown recently in clinical studies (Sagel et al., 2018). 
The experiments described in this chapter investigate the role of CFTR in the regulation of 
IL-8 synthesis by HLMVECs, and the role of CFTR in neutrophil elastase activity on 
neutrophils.  
5.2 Aims and objectives: 
The aim of the experiments described in this chapter is to investigate the anti-
inflammatory effect of normal CFTR channel activity in microvascular endothelium. The 
objectives were to quantify changes in IL-8 expression using ELISA of cells and 
supernatants following CFTR inhibition and gene silencing. A further objective was to 
define changes in transcriptional factor expression and activity following CFTR inhibition, 
using immunocytochemistry and Western blotting for the NF-kB subunit p65 and 
phosphorylated c-jun. In addition, to investigate the direct effect of CFTR inhibition on 
neutrophil elastase activity after priming the cells with opsonized zymosan A to mimic 
bacterial infections in CF airways.  
5.3 Materials and methods: 
5.3.1 Quantification of IL-8 by ELISA: 
HLMVECs (5 X 104 cells/well/ 300 µl of FGM ) were seeded in 24 well plate coated with 
collagen (IV) (as described in chapter 2 section 2.2) , left to attach overnight, and full 
growth medium was changed next day. After treating the cells with CFTR inhibitor GlyH-
101 for 16 hour with concentration range (5- 20 µM) in the present and absence of TNF-α 
(10ng/ml), and with GlyH-101 (20 µM) with different timing (6, 16, 24 hr) in the present 
and absence of TNF-α (10ng/ml), and  in another experiment ECs were treated with NAC 
(5 mM), CuT (1 µM) and AG-1478 (10 µM) for 3 hours followed by challenging with GlyH-
101 (20 µM) and TNF-α (10 ng/ml) for 16 and 24 hour, supernatant and cell lysate were 
harvested and processed (chapter 2 Section 2.3)  . CXCL8/IL-8 (R & D, DY 208) ELISA kit 
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were used to detected IL-8 in HLMVECs supernatant and cell lysate, according to the 
manufacturer’s instructions. A standard curve, with the range (15.625-1000 pg/ml) was 
setup on each plate. Prior to assay, supernatants were diluted in reagent diluent (0.1% 
BSA in PBS without Ca/Mg with 0.05% Tween-20), 200 times if the samples were treated 
with TNF-α (10 ng/ml) 10 times if not.  The cell lysate samples with or without TNF-α were 
used without diluting. 
 
5.3.2 Electroporation and CFTR silencing: 
Electroporation were used to introduce small interfering RNA to target CFTR gene in 
HLMVECs. These cells after being fully confluent in 75 cm flask, harvested, centrifuged 
(Chapter 2, section 2.1.2), after that the cells from each flask were washed twice with 5 
ml each time in Opti-MEM reduced serum medium (Gibco-31985-062), and re-suspended 
in in 300 µl of OptiMEM medium and counted using trypan blue , then each 0.75 X 10 ⁶ 
cell were diluted in 100 µl of OptiMEM, these cell were transferred in to NEPA21 sterile 
cuvette, and 2 µl of siRNA from non-targeting or CFTR stock (5 nmol , 66.5 µg). For CFTR 
siRNA (ON-TARGET plus Human CFTR (1080) siRNA- SMART pool (Dharmacon) which 
consist of 4 siRNA mixture with target sequence as the following: 
1- GAACACAUACCUUCGAUAU 
2- GUACAAACAUGGUAUGACU 
3- GUGAAAGACUUGUGAUUAC 
4- GCAGGUGGGAUUCUUAAUA 
Either CFTR siRNA or non-targeted siRNA were added to each cuvette to reach (1000 nM) 
final concentration. For each well of a 6 well plate two cuvettes were prepared so the 
number of cells reaches 1.5 X 10 ⁶ cell/well/ 2ml of FGM. 
The cells were electroporated according to the relevant pulse setting (Table 5.1): 
Table 5.1: HLMVECs electroporation settings. 
 Poring Pulse Transfer Pulse 
 V Length 
ms 
Interval 
ms 
No. D. 
Rate 
(%) 
Polarity V Length 
ms 
Interval 
ms 
No. D. 
Rate 
(%) 
Polarity 
9 170 2.5 50 2 10 + 20 50 50 5 40 +/- 
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After electroporation cells from each cuvette were resuspended in 400 µl of pre-warmed 
full growth medium. Then each 2 cuvette were pooled into one well of 6 well plate coated 
with collagen (Chapter 2 section 2.2). Before adding the electroporated cell, each well of 
the 6 well plates were incubated with 1 ml of full growth medium for 30 minutes in 370C 
and 5% CO2. The medium then was changed every 24 hour, for a total of 72 hour, then 
the supernatant were harvested and processed (chapter 2, section 2.3) and used to 
analyse IL-8 changes with ELISA. 
5.3.3 NF-kB immunocytochemistry: 
HLMVECs were seeded in 8 well chamber slide (2 X 104 cell/well/ 200 µl FGM), pre-coated 
with collagen IV (chapter 2, section 2.2), and left overnight to attach. For studies on the 
NF-kB localization in these cells, media was then replaced with fresh media either alone 
or contain DMSO (0.1%), GlyH-101 (20 µm), TNF-α (10 ng/ml) for 1 hour. 
Paraformaldehyde (4%) were used to fix the cells, and for permeabilizing Triton X-100 
(0.1%) were used. The cells then were incubated with rabbit serum (5%) for one hour, to 
block the non-specific binding sites. Primary antibody NF-kB mouse monoclonal IgG, 
(Santa Cruz, p 65 (F-6) sc-8008) (200 µg/ml) working concentration (4 µg/ml, 1:50 
dilution) was incubated with the cells for 16 hour at 4˚C, with one well left for non-
primary antibody control, followed by incubating the cells for one hour with the 
secondary antibody, rabbit anti-mouse antibody conjugated to Alex Fluor-488 (Molecular 
Probes, A21204) (2 mg/ml), working concentration ( 2µg/ml, 1:1000 dilution). Slides were 
stained with Hoechst 33342 (Molecular Probes, H1399) for 10 minutes, and mounted in 
Fluor-Preserve Reagent (Calbiochem/Merck Chemicals Ltd.) and Imaged with Zeiss LSM 
710 confocal microscope. 
5.3.4 Phospho-c-jun immunocytochemistry: 
HLMVECs were seeded in 8 well chamber slide (2 X 104 cell/well/ 200 µl FGM), coated 
with collagen IV (chapter 2, section 2.2). Next day the media were changed with full 
growth medium in the absence and presence of DMSO (0.1%), GlyH-101 (20 µM), TNF-α 
(10 ng/ml). These reagent were incubated with the cells for 30 minutes, then the cells 
were fixed with 4% (w/v) paraformaldehyde (chapter 2, section 2.5), permeabilized with 
200 µl of 0.1 % of Triton-X 100 (chapter 2, section 2.5), and incubated with (5%) goat 
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serum blocking buffer for 16 hour at (4˚C), the next day the cells were stained with the 
primary antibody p-c-Jun (Ser 63/73) sc-16312-R, Santa Cruz) rabbit polyclonal antibody 
(200 µg/ml), after (1:250) dilution in (5%) goat serum to working concentration (0.8 
µg/ml) incubated with the cells for one hour at (4˚C), one well were left as no primary 
antibody control. Then the cells were incubated with the secondary antibody,   goat anti-
rabbit IgG-Alexa Fluor 555 (Molecular Probe; A21430) (2mg/ml), diluted (1:1000) to (2 
µg/ml) diluted in (5%) goat serum, the cell were incubated with the secondary antibody 
for one hour at room temperature. Followed by staining the nuclei with Hoechst, then 
preparing the slide to me imaged with Zeiss LSM 710 confocal microscope.  
5.3.5 Phospho-c-jun Western blotting: 
HLMVECs were seeded in 6 well plate (2.5 X 105 cell/well/ 2ml of FGM), coated with 
collagen (IV) (chapter 2, section 2.2), the next day after the cells were attached and fully 
confluent the media were refreshed, with and without the addition of treatments, DMSO 
(0.1%), GlyH-101 (20µM), TNF-α (10 ng/ml) were added to the cells for 30 minutes, then 
the supernatant were harvested and processed (chapter 2 section 2.3), and the cells were 
lysed in lysis buffer (125 mM NaCl, 1 mM MgCl₂, 20 mM Tris-HCl, 1%  Triton X-100, 
complete protease inhibitor tablet (Roche: 11836153001) and  phosphatase inhibitor 
tablet (PhosSTOP, Roche: 04906845001)), 100 µl/well  of lysis buffer were added, and the 
cells were scraped, and incubated at 4˚C for 30 minutes, then the cell lysate were 
centrifuged at 14000 rpm, at 4˚C for 30 minutes, stored at -80˚C. At the day of Western 
blot, the cell lysate were mixed 4X sample buffer (30% vvˉ¹ glycerol, 200mM Tris-HCL pH 
6.8, 8% wvˉ¹ sodium dodecyl sulphate (SDS), 400 mM DL-Dithiothreitol (DTT), (Sigma; 
D9779-5G), 0.04% wvˉ¹ bromophenol blue (Sigma; B-6896)), each 30 µl of the samples 
were mixed with 10 µl of the loading buffer, the samples then were placed in water bath 
(95 ˚C) for 4 minutes.  
After the samples were prepared 35 µl was loaded to 10% SDS gel, and transferred to 
nitrocellulose membrane (0.45 µm) (Bio-Rad; 1620115), the blots with the gel were left 
for 45 minutes at 22 V.  
The blots were blocked for 3 hours in room temperature with blocking buffer consisting 
of 3% skimmed powder milk in Tris Buffer Saline (3 % TBST)( Tris base 20 mM, NaCl 
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0.15M, pH 7.6 adjusted with 12N HCl), with 0.1 % Tween 20 (Fisher chemicals; 
T/4206/60). Then the blots were stained with the primary antibody p-c-Jun ((Ser 63/73) 
sc-16312-R, Santa Cruz) rabbit polyclonal antibody, working concentration (0.2 µg/ml), 
and overnight at 4˚C on roller mixer in 3% TBST.  
Finally the blots were stained with the secondary antibody, goat ant-rabbit-HRP (DAKO, 
Ref: P0448) in TBST, 1:2000 dilution to the working concentration (0.0125 µg/ml),for 2 
hours in room temperature. Chemiluminescence (Promega ECL Western Blotting 
Substrate W1015) then were added to the blot for 5 minutes, and the blot were imaged 
with Western blot developer (ChemiDoc™ MP System 1708280). 
5.3.6 Neutrophil isolation: 
Neutrophils were isolated from freshly obtained normal whole human blood. Blood was 
collected in EDTA tube. Two volumes of whole blood were mixed with 1 volume of 
Macrodex (6% wvˉ¹ Dextran 70, 0.9% wvˉ¹ NaCl, autoclaved) in 50 ml Falcon tube, the 
tubes were left at 45 degree angle for 30-45 minutes at room temperature to allowed red 
blood cells to sediment under gravity. The plasma layer then as transferred to a new 15 
ml Falcon tube, and equal volume of Lymphoprep (Axis-Shield Diagnostic) were layered 
underneath it via a long-neck pasture pipette. Tubes were centrifuged for 30 minutes at 
1500 rpm and 20˚C. The supernatant were aspirated and discarded, and the pellet 
containing the Granulocyte cell and RBCs retained. The neutrophil pellet was 
resuspended in 5 ml hypotonic lysis buffer (0.2 % NaCl) for no more than 45 seconds to 
lyse the remaining RBCs, followed by addition of 1.6 % NaCl (5 ml) to return the solution 
to (0.9 % NaCl) solution. Neutrophils were collected by centrifugation at 2000 xg for 10 
minutes at 4˚C. After this last centrifugation the neutrophils were resuspended in assay 
buffer, HBSS without phenol red and with Ca/Mg containing 20 mM HEPES and counted. 
5.3.7 Neutrophil elastase activity assay: 
The EnzChek Elastase AssayKit (E-12056, Molecular Probes) were used to determine 
neutrophil elastase activity on the cells surface. This kit contains DQ elastin substrate, a 
soluble elastin from bovine neck ligaments labelled with quenched BODIPY®FL conjugated 
fluorescent dye. Substrate stock concentration (1 mg/ml), diluted to working 
concentration (0.1 mg/ml), 50 µl/ well of substrate was added to each well. This non-
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fluorescent dye transformed to fluorescent when digested by neutrophil elastase. A 
standard curve of elastase was prepared from porcine pancreatic elastase in the range 
between (0.016 – 0.5 U/ml) diluted in HBSS (+ Ca/Mg) with HEPES.  
The experiment was carried out in HBSS (without phenol red) (+ Ca/Mg) containing 20 
mM HEPES (Fisher Bioreagent; BPE 310-500) pH 7.4 in duplicate. Neutrophils (5 X 106 
cell/ml, 100 µl)/ well were added to black 96-well plates. To induce experimental sterile 
inflammation, cells were activated by opsonized zymosan (OPZ) at (0.062, 0.125, 0.25 
mg/ml) working concentrations, and with N-Formyl-Met-Phe (fMLP) (Sigma; at working 
concentration (10-8, 10-7, 10-6 M), OPZ and fMLP were diluted with HBSS + Ca/Mg + HEPES 
buffer. After activation of neutrophils the cells were incubated in 370 C in SpectraMax i3X 
plate reader, and fluorescence with excitation wavelength of 505 nm and emission of 515 
nm were recorded every 10 minutes, for a duration of one hour.  
The fluorescent light then were transferred into units of enzyme activity by the mean of 
the standard curve.  
5.3.8 Opsonisation of Zymosan A: 
Serum was prepared form normal human venous blood collected into 2 tubes of Vacuette 
clot activator tubes (Greiner Bio-One), the blood was allowed to clot for 20 minutes at 
room temperature and centrifuged at 1500xg for 10 minutes at 40C.  
Zymosan A from Saccharomyces cerevisae (Sigma) was prepared at a concentration of 10 
mg/1ml of dH2O. Centrifuged for 10 minutes at 900 xg at 40C to pellet the particles. The 
supernatant was discarded, and the pellet was resuspended in 2 ml of dH2O and filled up 
to 20 ml of dH2O. Centrifuged again for 10 minutes at 900xg at 40C. Zymosan A was 
opsonised in 2 ml of fresh human serum for 60 minutes at 370C, with gentle shaking. The 
reaction was stopped by placing the tube on ice. The opsonized zymosan (OPZ) was 
washed twice with ice-cooled water and centrifuged at 1500 X g for 10 minutes at 40C. A 
final resuspension was made in HBSS (+ Ca/Mg) containing 20 mM HEPES, pH 7.4 at 10 
mg/ml concentration.  
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5.4 Results 
5.4.1 The effect of CFTR inhibition on IL-8 expression: 
The effect of the CFTR inhibitor GlyH-101 on cell associated and soluble IL-8 was studied 
in a range of concentration from 5-20 µM. Most IL-8 was detected in the supernatant. IL-8 
in cell lysates increased significantly from 42.5 ± 9.8 pg/ml in control cells, to 91.3 ± 4.9 
pg/ml in the presence of 20 µM GlyH-101 (Figure 5.4 A). A significant increase in IL-8 in 
the supernatants was also detected with the CFTR inhibitor at 20 µM. IL-8 increased 
significantly from 3789.3 ± 299.9 pg/ml in control cells treated with DMSO (0.1 % v/v), to 
5852.6 ± 1108.8 pg/ml with 20 µM of GlyH-101 (Figure 5.4 B).  
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Figure 5.4: Concentration dependent effect of GlyH-101 on IL-8 concentration in 
HLMVECs lysate A and supernatant B: 
Changes in IL-8 in HLMVECs in cell Lysate (figure A), and in supernatant (figure B) after 
inhibition of CFTR with concentration range of GlyH-101 from (5- 20 µM) for 16 hour, (*p 
value < 0.05, n=3). Numbers expressed as the average ± SEM of three experiments, each 
condition were tested in triplicate. The data were analysed with one way ANOVA and 
Dunnett’s multiple comparison test. 
A 
B 
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5.4.2 The effect of TNF-α in the presence and absence of CFTR inhibitor GlyH-101 
on IL-8 expression in HLMVECs: 
 IL-8 is expressed constitutively in unstimulated control cells. TNF-α (10 ng/ml) was added 
in the absence and presence of CFTR inhibitor GlyH-101 in the concentrations range 5, 10, 
and 20 µM. IL-8 was measured both in cell lysate (Figure 5.5 A) and in supernatant (Figure 
5.5 B).  
IL-8 in In HLMVECs cell lysates treated with TNF-α (10 ng/ml) significantly increased from 
42.5 ± 9.8 pg/ml in the control cells to 256.8 ± 10.9 pg/ml. Addition of 5 µM of Gly did not 
further increase IL-8 (253.6 ± 11.8 pg/ml). However, when GlyH-101 was added at 10 µM, 
IL-8 levels increased significantly in comparison to control to reach 467.1 ± 85.1 pg/ml. A 
further significant increase was seen in the presence of GlyH-101 20 µM 534.5 ± 85.4 
pg/ml. The effect of TNF-α plus GlyH-101 was significantly higher than the effect of TNF-α 
alone.   
In the supernatant, TNF-α alone significantly increased IL-8 levels by 10-fold from 3,789.3 
± 299.9 pg/ml to 31,701.1 ± 2115.4 pg/ml. Addition of CFTR inhibitor at 5 µM did not 
significantly further increase IL-8 levels (39165.6 ± 2910.9 pg/ml) in comparison to TNF-α 
alone. However, adding GlyH-101 at 10 µM resulted in a significant increase in IL-8 to 
43080.7± 875 pg/ml in comparison to both control and TNF-α alone. The 20 µM GlyH-101 
concentration, IL-8 levels were still significantly higher than TNF-α alone 46,192.9 ± 775.8 
pg/ml and in comparison to control . 
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Figure 5.5: IL-8 levels in HLMVECs lysate A and supernatant B response to TNF-α in the 
absence and presence of the CFTR inhibitor GlyH-101: 
Cells were treated with TNF-α (10 ng/ml) for 16 hours with CFTR inhibitor in 
concentration ranged 5, 10, and 20 µM (* p value <0.05, ***p value <0.001, ****p value 
<0.001, n=3) in comparison to control. † value ˂ 0.01, †† value ˂ 0.001 in comparison to 
TNF-α alone. Data were expressed as average ± SEM, and it was analysed by one way 
ANOVA test, and Tukey’s multiple comparison test. 
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5.4.3 Time dependent changes in IL-8 production HLMVECs: 
HLMVECs were treated with CFTR inhibitor GlyH-101 at 20 µM concentration, and IL-8 
levels were measured in supernatant at 6 hours, 16 hour and 24 hour (Figure 5.6). The 
result were compared with DMSO (0.1%, v/v) vehicle control. IL-8 increased significantly 
after 6 hours of adding GlyH-101, and the concentration of IL-8 elevated from 335.6 ± 
46.2 pg/ml in supernatant from cells with DMSO, to 827.1 ± 64.7 pg/ml. The effect of 
GlyH-101 was time dependent and IL-8 in the supernatant continued to increase 
significantly to 1066.2 ± 116.4 pg/ml at 16 hour of CFTR inhibition, and 1440.263 ± 203.8 
pg/ml at 24 hour. 
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Figure 5. 6: Time dependent increase in IL-8 release from HLMVECs treated with GlyH-
101 (20 µM) 
HLMVECs were treated with GlyH-101 (20 µM) and IL-8 levels were measured in 
supernatant after 6, 16, and 24 hour of CFTR inhibition. Samples were analysed with one 
way ANOVA test, and Sidak’s multiple comparison test (* p value <0.05, **** p value 
<0.0001. n=6) in comparison to DMSO control. 
 
 
5.4.4 Additive effect of CFTR inhibitor GlyH-101 and TNF-α for IL-8 production: 
TNF-α (10 ng/ml) produce an increase in IL-8 production from HLMVECs, from 380.8 ± 
41.4 pg/ml  to 4,178.4 ± 851.7 pg/ml after 6 hour of treating the cells with TNF. After 16 
hour IL-8 was further significantly increased 31,474.7 ± 6,303.2 pg/ml, and remained high 
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over 24 hour of incubating the cells with TNF-α (23,210.7± 2,980.2 pg/ml). When the cells 
were treated with 20 µM of GlyH-101  plus 10 ng/ml of TNF-α together, the effect on IL-8 
levels in HLMVECs were increased starting from 6 hours of both TNF-α and GlyH-101 to 
6,149 ± 1,306.9 pg/ml, which indicate that GlyH-101 increased IL-8 levels almost by 47.2% 
compared to TNF-α alone starting from 6 hours. After 16 hour of incubating HLMVEC with 
both TNF-α and GlyH-101, there was a significant increase in IL-8 levels to reach 55154.4 ± 
1412.9 pg/ml. The effect of GlyH-101 with TNF-α on IL-8 level was significantly higher 
than TNF alone at 16 hour. At 24 hour the effect of GlyH-101 and TNF-α together 
increased IL-8 significantly to 82847.9 ±16071.6 pg/ml, which was significantly higher that 
TNF-α alone (Figure 5.7).  
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Figure 5.7: IL-8 levels in HLMVECs supernatant after treating the cells with TNF-α (       ) 
and the additive effect of GlyH-101 with TNF- α (          ). 
(**** p value <0.0001) compared to control, († value <0.01, †† value <0.0001) compared 
to TNF-α alone, (n=3). Numbers were expressed in average ± SEM, the samples were 
analysed with two way ANOVA, Tukey’s multiple comparison test, and Sidak’s multiple 
comparison test. 
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5.4.5 The effect of CFTR gene siRNA on IL-8 in HLMVECs supernatant: 
HLMVECs were transfected by electroporation with small interfering RNA targeting CFTR 
mRNA. The cells were then seeded in 6-well plates and left to attach and grow for three 
days. Supernatants were collected after three days to measure IL-8. The results showed a 
significant increase in IL-8 released from transfected endothelial cells compared with cells 
transfected with non-targeting small interfering RNA (Scrambled). The non-targeting cells 
yield 160.01 ± 17.2 pg/ml in HLMVECs supernatant from unstimulated cells, while 
silencing of CFTR (siCFTR) in HLMVECs gave 265.4 ± 36.7 pg/ml IL-8 in the supernatant 
(Figure 5.8) .  
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Figure 5.8: Effect of CFTR gene silencing in HLMVECs 
Changes in IL-8 in HLMVECs supernatant after targeting CFTR mRNA for 72 hour, the 
result were compared with non-targeting gene silencing as negative control. (*p value 
<0.5, n=4) each experiment were done in duplicate. Numbers were analysed by T-Test. 
Numbers were expressed by average ± SEM. 
 
5.4.6 NF-kB immunocytochemistry: 
The additive effects of GlyH-101 and TNF-α on IL-8 synthesis indicates different signaling 
pathways may be involved. To investigate if the effect of CFTR inhibition in HLMVECs in 
increasing IL-8 expression was mediated through the activation of NF-kB, these cells were 
stained with antibody against NF-kB (P65), after the cells were challenged for one hour 
with GlyH-101 ( 20 µM). The effect of GlyH-101 were compared with the effect of TNF-α 
(10 ng/ml). NF-kB normally distributes predominantly in the cytoplasm as shown in Figure 
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5.9 A control. B. Stimulation HLMVECs with TNF-α result intranslocation of NF-kB to the 
nuclei. C. Inhibition of CFTR with GlyH-101 in HLMVECs had no effect on NF-kB,   
A-DMSO(0.1%v/v) 
 
B- TNF-α (10 ng/ml) 
 
C-GlyH-101 (20 µM) 
 
Figure 5.9: HLMVECs stained for NF-kB: 
HLMVECs were stained for NF-kB after one hour treatment with DMSO (0.1% v/v) as CFTR 
inhibitor vehicle control (A), TNF-α (10ng/ml) (B), and GlyH-101 (20µM) (C). Microscope 
magnification 40x, Scale bar 50 µm. n=3. 
 
109 
 
5.4.7 The effect of antioxidants on IL-8 increase in HLMVECs: 
IL-8 release increased in HLMVECs after inhibition of CFTR. This increase was significant 
after 16 and 24 hour. At these two specific time points cells were treated with 
antioxidants, NAC 5 mM and CuT 1 µM for 3 hours before adding the triggers (GlyH-101 
and TNF-α). When the cells were challenged with TNF-α and GlyH-101, antioxidant 
treatments were refreshed, so that antioxidant were incubated with the cells for total of 
19 hour. For NAC (5 mM) IL-8 levels decreased significantly from 55,154.4 ± 1,412.9 pg/ml 
for TNF-α and GlyH-101 to 27,420.7 ± 4,631.7 pg/ml, CuT at 1 µM significantly decreased 
IL-8 to 28,337.2 ± 2,769 pg/ml. The results are shown in figure 5.10. 
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Figure 5.10: Effect of NAC (5mM) and CuT (1 µM) on IL-8 levels in supernatant after 
treating the cells with GlyH-101 and TNF-α for 16 hour: 
Both NAC (5 mM) and CuT (1 µM) decreased IL-8 levels significantly after it was elevated 
due to the additive effect of both TNF-α (10 ng/ml) and GlyH101 (20 µM) for 16 hour. 
Samples were analysed with one way ANOVA and Dunnett’s multiple comparison test. 
(*** p value <0.001, n=4). Numbers were expressed in average ± SEM. 
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5.4.8: The effect of EGFR inhibitor AG-1478 effect on IL-8 levels at 16 hour 
incubation with GlyH-101 with and without TNF-α: 
Normal CFTR inhibits EGFR-dependent chemokine production in human airway epithelial 
cells (Kim et al., 201). Therefore,  to investigate wither GlyH-101 affected alternative 
pathways in addition to oxidative stress, leading to increased IL-8 levels as part of 
inflammatory effect of inhibition of CFTR in HLMVECs, the EGFR inhibitor AG-1478 was 
used with GlyH-101 in the absence (Figure 5.11 A) and presence of TNF-α (Figure 5.11 B).  
GlyH-101 increased IL-8 significantly from 302.7± 22.3 pg/ml in control cells treated with 
DMSO 0.1% v/v to 909.4 ± 72.7 pg/ml. When the cells was treated for 3 hours with AG-
1478 10 µM prior to adding GlyH-101, IL-8 levels were reduced significantly to normal 
levels 355.3 ±50.2 pg/ml. The same effect of AG-1478 were noticed with the presence of 
TNF-α (Figure 5.11 B). TNF-α increased significantly  IL-8 production in HLMVECs from 
447.6 ± 61.8 pg/ml in control cells (FGM) to reach 31,474.7 ± 6,303.2 pg/ml after 16 hour 
of incubation with HLMVECs. This effect was significantly increased when GlyH-101 
(20µM) was added with TNF-α to 55,154.4 ± 1,412.9 pg/ml, EGFR inhibition with 10 µM of 
AG-1478 significantly decreased IL-8 production to 16027.1 ± 1343.2 pg/ml.  
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Figure 5.11: A: The effect of the EGFR inhibitor AG-1478 on GlyH-101 induced IL-8 
synthesis: 
The effect of GlyH-101 on IL-8 levels after 16 hour CFTR inhibition was reduced 
significantly with EGFR inhibitor AG-1478. (*** p value <0.001, n=4). Numbers expressed 
as average ± SEM. Samples were analysed with two way ANOVA and Tukey’s multiple 
comparison test. 
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Figure 5.11 B The effect of the EGFR inhibitor AG-1478 on TNF-α plus GlyH-101 induced 
IL-8 synthesis: 
The effect of TNF-α on IL-8 levels were increased when GlyH-101 were incubated together 
overnight (16 hour) with HLMVECs, this effect were reduced significantly when the cells 
were treated with AG-1478 for 3 hours before adding TNF- α and GlyH-101. (**** p value 
<0.0001, n=4).   
 
5.4.9 Antioxidant effect on IL-8 levels after 24 hour incubation with TNF-α plus 
GlyH-101: 
HLMVECs were treated with antioxidant, NAC 5 mM and CuT 1 µM for three hours before 
triggering HLMVECs with TNF-α 10 ng/ml and GlyH-101 20µM for 24 hour. Antioxidants 
were refreshed when TNF-α and GlyH-101 was added resulting in 27 hour total incubation 
time of antioxidant with the cells.  
 TNF-α plus GlyH-101 had significantly increased IL-8 to 82,847.9 ± 16,071.6 pg/ml 
compare to control. NAC 5 mM significantly decreased IL-8 to 38,704.3 ± 3,514.2 pg/ml. 
Also CuT at 1µM decreased the effect of TNF-α plus GlyH-101 to 54,100.9 ± 8,956.6 pg/ml 
(Figure 5.12). 
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Figure 5.12: Effect of antioxidant treatment on IL-8 levels in supernatants of HLMVECs 
that were incubated for 24 hour with TNF-α plus CFTR inhibitor GlyH-101: 
Both antioxidant decreased IL-8 released form HLMVECs after 24 hour of incubation of 
cells with GlyH-101 plus TNF-α (*p value <0.05, n= 4). Numbers were expressed as mean ± 
SEM. Date were analysed with one way ANOVA test and Dunnett’s multiple comparison. 
 
5.4.10: The effect of EGFR inhibitor AG-1478 effect on IL-8 levels at 24 hour 
incubation with GlyH-101 in the absence and presence of TNF-α: 
The effect of the EGFR inhibitor AG-1478 (10 µM) on IL-8 levels in HLMVECs supernatants 
of cells incubated for 24 hour with 20 µM of CFTR inhibitor GlyH-101 was investigated. 
GlyH-101 significantly increased IL-8 from 369.9 ± 87.9 pg/ml in 0.1% v/v DMSO control 
cells to 1140.5 ± 88.7 pg/ml (Figure 5.13 A), this effect was significantly reversed and IL-8 
was reduced to baseline levels (270.4 ± 78.9 pg/ml) (Figure 5.13 A). HLMVECs were 
treated with AG-1478 10 µM for 3 hours, then triggered with TNF-α alone or TNF-α 10 
ng/ml plus GlyH-101 (20 µM), TNF-α alone significantly increased IL-8 from 413.2 ± 62.5 
pg/ml in control cells supernatants to 23,210.7 ± 2,980.2 pg/ml (Figure 5.13 B). The 
addition of TNF-α plus GlyH-101 significantly increased IL-8 compared to TNF-α alone 
(82,847.9 ± 16,071.6 pg/ml). When HLMVECs were treated with AG-1478  10 µM for three 
hours before treating with TNFα plus GlyH-101, IL-8 levels were significantly reduced by 
84% to 13,167.3 ± 5,333.4 pg/ml, which was not significantly difference to the effect of 
TNF-α alone. Therefore, AG-1478 reversed the additional effect of GlyH-101 on IL-8 levels.  
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Figure 5.13 A: The effect of the EGFR inhibitor AG-1478 on GlyH-101 induced IL-8 
synthesis: 
After the increase in IL-8 levels due to the effect of GlyH-101 on HLMVECs after 24 hour, 
AG-1478 reversed GlyH-101 effect on IL-8. (*** p value <0.001, **** p value <0.0001, 
n=4). Data were analysed with one way ANOVA test and Tukey’s multiple comparison. 
Numbers were expressed as mean ± SEM. 
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Figure 5.13 B: The effect of EGFR inhibitor AG-1478 on TNF-α plus GlyH-101 induced IL-8 
synthesis: 
HLMVECs supernatant IL-8 levels were increased significantly with 24 hour incubation 
with TNF-α and GlyH-101, AG reduced IL-8 levels. (*** p value <0.001, ****pP value 
<0.0001, n=4). Data were analysed with one way ANOVA test and Tukey’s multiple 
comparison. Numbers were expressed as mean ± SEM. 
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5.4.11: Concentration-dependent effect of CuT on IL-8 levels in HLMVECs 
supernatant from cells treated with GlyH-101 for 24 hour:  
The effect of CuT on IL-8 levels was tested over range of concentrations 0.5, 1 and 5 µM. 
HLMVECs were treated with CuT for 3 hours before adding CFTR inhibitor GlyH-101 20µM 
for 24 hour. 
GlyH-101 alone significantly increased IL-8 from 588.6 ± 61.8 pg/ml in control cells treated 
with DMSO (0.1%) to 2208.3 ± 176.5 pg/ml. CuT at 0.5 µM significantly decreased IL-8 to 
1667.5 ± 99.6 pg/ml, 1 µM of CuT significantly reduced IL-8 to 1563.4 ± 50.2 pg/ml, and at 
5 µM concentration of CuT, IL-8 significantly reduced to 1310.2 ± 40.4 pg/ml (Figure 5.14). 
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Figure 5.14: CuT concentration-dependent decrease in IL-8 levels 
Treatment of HLMVECs with CuT with concentration ranged 0.5, 1 and 5 µM, after 
increasing IL-8 by CFTR inhibitor GlyH-101 (20µM) for 24 hour. (** p value <0.01, *** p 
value < 0.001, **** p value < 0.0001, n=5). Concentrations were expressed in average ± 
SEM. And data were analysed with one way ANOVA and Tukey’s multiple comparison 
test. 
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5.4.12: Western blot of phospho-C-Jun: 
Stimulation of IL-8 expression by the CFTR inhibitor GlyH-101 was clearly independent of 
NF-kB activation. Therefore, the activation of AP-1, a transcriptional factor also implicate 
in IL-8 expression was analysed. An increase in phospho-c-jun was indicative of AP-1 
activation. 
HLMVEC were treated with CFTR inhibitor GlyH-101 (20 µM), DMSO (0.1%) as vehicle 
control or TNF-α (10 ng/ml) for 30 minutes. HLMVECs cell lysate were then analysed for p-
c-jun by Western blot. The antibody was predicted to stain p-c-jun with molecular weight 
39 kDa. The results of Western blot (Figure 5.15) show 3 different bands (45, 55 and 80 
kDa)in control cells. C-Jun is constitutively found in nuclei in control cells at low level, and 
it is activated by phosphorylation.  A significant increase in the band at 80 kDa in response 
to Gly and TNF-α was found. Phospho-c-jun had the ability to form different stable 
heterodimers and homodimers. The formation of dimers start after the phosphorylation 
of c-jun. P-c-jun can form heterodimers with c-Fos, ATF family members, CREB DNA 
promoters (Jiang et al., 2008), and they can homodimerize among themselves (Karin et 
al., 1997). Potentially, dimers formed from these monomers form ≈80 kDa complexes 
containing phospho-c-jun (Table 5.2).   
Table 5. 2: The predicted molecular weight of AP-1 subunits and binding partners 
Accession number Name  Theoretical Molecular weight 
(Da)  
PO5412 c-Jun 35675.57 
PO1100 c-Fos 40695.41 
P18848 CREB2  38589.54 
 
The predicted molecular weight was obtained through input of the protein sequence into 
UniPort data base, then loading the entry number into the ExPASY Portal to get the 
theoretical molecular weight 
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Figure 5.15: Analysis of phospho-c-jun by Western blot: 
A representative blot shows the significant increase in the bands (arrow) of phospho-c-jun 
after 30 minutes of treating the cells with GlyH-101 (20µM), and TNF-α (10 ng/ml) 
compared to DMSO (0.1%). Data were analysed with one way ANOVA and Fisher LSD test, 
numbers were expressed in average of 3 bands measurement normalised to β-actin (*p 
value ˂ 0.05, n=3) comparing with control. 
 
5.4.13: Phospho-c-jun immunocytochemistry: 
HLMVECs were stained for phospho-c-jun under four different conditions (Figure 5.16). 
HLMVECs were in(A) full growth medium,(B) TNF-α  (10 ng/ml), (C) DMSO (0.1%),and (D) 
CFTR inhibitor GlyH-101 (20 µM) for 30 minutes. Cells treated with GlyH-101 were 
compared to 0.1% DMSO, and cells treated with TNF-α were compared with cells in full 
growth medium. Phospho-c-jun normally present in nuclei before adding a stimuli (A) at 
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basal level regulates constitutive levels of IL-8 production. Treating HLMVECs with TNF-α 
(B) increased AP-1 intensity in nucleus, and GlyH-101 (D) also appears to increase the 
intensity of nuclear p-c-jun staining. 
  A-Full growth medium  
 
 
 
 
 
   B-TNF-α (10ng/ml)  
 
 
                         C-DMOS (0.1%) 
 
 
C-DMSO (0.1%) 
 
 
                         
 
 
 D-GlyH-101 
 
 
 
 
 
 
Figure 5.16: HLMVECs stained for phospho-c-jun: 
HLMVECs stained for phospho-c-jun with counterstained nucleus (Hoechst blue)(left hand 
side). Increase in p-c-jun nuclear intensity (middle) after 30 minutes treatment with TNF-α 
10 ng/ml (B), and GlyH-101 20 µM (B), n=3 independent experiments. Scale bar 50 µM. 
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5.4.14: Quantification of the intensity of phospho-c-jun: 
In order to quantify the intensity of phospho-c-jun in the nucleus normalised to the 
cytoplasm, z-stack images were taken to confirm that phospho-c-jun is in the nucleus not 
in the surrounding cytoplasm (Figure 5.17. A-D). These images were quantified by dividing 
the integrated density of the nucleus by integrated density of the same area in the 
cytoplasm for the same cell. The images that are shown are representative of three 
independent experiments. For each condition 20 cells were analysed, and the data 
averaged.  
After 30 minutes GlyH-101 20 µM significantly increased the relative nuclear cytoplasmic 
intensity (RNCI) form 4.8 ± 0.6 RNCI in DMSO control cells to 7.4 ± 0.6 RNCI (Figure 5.18). 
TNF-α (10 ng/ml) as a positive control significantly increased RNCI from 5.65 ± 0.4 RNCI in 
full growth medium control cells to 8.42 ± 1 RNCI.  
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A-FGM  
 
B-TNF-α (10 ng/ml)  
 
Figure 5.17 A-B. Z-stack of HLMVECs stained for p-c-jun 
Z-stack of HLMVECs stained for p-c-jun and treated with medium as control (A), and for 
30 minutes TNF-α (10 ng/ml) (B). Scale bar 50 µM. 
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C-DMSO (0.1 % v/v) 
 
D-GlyH-101 (20 µM) 
Z- 
Figure 5.17 C-D  Z-stack of HLMVECs stained for p-c-jun 
Z-stack of HLMVECs stained for p-c-jun treated with DMSO 0.1% as control (C), and with 
CFTR inhibitor GlyH-101 (20 µM) for 30 minutes. Scale bar 50 µM. 
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Figure 5.18: Changes in RNCI after 30 minutes of treating HLMVECs with GlyH-101, TNF-
α. 
Significant elevation of RNCI after 30 minutes treating HLMVECs with both of GlyH-101, 
and TNF-α. (* p value ˂ 0.05) GlyH-101 in comparison to DMSO, (** p value ˂ 0.01) TNF-α 
in comparison to medium. Data were analysed with one way ANOVA test, and Fisher’s 
test. Image J software were used to analyse a total of 60 cell under each condition. 
 
5.4.15: Concentration response curve of neutrophil elastase activity to OPZ: 
Freshly isolated PMN were treated with OPZ in a range of concentrations 0.062, 0.125 
and 0.25 mg/ml. A significant increase in surface NE activity was measured after treating 
PMN with 0.062 mg/ml of OPZ from 0.33 ± 0.04 U/ml to 0.44 ± 0.05 U/ml. This significant 
increase was also seen with 0.125 mg/ml of OPZ to 0.47 ± 0.04 U/ml, and a higher 
concentration of OPZ 0.25 mg/ml and gave 0.46 ± 0.04 U/ml (Figure 5.19). 
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Figure 5.19: NE activity PMN in response to OPZ: 
Changes in NE on PMN surface in control cells, and after treating the cells with OPZ with 
concentration range 0.062, 0.125 and 0.25 mg/ml. (*** p value ˂ 0.001, **** p value ˂ 
0.0001). Data were analysed with repeated measurements one way ANOVA test and 
Dunnett’s multiple comparison test. Numbers expressed as average ± SEM, n=4.   
 
5.4.16: Neutrophil elastase response to OPZ in the presence of the CFTR inhibitor 
GlyH-101: 
Changes in neutrophil elastase activity on the cell surface were measured after 
challenging the cells with range of OPZ concentration 0.062, 0.125, 0.25 mg/ml, in the 
presence and absence of CFTR inhibitor GlyH-101 20 µM. OPZ was used to produce a 
model of bacterial inflammation, and CFTR inhibitor to produce a model of cystic fibrosis. 
In these experiments (Figure 5.20) OPZ alone increased surface NE activity at 0.125 
mg/ml, where NE activity was increased from 0.325 ± 0.04 U/ml to 0.47 ± 0.04 U/ml. 
When neutrophils were treated concomitantly with CFTR inhibitor GlyH-101 (20 µM) NE 
activity significantly increased at 0.125 mg/ml of OPZ to 0.549 ± 0.05 U/ml. A significant 
increase in NE to 0.596 ± 0.07 U/ml was also seen when PMN were treated with both 
GlyH-101 and 0.25 mg/ml of OPZ (Figure 5.20).  
123 
 
P M N +  0 .1 % 
D M S O
+  0 .0 6 2  
O P Z
 +  0 .1 2 5  
O P Z
 +  0 .2 5  
O P Z
0 .0
0 .2
0 .4
0 .6
0 .8
N
e
u
tr
o
p
h
il
 E
la
s
ta
s
e
 (
U
/m
l)
*
* *
P M N  +  G lyH
P M N
 
Figure 5.20: Effect of OPZ and GlyH-101 on neutrophil elastase activity: 
Changes in NE activity after treating neutrophils with concentration range of OPZ 0.062, 
0.125 and 0.25 mg/ml, in the presence and absence of CFTR inhibitor GlyH-101 (20 µM). 
The addition of CFTR inhibitor significantly increase NE release with two concentration of 
OPZ 0.125, 0.25 mg/ml. Date were analysed with two way ANOVA test, and Tukey’s 
multiple comparison (* p value <0.05, ** p value < 0.01, n=4) NE in comparison to PMN 
alone. Numbers were expressed by mean ± SEM. 
 
 
5.4.17: Neutrophil response to fMLP: 
Neutrophils were treated with the bacterial peptide mimetic fMLP 10ˉ⁸, 10 ˉ⁷and 10ˉ⁶ M 
concentration, with and without CFTR inhibitor GlyH-101 (20µM), and surface NE activity 
were measured. Results shows that fMLP did not increase detectable surface NE at all 
three concentrations. Although treating PMN with CFTR inhibitor increased NE activity on 
PMN, the effect was not significant as shown in table 5.3. 
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Table 5. 3: Surface NE activity from PMN after treatment with fMLP in the presence and 
absence of CFTR inhibitor GlyH-101 
 PMN NE with fMLP alone NE fMLP + GlyH-101 20 µM 
Control  0.325 ± 0.04 U/ml 0.383 ± 0.03 U/ml 
DMSO 0.1% 0.392 ± 0.02 U/ml 0.387 ± 0.03 U/ml 
10-8 M fMLP 0.280 ± 0.05 U/ml 0.333 ± 0.03 U/ml 
10-7 M fMLP 0.310 ± 0.05 U/ml 0.345 ± 0.02 U/ml 
10-6 M fMLP 0.357 ± 0.03 U/ml 0.398 ± 0.03 U/ml 
 
 
5.5 Summary of results: 
• Inhibition of CFTR with GlyH-101 increased IL-8 concentration in a dose- and time- 
dependent manner.  
• Silencing of CFTR in HLMVECs increased IL-8 release. 
• Treatment of HLMVECs with antioxidant decreased IL-8 expression. 
• CFTR inhibition did not induce NF-kB activation and nuclear translocation of p65. 
• CFTR inhibition resulted in increased nuclear p-c-jun translocation and 
phosphorylation. 
• Inhibition of EGFR with AG1478 abolished the effect of CFTR inhibition on the 
inflammatory response. 
• Neutrophil elastase activity increased when neutrophils were primed with 
opsonized zymosan A and CFTR inhibition with GlyH-101 increased surface-bound 
NE activity.  
 
5.6 Discussion: 
CFTR inhibition and CFTR gene silencing increased IL-8 expression by HLMVECs. This 
increase was not mediated through the NF-kB pathway, but was through activation 
phosphorylation of c-jun, the AP-1 transcriptional factor. Treating HLMVECs with 
antioxidants (NAC, CuT) significantly reduced IL-8 produced in CFTR inhibited cells, 
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indicating ROS mediated synthesis of IL-8. Treating the cells with the EGFR tyrosine kinase 
inhibitor AG-1478 completely abolished the effect of the CFTR inhibitor on IL-8 levels, 
indicating a role for EGFR in the regulation of IL-8 synthesis by CFTR. 
Another aspect of CF lung inflammation is the response of neutrophils to bacterial 
infection. Neutrophils phagocytose and kill opsonized bacteria and NE is involved in the 
process. Opsonized zymosan significantly increased neutrophil elastase activity at the 
surface, and inhibition of CFTR in neutrophil further increase neutrophil elastase activity.  
The relationship between inflammation and the CFTR defect was previously studied 
extensively. The inhibition of CFTR in CF epithelial cells results in increase in IL-8 
production through either activation of NF-kB (Perez et al., 2007), or through activation of 
EGFR receptors (Kim et al., 2013). In the current study, the CFTR inhibitor GlyH-101 was 
used to inhibit CFTR in human lung microvascular endothelial cells, which resulted in 
increase in the protein level of IL-8 in a concentration and time dependent manner. 
However, in the endothelial cells GlyH-101 had no effect on NF-kB activation and nuclear 
translocation. The IL-8 increase was clearly due to alternative pathways. Inhibition of 
EGFR with tyrosine kinase inhibitor AG-1478 significantly reduced IL-8 production, 
indicating the increase in IL-8 synthesis in microvascular endothelial cells was mediated 
through EGFR activation (Figure 5.21). 
 
Figure 5.21: Inhibition of CFTR: 
Inhibition of CFTR removes the suppressor effect of CFTR on EGFR-mediated IL-8 
synthesis (Kim et al., 2013). 
 
GlyH-101  
ROS  
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CFTR inhibition in microvascular endothelial cells resulted in a rapid increase in the 
intracellular concentration of reactive oxygen species, especially hydrogen peroxide 
(Chapter 4). Pre-treatment with antioxidants, N-acetyl cysteine (NAC), and copper 
tobramycin (CuT) significantly decreased IL-8 levels produced in response to TNF-α plus 
GlyH-101, indicating that oxidative stress in HLMVEC initiated IL-8 synthesis. 
The tyrosine kinase inhibitor AG-1478 completely inhibited the IL-8 response to GlyH-101, 
which indicates that ROS increase due to CFTR inhibition with GlyH-101 was signaling 
through EGFR.  
The effect of ROS, more specifically hydrogen peroxide, on EGFR phosphorylation was 
previously reported in HUVECs (Chen et al., 2001), where researchers had reported that 
EGFR is activated by hydrogen peroxide through Scr-dependent transactivation pathway 
of the receptor, and not through EGFR autophosphorylation, and EGFR activation 
downstream activated JNK which phosphorylated c-jun, and the hydrogen peroxide effect 
on EGFR activation was prevented by AG-1478 (10 µM). 
And in human tracheal epithelia cells, ROS were shown to promote hyperacetylation of 
the IL-8 promoters and increase the transcription of IL-8 (Bartling & Drumm, 2009). 
In epithelial cells, CFTR inhibition increased IL-8 through increase in H₂O₂ (Chen et al., 
2008), which was proposed to activate NF-kB. The majority of studies focused on NF-kB, 
such as Perez et al. (2006) where researchers had demonstrated that inhibition of CFTR in 
human tracheal epithelia cells increase P65 activation, and nuclear translocation, when 
epithelia cells were activated with either IL-1 β ot TNF-α.  
Others found that activator protein-1 (AP-1) transcriptional factor is essential for 
increased expression of IL-8 (Holtmann et al., 1999), and it was important pathway for 
increased IL-8 production in cystic fibrosis cells (Kim et al., 2013).  AP-1 activation in CF 
epithelial cells is mediated through MAPKs inducing JNK (Saadane et al., 2011). In this 
current study, CFTR inhibition in endothelial cells resulted in increase in the intracellular 
ROS, and increase in IL-8 synthesis, without activation of NF-kB, but with evidence of 
stimulated activator protein 1 (AP-1) via phosphorylation of c-jun. JNK mediated 
phosphorylation of c-jun in endothelial cells was previously reported, downstream of 
EGFR phosphorylation, leading to IL-8 synthesis (Katz et al., 2007). 
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The intracellular pathway signal that led to increase in IL-8 production after endothelial 
CFTR inhibition was stopped by tyrosine kinase inhibitor AG-1478, that specifically inhibits 
EGFR receptor activation by receptor autophosphorylation. 
 The molecular weight of p-c-jun in cell lysates was higher than that predicted to be 
detected by the antibody used based on theoretical molecular weight on Western blot. 
However, because p-c-jun forms heterodimers after phosphorylation with either c-Fos or 
with CREB or ATF family members (Smeal et al., 1989, Hai & Curran, 1991, Jiang et al., 
2008), the 80 kDa band indicates homo- and/or heterodimers formation following 
activation by TNF-α and GlyH-101.  
An increase in IL-8 production from endothelial cells independent of NF-kB pathway was 
reported previously in human arterial endothelial cells by Hipp et al. in 2002, where 
researchers used MG132 proteasome inhibitor. Block NF-kB pathway, resulted in increase 
in IL-8 transcription which was dependent totally on AP-1 activation through 
phosphorylation of c-jun (Hipp et al., 2002). 
Furthermore, endothelial cells transfected with small interfering silencing CFTR gene 
significantly increased synthesis of IL-8 in comparison with non-targeting silencing of 
genes.  
These results confirm that a non-functional CFTR in microvascular endothelial cells results 
in increase in the production of IL-8 which with IL-8 produced by CF epithelial cells, result 
in excessive neutrophil inflammatory lesions in CF lung. Antioxidant treatments reduces 
oxidative stress, eventually reduces the inflammatory changes in endothelial cells, and 
reduce production of IL-8.  
In the current study, neutrophils were isolated from healthy donors, and were activated 
with opsonised zymosan a (OPZ) and N-formylmethionyl-leucyl-phenylalanine (fMLP). OPZ 
was the stronger activator of NE surface expression on PMN than fMLP, it was as 
previously reported (Ramasamy et al., 2010). To create a model of CF as well as testing 
the effect of CFTR inhibition on NE activity on PMN, neutrophils were activated using 
opsonized zymosan as well as CFTR inhibitor GlyH-101. CFTR inhibition increased the 
amount of NE activity on the surface, indicating that CFTR protein is expressed in 
neutrophils, and although CFTR expression in neutrophils was previously reported 
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(Painter et al., 2006), the effect of CFTR inhibition on NE activity through direct effect on 
PMN has not been reported. 
Normally NE activity is inhibited by two antiprotease inhibitors α1-antitrypsin (α1AT) and 
secretory leucoprotease inhibitor (SLPI). In cystic fibrosis the balance between the 
produced NE serine protease and the antiprotease are disturbed due to increase in NE 
that overwhelm the antiprotease capacity (Birrer et al., 1994). α1AT is made in the liver 
with main function to protect lung tissue from neutrophil elastase damaging effect. In 
cystic fibrosis α1AT was found with in the normal level (Birrer et al., 1994), but the 
increase in NE due to high numbers of infiltrated neutrophils damaged the protective 
effect of antiprotease.  SLPI is downregulated in cystic fibrosis (Weldon et al., 2009). Two 
factors contributed in the reduction of SLPI, one is that SLPI is cleaved by NE, and NE 
inhibitors prevented SLPI cleavage (Weldon et al., 2009). The other factor is related to the 
regulation of SLPI expression which is controlled by Nrf2 (Meyer et al., 2013), and Nrf2 is 
down regulated in CF epithelial cells (Chen et al., 2008). So medication that increases the 
expression of Nrf2, rather than activity, maybe useful in the treatment of cystic fibrosis, 
as discussed in Chapter 4.  
In addition, cell surface bound NE is catalytically active (Owen et al., 1995), and causes 
damage to lung tissue. Because NE is bound to neutrophil surface, NE cannot be inhibited 
by α1AT and SLPI that inhibits the activity of released NE not surface bound form. Results 
showed a significant increase in surface bound NE activity when neutrophils were 
incubated with opsonized zymosan, and treating neutrophils with CFTR inhibitor GlyH-101 
led to further increase in NE activity. This will potentially have important consequences, 
as uninhibited NE on the cell surface degrades elastin, leading to bronchoctasis, and 
cripple the immune response.  
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Chapter six 
Microvascular endothelial cells and shear stress 
 
6.1 Introduction  
6.1.1: Shear stress and the mechanosensory role of vascular endothelial cells: 
Two types of pressure affect microvascular endothelial cells, transmural pressure which 
arises from the difference in pressure between the two sides of vascular wall, and shear 
stress that results from the movement and friction of blood over the walls of blood 
vessels (Figure 6.1). ECs are a barrier between blood and interstitial tissue.  
 
Figure 6.1: Shear stress and endothelial cells: 
Diagram shows shear stress arises from the parallel linear movement of blood flow on the 
surface of endothelial cells, and the second type of transmural pressure (white arrow) 
which is vertical on the endothelial cells surfaces (Chiu & Chien, 2011). 
 
Endothelial cells respond to the changes in shear stress and transform the movement of 
fluid on the surface to intracellular signals. This mechanosensory biology of ECs involves 
multiple different mechanosensory molecules expressed on the endothelial cell surface: 
(1) occludins; (2) integrins; (3) the mechanosensory complex (including VEGFR2, VE-
cadherin, and platelet-endothelial cell adhesion molecules (PECAM-1)); (4) bradykinin B2 
receptor which belong to the G protein-coupled receptors family, in ligand-independent 
pathway (Chachisvilis et al., 2006); (5) intracellular junction proteins; (6) ion channels 
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such as potassium ion channel which when activated causes hyperpolarization, chloride 
channel which on activation causes membrane depolarization, and Ca+ channels, 
especially P2X4 purinoceptors and transient receptor potential (trp) channels both 
transport extracellular calcium into inside the ECs ; (7) focal adhesion; and (8) endothelial 
glycocalyx (Zhou et al., 2014, Chistiakov et al., 2017) (Figure 6.2). 
Integrins are a family of 20 transmembrane heterodimeric proteins consisting of α and β 
subunits. Activation of integrins results in phosphorylation of focal adhesion kinase (FAK), 
which subsequently leads to activation of mitogen-activated protein kinase (MAPKs) (Shyy 
& Chien, 2002), and downstream signalling events. 
Another important biomolecule that sense the changes in blood flow is occludin, which is 
an integral protein in the tight junctions between endothelial cells. Occludin is responsible 
for transmitting extracellular mechanical tension to cytoskeleton actin through the C-
terminal tail of occludin which is connected to F-actin (Li et al., 2005). Any disturbance 
such as a decrease in shear stress results in phosphorylation of occludin, a decrease in the 
integrity of tight junctions and subsequently results in an increase in permeability and 
barrier dysfunction. However, stable shear stress elevates the occludin amount due 
decrease occludin phosphorylation in tight junctions (Colgan et al., 2007). In addition, 
stable shear stress stimulates Rho GTPase-dependent F-actin fibre cytoskeleton 
reorganisation in the direction of flow (Tzima, 2006). 
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Figure 6.2: Multiple mechanosensors involved in mediating response of endothelial cells 
to shear stress: 
Mechanosensory pathways include involvement of integrins, ion channels, plasma 
membrane lipids, tyrosine kinase receptors (TKRs), G protein-coupled receptors (GPCRs), 
glycocalyx, caveolae, cell to matrix and cell to cell adhesion complexes such as    PECAM-
1, VE-cadherin that transduce signals intracellularly to multiple signaling molecules such 
as mitogen-activated protein kinases (MAPKs), phosphatidylinositol-3-kinase (PI3K) , AMP 
activated protein kinase (AMPK), which activate downstream transcriptional factors (Nrf2, 
NF-kB, AP-1) and increase e-NOS expression. Ultimately transcriptional factors regulates 
the expression of several functional genes, thereby altering endothelial cells function and 
morphology (Zhou et al., 2014).  
 
The mechanosensory complex (Figure 6.2) which consists of VEGFR2, VE-cadherin, and 
platelet endothelial cell adhesion molecules (PECAM-1) plays an important role as a 
sensor of shear stress force. This complex is located in and near the intracellular junction 
between adjacent endothelial cells. When cells are exposed to shear stress, fyn (src-
family kinase) is phosphorylated which phosphorylates and activates PECAM-1. The 
activation of PECAM-1 stimulates VE-cadherin to recruit VEGFR2 to assemble with the 
complex. After the recruitment of VEGFR2 src kinase phosphorylates it in a ligand-
independent reaction, and subsequently this activates MAP kinase (Conway & Schwartz, 
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2012). Shear stress activates several members of MAPKs family such as p38 MAPK, 
extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), which 
downstream regulate transcriptional factors NE-kB, AP-1 activation depending of shear 
stress type (low or high) (Brayan et al., 2014). 
Src kinase activation of MAPKs required phosphatidylinositol-3-OH kinase (PI(3)K), PI(3)K 
is phosphorylated at p85 subunit to produce phosphatidylinositol-3,4,5-trisphosphate in 
endothelial cells. Phosphorylation of PI(3)K starts after 15 second of applying shear stress 
(Tzima et al., 2005)  
Applied shear stress in experimental settings regulates endothelial cell alignment with the 
direction of flow, and induces morphological changes that imitate the movement of fluid 
on the surface of endothelial cells lining blood vessels. The effect of shear stress on ECs is 
mediated through increasing the formation of actin stress fibres (Section 6.1.7.1), which is 
mediated through the activation of Rho family GTPases (Tzima, 2006). 
6.1.2 Shear stress effect on morphology on endothelial cells: 
Vascular endothelial cells respond to shear stress by changing their morphology to 
become elongated and aligned with the direction of flow. This change is considered part 
of the adaptation of ECs to fluid movement.  Morphological changes of cultured ECs 
depended upon duration of exposure in addition to velocity of fluid movement. 
Ookawa in 1992 studied and quantified the changes in morphology of cultured porcine 
aortic endothelial cells and found that F-actin is the first responder to fluid movement, 
and that F- actin orientation with the flow preceded the morphological changes 
(elongation) of ECs. The changes in F-actin fibres to well-organised, long central region 
distributed stress fibres requires exposure of ECs (HUVECs) to comparatively high shear 
stress (20 dyne/cm2). In contrast with ECs cultured in stagnant flow area, where the actin 
filament were shorter and distributed randomly (Chiu et al., 1998).  
When endothelial cells are exposed to shear stress F-actin microfilament forms a new 
structure by reorganisation and assembly at the margin of cells to form a finger like 
projections called filopodia, or processes which are foot-like called lamellipodia (Pankov 
et al., 2000). These cell membrane protrusions in addition of redistribution of focal 
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adhesions intracellularly are responsible of changing the morphology of endothelial cells 
to the direction of flow.  
6.1.3 Shear stress effect on junctional proteins and permeability: 
Permeability of endothelial cells is a cardinal feature in inflammatory lung diseases, by 
which ECs controls the movement of fluid and macromolecules (e.g. lipoproteins) 
between blood and underlining interstitum and alveolar spaces. The endothelial 
semipermeable monolayer has two pathways for the movement of fluids and leukocytes. 
The transcellular pathway, in which for example the leukocytes are transported directly 
through endothelial cells body from apical to basolateral membrane, this pathway 
depends on tyrosine kinases, and it is the less common transport pathway.  
The majority of transendothelial transport is through the paracellular pathway. This 
pathway requires formation of gaps between adjacent endothelial cells, which usually 
take place when the balance between the two competing forces of actinomycin 
contractile microfilaments and cell-cell and cell-matrix adhesion forces which control ECs 
shape and permeability is disturbed. These forces work against each other. If the 
actinomycin force is higher cells pull apart (retract), allowing the formation of gaps, while 
if cellular adhesion forces are higher that results in an increase in ECs barrier integrity 
(Figure 6.3) (Dudek & Garcia, 2001). 
ECs barrier function and gap formation that regulate ECs permeability depends upon the 
interaction between endothelial adherens junction components (E-cadherin and p 120-
catenin, β-catenin and α- catenin) and ECs tight junction component (occludin, claudin, 
zonula occludens proteins (ZO) which include: ZO-1, -2, and -3) on one side, with ECs 
cytoskeleton on the other side (Hartsock & Nelson, 2008). ECs cytoskeleton is composed 
from three structural parts. Actin microfilaments, intermediate filaments, and 
microtubules.  
Adherens junctions (AJs) are responsible for initiation of neighbouring ECs contact and 
maintaining this contact. AJs comprises several different proteins, but the main one is 
cadherin. Cadherin from opposite cells binds together to form intercellular contact. In 
addition, cadherin also binds to catenin family (p-120, β, and α catenin), and catenins 
family links cadherin to actin cytoskeleton (Gumbiner, 2005). 
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Tight junctions (TJs) are responsible for regulation of the paracellular transport pathway. 
TJs consist of transmembrane proteins (occludin, claudin and junction adhesion 
molecules) and intracellular proteins (zona occludens (ZO) 1, 2 and 3). ZO-1 links 
transmembrane TJs proteins to actin microfilaments. In addition, ZO-1 functions as a 
scaffold through binding several tight junctional proteins and facilities their interactions, 
for example ZO-1 binds claudin, occludin and junctional adhesion molecules to 
cytoskeleton proteins (cingulin, cortactin and α-catenin) (Dejana, 2004) (Figure 6.3). 
 
Figure 6.3: Endothelial permeability 
A balance between the two contractile forces influence endothelial cells permeability. On 
the left ECs are stimulated with thrombin which increases ECs permeability through 
increasing intracellular Ca+. Ca+ interact with calmodulin and stimulate myosin light chain 
phosphorylation, which increases actinomycin interaction, subsequently this results in ECs 
retraction and increase in gaps between cells. On the right ECs are treated with 
sphingosine-1-phosphate (S1P), which is  lysosphingolipid found in blood (Wilkerson BA & 
Argraves, 2014), and plays an important role in maintaining ECs barrier integrity though 
binding to multiple G protein coupled receptors expressed on ECs (Dudek & Garcia, 2001). 
 
The effect of shear stress on the integrity of tight junctions, and subsequently of ECs 
permeability in vitro depends on the onset, velocity and duration of shear stress. For 
bovine aortic endothelial cells, 5 minutes of exposure to shear stress resulted in increase 
in occludin phosphorylation and decrease in occludin expression in time (1-4 hours) and 
concentration (10-20 dyne/cm 2) dependent manner (DeMaio et al., 2001). While longer 
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duration study (24 hour) on bovine brain microvascular endothelial cells reported an 
increase in occludin mRNA, subsequently increase in occludin expression, in addition 
there was an increase in occludin association with ZO-1 which is important to TJs 
integrity, and localisation of both of occludin and ZO-1 in cell-cell boarder after exposure 
to (10-14 dyne/cm2) shear stress, these changes resulted in decrease in permeability of 
endothelial cells (Colgan et al., 2007). 
6.1.4 Shear stress effect on nitric oxide: 
6.1.4.1 Nitric oxide: 
Nitric oxide (NO•) is a free radical gas with short biological half-life between seconds and 
few minutes (Kelm, 1999) depending on scavenging reaction with haemoglobin, 
myoglobin (Lundberg et al., 2008). Shortly after production NO• react with oxygen to form 
peroxynitrite, which forms dimers (N2O4) (equation 6.1), then N2O4 spontaneously 
dismutase to nitrate (NO3ˉ) and nitrite (NO2ˉ) metabolites (Equation 6.2).  
Equation 6.1: 
NO +O2 ↔ OONO 
OONO +NO ↔ ONOONO → 2NO2 → O2NNO2 (N2O4) 
Equation 6.2: 
N2O4 + H2O → NO2- + NO3- + 2H+ 
Nitric oxide is synthesised by three isoforms of nitric oxide synthase (NOS) enzymes, 
neural NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). Both nNOS and 
eNOS are constitutively expressed by endothelial cells and other cells types like neuronal 
cells (central and peripheral) smooth muscle cells, cardiac and skeletal myocytes, while 
iNOS is expressed and increases in response to infection (LPS), inflammation (Kröncke et 
al., 1998). Both of nNOS and eNOS requires calcium ions to produce NO, but iNOS does 
not require calcium ion for production of NO (Zhao, 2015).  
All NOS isoforms produces NO from substrate L-arginine ,oxygen and NADPH co-
substrates in the presence of multiple co-factors such as flavin adenin nucleotide (FAD), 
136 
 
flavin mononucleotide (FMN) and tetrahydrobiopterin (BH4) (Förstermann & Sessa, 2012) 
Equation 6.3. 
Equation 6.3:                                                                                                                                                                                                                                                               
2 L-arginine + 3 NADPH + 3 H+ + 4 O2                2 citrulline + 2 NO• + 4 H2O + 3 NADP+ 
 
Endothelial cells produces vasodilator active NO as part of their function to modulate the 
vascular tone (Figure 6. 4). Acetylcholine, bradykinin, substance P and adenosine 
stimulate NO production. Defects in the production of nitric oxide has been implicated in 
several diseases, mainly cardiovascular diseases such as atherosclerosis (Naseem KM, 
2005). In addition to the primary function of NO as a vasodilator, that counteracts 
vasoconstrictors such as endothelin-1 normally released from vasculature cells, NO had 
additional effects on repressing platelet aggregation, and inhibits the expression of 
adhesion molecules expressed on the vascular endothelium. As result, NO decreases the 
migration of inflammatory cells (monocytes, and neutrophils). Furthermore, the 
formation of nitric oxide lowers the concentration of superoxide anion by forming 
peroxynitrite (Equation 6.4), thus decreasing oxidative stress (Vallance & Chan, 2001) 
 
Figure 6.4: Endothelial cell-derived nitric oxide effect on vascular smooth muscle tone: 
L-Arg (L-arginine) precursor of nitric oxide, sGS is nitric oxide-sensitive guanylyl-cyclase 
which forms Cyclic guanosine monophosphate (Cyclic GMP) from Guanosine-5'-
triphosphate (GTP) (Aldámiz-Echevarría & Andrade, 2012). 
 
NOS 
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Equation 6.4:           
  O2• + NO• → ONO-2 (peroxynitrite) 
6.1.4.2 Shear stress and nitric oxide release: 
Mechanical activation of ECs by shear stress initiate a complicated series of biological 
reactions. The downstream results of these reactions is activation of eNOS and increase 
production of NO. This activation involves several enzymes and mechanosensory 
molecules, that results in increase in intracellular concentration of Ca+ ions due to 
activation of mechanosensory ion channels (MSICs), and increase in Ca+ influx, in addition 
to release intracellular stored Ca+ due to shear stress force. Increased calcium then forms 
a complex with calmodulin, which activates the recruitment and activation of eNOS 
around this complex, and followed by phosphorylation activation of eNOS by protein 
kinase B (AKT), which is activated by phosphoinoisitol 3 phosphate (PI3K), that is 
upstream activated by mechanosensory integrins and G protein coupled receptors.  
Stress induced activation of eNOS results in rapid (within 1-5 minutes) increase in NO 
production from endothelial cells (Mount et al., 2007). NO production in vitro is higher 
than in static condition, and this is due to the effect of AKT activation. The effect is not 
long-lived, due to decreased PI3K levels, which subsequently decrease AKT activation 
(Sriram et al., 2016) 
6.1.4.3 Nitric oxide release in CF: 
Nitric oxide release in the airways is reduced in CF. The reduction in exhaled nitric oxide 
had multiple factors, such as CF epithelial cells have lower expression of eNOS than 
normal cells, and this decrease preceded inflammation and infection, which may suggest 
that there is genetic regulation of eNOS expression that is correlated to the CFTR defect 
(Elphick et al., 2001). Other researchers had pointed out that inhibition of CFTR in 
epithelial cells results in decrease in the expression of eNOS mRNA, and overexpression of 
CFTR restored eNOS normal expression (Steagall et al., 2000). Another causative agent 
that contributes to the reduction in NO is decrease in L-arginine (the precursor of nitric 
oxide) which is due to an increase in arginase in cystic fibrosis patients blood (Grasemann 
et al., 2006). However, treatment of patients with L-arginine supplementation did not 
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increase NO concentration in CF lung, which may be due to the multiple factors related to 
decreased NO in CF lung (Grasemann et al., 2005). 
6.1.5 Shear stress effect on endothelin: 
6.1.5.1 Endothelin-1: 
Endothelin-1 is a potent vasoconstrictor peptide consisting of 21 amino acids. Endothelins 
(ET) have three isoforms, ET-1, ET2 and ET3. These isoforms differ in their distribution and 
effect, and ET-1 is the most abundant isoform. 
ET-1 is synthesised in endothelial cells by three main steps. The first step starts by the 
formation of 212 amino acid protein prepro-ET-1 from prepro-ET-1 messenger RNA, the 
second step includes cleavage of this 212 amino acid protein by furin to form 39 amino 
acid ET-1 precursor named bigET-1 (Denault et al., 1995), and the final third step consists 
of the transformation of bigET-1 to ET-1 by the action of a metalloprotease, zinc 
containing, enzyme called endothelin converting enzyme-1 (ECE-1) (Davenport et al., 
2016). 
Endothelins exert their effect through two G protein coupled receptors, endothelin 
receptor A (ETA) and endothelin receptor B (ETB). ET3 had a lower affinity for ETA, but both 
ET1 and ET2 have equal affinity to both receptors. When endothelins bind their receptors 
they stimulate an increase in intracellular calcium ion concentration which results in 
smooth muscle contraction of blood vessels, as well as endothelin helps in fibroblast 
transdifferentiation into myofibroblasts . Endothelins and predominantly endothelin-1 is 
produced mainly by vascular endothelial cells, and although ET-1 is produced by other cell 
types like lung, kidney and colon epithelial cells, as well as macrophages and monocytes, 
the main source is considered the vascular endothelial cells (Davenport et al., 2016). 
Production of ET-1 by endothelial cells is stimulated by many physical and chemical 
stimuli, such as the cytokines TNF-α, IL-1 β and IFN-ƴ, chemokines such as IL-8, MCP-1 
(Molet et al., 2000), and the peptide hormone angiotensin II (Moreau et al., 1997). 
Transcriptional factors that induce production of endothelin include hypoxia inducible 
factor (Kourembanas , 1991), AP-1, smad, GATA-2, and NF-kB (Kowalczyk et al., 2015). On 
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the contrary, there are multiple factors that inhibit endothelin-1 production, such as nitric 
oxide (Ohkita et al., 2002), fluid shear force (Malek et al., 1993), prostacyclin.  
Endothelin is a potent vasoconstrictor that playa an important role in the regulation of 
vascular tone in balance with other vasoactive substances like nitric oxide. In addition to 
the direct effect of ET-1 on vascular wall resistance through contraction of vascular 
smooth muscle, ET-1 had indirect effect on vascular tone mediated through the activation 
of secretion of multiple vasoconstrictor substances, like angiotensin II, norepinephrine, 
and serotonin. Furthermore, ET-1 stimulates vascular smooth muscle cell proliferation 
(Hafizi et al., 1999), and increases platelet and neutrophil adhesion to endothelial cells 
through stimulation of expression of adhesion molecules on endothelial cells (Marasciulo, 
2006). 
ET-1 expresses its effect through the activation of its receptors, ETA and ETB. Vascular 
smooth muscle cells (VSMC) express ETA receptor, through which ET-1 causes contraction 
of these cells. In addition, VSMC express one of ETB subtype (ETB2), which induces 
contraction of VSMC when ET-1 binds to it (Hynynen & Khalil, 2006). The other ETB 
subtype (ETB1) is expressed on endothelial cells, binding of ET-1 to this receptor modulate 
vasodilation through stimulation of production of nitric oxide, prostaglandin (Ohkita , 
2012), in addition ETB1 receptor mediate the clearance of ET-1 (Lüscher & Barton , 2000), 
and therefore limits vasoconstrictor response to ET-1. 
6.1.5.2 Shear stress and endothelin-1 release: 
Shear stress affects ET-1 expression. This effect depends on the force and duration of 
shear stress, both of applying either low shear stress (1.8 dyne/cm2) for long time, or 
short (less than one hour) higher shear stress (10 dyne/cm2) results in increase in ET-1 
release, while exposure to 6-25 dyne/cm2 for more than 6 hours, resulted in decrease in 
ET-1 released from primary HUVECs (Kuchan & Frangos, 1993). In general acute shear 
stress, where endothelial cells are exposed to shear stress after static conditions for only 
a short time (from seconds to few hours) induces increase in expression of ET-1 (Morita et 
al., 1993), while chronic shear stress inhibits the production of ET-1 in a time and 
concentration dependent manner. This inhibition is via downregulation of both ET-1 
precursor protein prepro-ET-1 (ppET-1) and endothelial converting enzyme mRNA. In 
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addition shear stress was found to upregulate ET-1 receptor (ETB1) mRNA, which 
contributes to deceased in ET-1 as it is responsible for ET-1 clearance (Malek et al., 1993, 
Morawietz et al., 2000) 
6.1.5.3 Cystic fibrosis and endothelin-1 release: 
Endothelin-1 was found increased in the sputum and saliva of CF patients (Chalmers et al., 
1999), and in serum of CF patients (Siahanidou et al., 2000), which indicates local 
production by airway epithelial cells, where ET-1 works as paracrine hormone through its 
effect on vascular smooth muscle cells.  
6.1.6 F-actin 
The cytoskeleton structure of ECs consists of three structural units: microtubules, 
intermediate filaments and microfilaments. These three structures intercommunicate to 
give ECs their shape, maintain ECs integrity and as a result affect endothelial permeability. 
Microfilaments are composed of actin, which is an abundant intracellular protein that 
comprises 5 – 10 % of total cell protein. Actin is composed of small globular monomeric 
molecules (G-actin), which polymerise to form filamentous actin (F-actin). This 
transformation is controlled by nucleotide hydrolysis, actin-binding proteins and ions 
(Dominguez &Holmes, 2011). In addition to its structural function, actin plays an 
important role in transforming extracellular signal into intracellular signal. Actin is 
connected to membrane focal adhesion molecules like cadherin, glycocalyx, and occludin. 
This connection translate biophysiological changes (shear stress), and stimuli like TNF-α, 
ROS to intracellular signals and formation of stress fibres (Figure 6.5). Stress fibres are F-
actin filaments cross linked by α-actinin with myosin II network.  
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Figure 6.5: Stress fibres structure 
Stress fibres consist of actin filaments, α-actinin and myosin II which is connected to focal 
adhesion proteins (vinculin, paxillin and talin). (Kaunas & Deguchi, 2011). 
Stress fibres increase in thickness and number in response to shear stress or 
inflammation. Stress fibres are responsible for cell contraction in non-muscle cells. Under 
normal condition, there are balance between actinomycin contractile and cellular 
adhesion force (cell-cell, cell-matrix). But when stress fibre formation increases, cells pull 
apart with the formation of paracellular gaps, and increase in the permeability of 
endothelium (Dudek & Garcia, 2001) (Figure 6.6) 
Figure 6.6: Stress fibre formation in endothelial cells causes an increase in endothelial 
cell permeability: 
Due to gap formation, and results in increase PMN and fluid movement from vessels to lung tissue 
(Dudek & Garcia, 2001). 
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6.1.7 Stress fibres: 
Stress fibres comprised of collected bundles of short F-actin microfilaments (10-30), with 
myosin II (non-muscle myosin II), and α-actinin cross linked in these bundles. The stress 
fibres are usually anchored with focal adhesions either from one side (dorsal stress fibres) 
or from two sides (ventral) or attached to focal adhesion through connecting to another 
type of stress fibres, such as transverse arc which is connected to focal adhesion through 
dorsal stress fibres (Figure 6.7).  
Each of these stress fibres have a different function. Dorsal stress fibres usually increase 
after applying shear stress, and increase the integrity of endothelial cells barrier (Colgan 
et al., 2007), while the ventral are increased in response to inflammatory mediators 
(thrombin) and causes the retraction of ECs and increase gaps and permeability of 
endothelial cells (Vouret-Carviari et al., 1998). 
 
Figure 6.7: Stress fibres 
Dorsal stress fibres, ventral stress fibres, and transverse arches. All three types are 
composed of F-actin microfilaments, myosin II, and cross linked by α-actinin, and either 
attached to focal adhesions like dorsal and ventral stress fibres, or not attached like 
transverse arc (Pellegrin & Mellor, 2007). 
 
6.1.7.1 Shear stress and stress fibres formation: 
Applying fluid shear stress on endothelial cells causes alignment of actin filaments with 
the direction of flow to form stress fibres. This step is required for the morphological 
changes that take place in ECs (elongation and orientation with the direction of flow), and 
are mediated through transformation of extracellular signals into intracellular signals. The 
effect of shear stress on stress fibre formation is mediated through RhoA, which is a 
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member of the small GTPase family (Rho, Rac and cdc 42). RhoA activate rho kinases 
(ROCK1, ROCK2), and these two kinases increase myosin light chain phosphorylation by 
calcium/CaM-dependent MLC kinase, that results in increase formation of actinomycin 
stress fibres (Prasain & Stevens, 2009). When GTPase Rho downstream signal was 
inhibited with P160ROCK in HUVECs after 16 hour of applying shear stress, actin 
orientation with flow direction was inhibited, while inhibition of VEGFR2 receptor 
resulted in weakening the effect of shear stress on actin filaments orientation (van der 
Meer et al., 2010). 
Another pathway for Rho in increasing stress fibres formation is mediated through 
phosphorylation deactivation of cofilin. The deactivated cofilin induces actin 
polymerization, and stress fibre formation (Gorovoy et al., 2005). 
Furthermore, in HUVECs, HMVECs and human aorta endothelial cells (HAEC), Boon et al. 
(2010) showed that shear stress of a value of 19 dyne/cm2 for 96 hour resulted in F actin 
assembly to distinct basolateral stress fibres was mediated through Krϋppel-like factor 2 
(KLF2) transcriptional factor, and it was independent of Rho kinase, and the results were 
confirmed by staining phosphorylated myosin light chain 2 which was co localized with 
actin filaments. 
All of the previously mentioned studies indicate that F-actin assembly and polymerisation 
is influenced by different pathways, and these pathways are sensitive to fluid 
movements. 
6.1.8 Cystic fibrosis and F-actin: 
The cytoskeleton, and particularly F-actin plays a role in endothelial morphology (Shao et 
al., 2014), gap junction formation (Yamada et al. 2005) and CFTR distribution at the 
plasma membrane (Chasan et al., 2002). In endothelial cells reorganisation of F-actin 
filament from its cortical position to stress fibre is part of the endothelial response to 
inflammation that leads to increase permeability of endothelial cells (Shasby et al., 1982). 
The structural connection between CFTR and F actin explains the complicated network 
between these two proteins. 
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The C terminus of  CFTR binds to the PDZ domain of several proteins know as Na+/H+ 
exchanger regulatory factor isoforms 1-4 (NHERF 1-4). Both NHERF1 and 2 have ERM 
protein binding domains for ezrin, radixin and moesin, through which NHERF1 and 2 link 
CFTR to the actin cytoskeleton in epithelial cells Figure 6.8 (Guggino & Stanton, 2006) 
 
Figure 6.8: CFTR connection to F actin cytoskeleton 
The connection between CFTR and F actin is mediated through multiple molecules, most 
importantly are NHERF1 and ERM proteins. These molecules do not just connect CFTR to 
actin, but form dimers of CFTR channels, which are more active that CFTR monomers 
(Guggino & Stanton, 2006). 
 
Studies have focused on the effect of disturbed F-actin on CFTR function. Cantiello (2001) 
discovered that even if CFTR was normally expressed in cells (CFTR-expressing mouse 
mammary adenocarcinoma cells (WT1)), normally organised non-disturbed F-actin is 
required for CFTR to function as a normal Cl- channel and respond to cAMP activation and 
PKA phosphorylation. Any disruption in F actin results in insensitivity of CFTR to cAMP 
activation. 
The effect of CFTR inhibition on endothelial barrier function was previously studied in 
human pulmonary microvascular endothelial cells treated with the CFTR inhibitor CFTRinh 
172 as well as GlyH-101. CFTR inhibition resulted in reduction in barrier function. This 
reduction was mediated through reduced in sphingosine-1 phosphate (S1P) and CFTR is 
transport of S1P (Boujaoude et al., 2001). S1P maintains endothelial cell barrier integrity 
mainly through inducing cortical actin formation (Brown et al., 2014). 
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6.1.9 Shear stress and cystic fibrosis: 
In cystic fibrosis, patients have a limited exercise tolerance, which may be associated with 
both decreased lung function and vascular function. There are few recent studies that 
focused on the beneficial effect of exercise on pulmonary lung function, such as physical 
activity to improve vital lung capacity (Krimler et al., 2013), and another study 
(Schneiderman-Walker et al., 2000), showing that reduction in pulmonary function in 
cystic fibrosis was slower in patients who performed exercises over 3 years.  
No longer studies to show the effect of exercise on life expectation of cystic fibrosis 
patients have been done yet.  
Further, although shear stress was found to decrease endothelin-1 and increase nitric 
oxide and cell permeability of normal endothelial and epithelial cell layers (Chistiakov et 
al., 2017), but there are few studies (Schrage et al., 2005) connecting shear stress to 
cystic fibrosis or CFTR function. 
Therefore the experiments described in this chapter investigate the effect of endothelial 
CFTR inhibition on the synthesis and release of NO and ET-1, the morphological response 
of ECs to shear stress, and the effect of F-actin polymerisation. 
6.2 Aims and objectives: 
The aim of the experiments described in this chapter is to investigate the role of CFTR in 
the response of HLMVECs to shear stress. The objectives were to develop a cell culture 
model of shear stress using an orbital shaker, and to measure HLMVEC nitric oxide and 
endothelin-1 production (by HPLC and ELISA, respectively). A further objective was to 
investigate the effect of CFTR on F-actin polymerisation and abundance using fluorescent 
staining, and to quantify the changes.  
6.3 Materials and methods: 
6.3.1 Shear stress experiments: 
HLMVECs (2.5 X 105 cell/well/ 2ml of FGM) were seeded in 6 well collagen IV coated 
plates (Chapter 2 section 2.2). The plates contained an adhesive silicon disk in the centre 
of each well to prevent the cells from attachment in the centre, because in the centre the 
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flow of medium is disturbed. The cells were left to attach overnight, medium was 
refreshed next day and the silicone disk was removed. Plates were incubated on plate 
shaker with speed of 220 rpm that gave 11.1 dyne/cm2 shear stress (Dardic et al., 2005) at 
370C and 5% CO2, or were incubated without shear stress. The treatments GlyH 20µM, 
TNF-α 10 ng/ml, and 0.1% DMSO were added to all 4 plates. 
Samples from supernatant were collected after 8, 24, and 48 hours of the start of the 
experiment as 1 ml out of each well and replaced with fresh 1 ml of medium that contain 
the same treatment at the same concentration. Collected supernatants were then were 
centrifuged at 1500 xg for 10 minutes at 40C, and stored in -80 0C, and were later analysed 
for endothelin-1 and nitric oxide. 
At the end of experiment, the cells were fixed with 4% paraformaldehyde for 2 minutes 
(2ml/well) and stained with crystal violet at the concentration 0.125% in UHQ water for 
10 minutes (1ml/well). The cells were then washed three times (2ml/well) with PBS 
(without Ca/Mg). The plates were imaged to detect the morphological changes after 
exposure to shear stress. 
6.3.2 Endothelin-1 measurement: 
Changes in endothelin-1 (ET-1) in HLMVECs supernatant were measured by endothelin 
pan specific (DY1160) ELISA kit with ET-1 standards, samples were diluted 1:2 before 
loading to the plates and data was transformed to concentration according to the 
standard ranging from 3.91- 250 pg/ml. ELISA were performed according to 
manufacturer’s instructions provided with the kit. Experiments were carried out in 
duplicate, and the results are from 3 independent experiments. 
6.3.3 Nitric oxide measurement: 
Supernatant from HLMVECs used in shear stress experiments were tested for nitric oxide 
indirectly through testing nitric oxide metabolite nitrite (NO2-) at Loughborough 
University. Samples were analysed using Sievers NOA 280i (Analytix Ltd), which is a 
chemiluminescence based nitric oxide analyser. This process started from reduction of 
nitrite (NO2-) as metabolite of nitric oxide in the samples into nitric oxide because of the 
instability of NO in samples. 4 % (w/v) of glacial acetic acid and sodium iodide solution 
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were used to reduce NO2- to NO. 150 µl of undiluted samples were injected in to the 
analyser were an inert gas (nitrogen) carried the sample through the reduction agent and 
cold trap to remove water and into the reaction cells where NO reacts with ozone (O3) to 
form nitrogen dioxide (NO2*) in the excited state, this electronically excited chemical then 
relax into the ground state and emit a photon that is detected by red-sensitive 
photomultiplier tube (PMT) Figure 6.9:  
 
Figure 6.9 Diagram of nitric oxide analyser and its compartments.  
 (Hetrick & Schoenfisch, 2009). 
 
6.3.4 HLMVECs cell count after shear stress: 
After recording HLMVECs morphological changes after exposure to shear stress for 48 
hours, crystal violet stain was extracted from the cells to estimate number of cells left 
after treatments. 2 ml of ethanol-acetone (80/20 %) was added to each well, and 
incubated for 5 minutes at RT. 200 µl was taken from each well was loaded into 96 well 
plates to measure the absorbance at 550. The experiment was repeated 3 times. 
6.3.5 F-actin staining: 
HLMVECs 2X 104 cell/well in 250 µl FGM were seeded in 8-well chamber coated with 
collagen IV (Chapter 2 section 2.2), the cells were left to attach overnight, and the 
medium was replaced with fresh medium that contained treatments the next day. The 
cells were treated with CFTR inhibitor GlyH-101 at concentrations of 5, 10 and 20 µM for 
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16, 24 and 48 hours, in addition to 0.1% DMSO control. After finishing the treatments, 
cells were washed twice with 250 µl of PBS (without Ca/Mg), then fixed with 250 µl of 
3.7% formaldehyde prepared in PBS (without Ca/Mg) for 10 minutes, followed by washing 
twice with PBS (without Ca/Mg). Then the cells were permeabilized by incubating in 100 
µl of 0.1% Triton X-100 for 3-5 minutes, followed by repeating the washing step. 
Rhodamine Phalloidin (ThermoFisher. R415) stock was prepared by dissolving the vial in 
1.5 ml of methanol to concentration of 200 U/ml (6.6 µM), then stock was diluted 41 fold 
to a final concentration of 4.9 U/ml in 1% of BSA prepared in PBS (without Ca/Mg) to 
reduce nonspecific background, and 200 µl was added to each well and incubated for 20 
minutes at RT, followed by repeating the washing step. Then the slides were co-stained 
with Hoechst 33342 (Molecular Probes: H 1399, Invitrogen Ltd.), prepared in PBS (-
Ca/Mg), diluted 2000 fold to (5µg/ml) final concentration, 250 µl was loaded each well, 
Incubated with the cells for no longer than 10 minutes. Finally the cells were washed with 
500 µl of PBS (-Ca/Mg). The slides were mounted with Fluor Preservative reagent 
(Calbiochem), and covered with a cover slip. The slides were imaged using a Zeiss LSM 
710 confocal microscopy, the excitation was 540nm and emission 565 nm. Experiment 
were carried out in duplicate and the results are from 3 independent experiments. F-actin 
staining was quantified using Image J of captured images. 
6.4 Results:  
6.4.1 The effect of shear stress on endothelin-1 release: 
Changes in endothelin-1 release from HLMVECs after exposure to shear stress were 
measured after 8, 24 and 48 hour of starting shear stress (Figure 6.10 A). Values were 
compared with cells under static condition at the same time points. Under both 
conditions there was a time dependent increase in ET-1 in supernatant. Shear stress 
decreased the level of ET-1 at each time point, but this was only statistically significant at 
24 hours.  
In view of the large standard error on some data points, data at each time point was 
normalised to 100% for control (static condition) as shown in Figure 6.10 B. These results 
show a significant 40.5 ± 5.13 % reduction in ET-1 released 8 hour after starting shear 
stress.  HLMVEC in static condition released 81.3 ± 31.8 pg/ml, whereas after shear stress 
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for 8 hours this value was 49 ± 21.6 pg/ml. At 24 hour of culture a significant 63.5 ± 5.6 % 
reduction in ET-1 was released from HLMVECs under shear stress conditions compared to 
static condition. Under static condition the cells released 305.6 ± 146 pg/ml but only 96 ± 
29.2 pg/ml with shear stress for 24 hour. Finally, after 48 hour of shear stress the 
reduction in ET-1 was 57.9 ± 3.6 %, significantly less than ET-1 produced by HLMVECs in 
static condition. Under static condition 281.62 ± 18 pg/ml ET-1 produced from HLMVECs 
over 48 hour (Figure 6.10.A).  
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Figure 6.10 A: ET-1 released from HLMVECs in response to shear stress.                                                     
Concentration of ET-1 (pg/ml) released from HLMVECs in response to shear stress. Data were 
analysed with two way ANOVA, and Fisher LSD test. *p value ˂ 0.05 for comparing of shear and no 
shear measurement of endothelin-1. At 48 hour the p value for the difference was 0.07. Data 
were expressed as mean of concentration ± SEM, (n=3). 
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Figure 6.10 B ET-1 released from HLMVECs in response to shear stress:                                                     
Percentage of ET-1 released from HLMVECs in response to 11.1 dyne/cm2 shear stress in 
comparison with HLMVECs incubated under static condition (100 %) at each time point. Data 
were expressed as mean of percentages ± SEM. Data were analysed with two way ANOVA and 
Sidak’s multiple comparison test, (* p value ˂ 0.05, ** p value ˂ 0.01 compared to the value of 
static conditions, without shear stress, n=3). 
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6.4.2 The effect of CFTR inhibitor GlyH-101 on endothelin-1 release: 
CFTR inhibition with 20 µM of GlyH-101 did not significantly affect endothelin release into 
the supernatant of HLMVECs, either with or without exposure of the cells to shear stress 
at any time point. Samples were collected 8, 24 and 48 hours after starting the 
treatments with and without exposure to shear stress. Endothelin-1 values for the effect 
of 20 µM of GlyH-101 and the vehicle control (0.1% (v/v) DMSO) are shown in table 6.1. In 
all of the treatments with DMSO and GlyH-101, shear stress reduced endothelin-1 release 
from endothelial cells, and the reduction was significant at 24 hour with both DMSO and 
GlyH-101. 
Table 6. 1: Effect of GlyH-101 20 µM compared to vehicle control (DMSO 0.1%) on 
endothelin-1 release in the supernatant of HLMVECs with and without shear stress 
at 8, 24, and 48 hours. (** p value ˂ 0.01, * p value ˂ 0.05 compared to value for static 
conditions, n=3). 
Time  Treatment  ET-1 with shear stress   ET-1 without shear stress  
8 hours DMSO 0.1% 46.45 ± 26.8   pg/ml 84.15 ± 40.6     pg/ml 
GlyH-101 20 µM 41.09 ± 15.5   pg/ml 60.53 ± 16.7     pg/ml 
24 hour  DMSO 0.1% 90.79 ± 31.9   pg/ml ** 270.71 ± 102.9 pg/ml 
GlyH-101 20 µM 77.13 ± 15.4   pg/ml * 197.99 ± 39.4   pg/ml 
48 hour  DMSO 0.1% 125.40 ± 17.0 pg/ml 201.45 ± 47.2   pg/ml 
GlyH-101 20 µM 96.09 ± 33.1   pg/ml 125.58 ± 20.3   pg/ml 
 
6.4.3 The effect of CFTR gene silencing on endothelin-1: 
After transfecting cells from passage (4-7) by electroporation with silencing gene 
targeting CFTR in HLMVECs for 72 hours (methods information chapter five, Section 
5.2.2), ET-1 was measured in supernatant. The results showed a significant increase in ET-
1 released from endothelial cells compared with cells transfected with non-targeting gene 
silencing (Scrambled). The non-targeting cells yield 115.35 ± 18.7 pg/ml in HLMVECs 
supernatant, while silencing of CFTR (siCFTR) in HLMVECs gave 169.06 ± 15.4 pg/ml ET-1 
in the supernatant (Figure 6.11) .  
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Figure 6. 11: Effect of CFTR gene silencing on ET-1 released form HLMVECS. 
Data expressed as average ± SEM. Samples represent 4 independent experiment, each 
experiment conducted in duplicate. (* p value ˂ 0.05). Data were analysed with paired T 
test. 
 
6.4.4 The effect of shear stress on nitrite: 
HLMVEC supernatants were examined for the nitric oxide metabolite nitrite (NO2-) as an 
indirect method of detecting changes in nitric oxide. Samples for analysis were collected 
after 8, 24 and 48 hour of starting exposure to shear stress.  
Results shows a non-significant decrease in nitrite after 8 hours of exposure to shear 
stress from 100% control (835.3 ± 327.7 nM) to 79.7 ± 12.5 %. After 24 hour of shear 
stress nitrite release increased non-significantly to 115.6 ± 18.3 % compared to control 
cells under static condition (100 % = 586 ± 63.6 nM). The nitrite concentration was 
significantly higher 146.2 ± 2 % after 48 hour of incubating the cells under shear stress 
condition, comparison to cells in static condition (100 % =823.7 ± 113.9 nM). Results in 
Figure 6.12 were expressed as percentage changes with and without shear stress. 
Nitrite concentrations at 8 hours were high at baseline under static condition (835.3 ± 
327.7 nM), and did not change significantly over 48 hour (823.7 ± 113.9 nM). 
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Figure 6.12: Nitrite changes in HLMVECs supernatant in response to shear stress: 
Changes in the percentage of nitrite (NO2-) at each time point after exposing HLMVECs to 
shear stress. The concentrations were compared with HLMVECs incubated under static 
condition (100 %) and converted to percentages. Data were analysed with two way 
ANOVA and Tukey`s multiple comparison test. (* p value ˂ 0.05 for the comparison 
between shear and no shear nitrite levels at 48 hour, † p value ˂ 0.05 for the comparison 
between nitrite levels from shear at 24 and 8 hours, ††† p value ˂ 0.001for the 
comparison 48 hour nitrite concentration to 8 hour nitrite concentration both cells 
exposed to shear stress. n=3 independent experiments). 
6.4.5 Effect of CFTR inhibitor GlyH-101 on nitrite: 
To investigate if CFTR inhibition affects nitric oxide production from endothelial cells 
under static and shear stress conditions, HLMVECs were treated with CFTR inhibitor GlyH-
101 20 µM and DMSO 0.1% (v/v) as vehicle control at 8, 24, and 48 hours (Figure 6.13 A 
and B). The results shows that CFTR inhibition did not interfere with nitrite production at 
any time point, and the increase was significant after 48 hours of starting the experiment 
under both static and shear stress experiments, with both DMSO and GlyH-101.   
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Figure 6.13 A: Nitrite concentration under static conditions 
A significant increase in nitrite concentration in a time-dependent manner was seen after 
treating the cells with CFTR inhibitor GlyH-101 and DMSO. Data expressed as mean ± 
SEM. Data was analysed with two way ANOVA and Sidak multiple comparison test, (* p 
value ˂ 0.05 comparing nitrite at 48 hour with 24 hour of GlyH-101 treatment, ** p value 
˂ 0.01 comparing 48 hours to 8 hours of treating the cells with GlyH-101, † p value ˂ 0.05 
comparing nitrite concentration between cells treated for 8 hours with DMSO and 48 
hours, n=3). 
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Figure 6.13 B Nitrite concentration under shear stress conditions: 
A significant increase in nitrite concentration on time dependent manner after treating 
the cells incubated under shear stress with CFTR inhibitor GlyH-101 and DMSO. Data 
expressed as mean ± SEM. Data analysed with two way ANOVA and Sidak multiple 
comparison test (* p value ˂ 0.05 comparing nitrite at 48 hour with 8 hours of GlyH-101 
treatment,† p value ˂ 0.05 comparing nitrite concentration between cells treated for 48 
hour with DMSO and 8 hours, n=3). 
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6.4.6 Morphological changes of HLMVECs after shear stress: 
Because changes in endothelial-derived nitric oxide and endothelin-1 strongly influence 
blood flow, and shear stress associated with blood flow is known to affect the 
morphology of endothelial cells (Cucina et al., 1995), the effect of shear stress on 
endothelial cells morphology in the absence and presence of the CFTR inhibitor (GlyH-
101) were examined.   
HLMVECs were stained with crystal violet and images were taken after incubating the 
cells on an orbital shaker for 48 hour. HLMVECs were treated with the CFTR inhibitor 
GlyH-101 20 µM and the images were compared to the effect of 0.1% DMSO as vehicle 
control (Figure 6.14 A). The cells were also treated separately with TNF-α (10 ng/ml) and 
the images were compared with cells incubated with full growth medium alone (Figure 
6.14 B). Images obtained showed that HLMVECs aligned after exposure to shear stress for 
48 hour when the cells were in FGM and 0.1 % DMSO. In cell treated with TNF-α, the cells 
appeared more organised in following the flow of the medium (Figure 6.14.B).  
 
Figure 6.14 A: HLMVEC stained with crystal violet: 
The first row represent the cells exposed to shear stress 11.1 dyne/cm2 for 48 hour with 0.1% 
DMSO (A) and 20 µM of GlyH-101 (B), the second row the same treatments under static 
conditions DMSO 0.1% (C) and GlyH-101 (D). Scale Bar 200 µm, magnification X10. The images are 
representative of three independent experiments. 
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Figure 6.14 B: HLMVEC stained with crystal violet: 
The first row represent the cells exposed to shear stress 11.1 dyne/cm2 for 48 hour with full 
growth medium (A) and 10 ng/ml of TNF-α (B), the second row the same treatments growth 
medium (C), TNF-α (D) but the cells were not exposed to shear stress. Scale Bar 200 µm, 
magnification X10. The images are representative of three independent experiments. 
 
However, with CFTR inhibitor GlyH-101 the cells looked less organised than with DMSO, 
FGM and TNF-α. The cells were reduced in number and not aligning with the flow of 
medium (Figure 6.14. A, D) 
6.4.7 HLMVECs cell count using crystal violet extraction:  
In order to investigate the effect of shear stress combined with treatments (TNF-α and 
GlyH-101) and their control on cell number, crystal violet which was used to stain 
HLMVECs for morphological changes was extracted, and the differences in optical density 
(OD) were measured. HLMVECs were seeded in 6 well plates with the exact numbers (2.5 
X105 cell/well) in each well, so the difference in crystal violet concentration after staining 
and extraction reflect that there are changes in cell numbers. Crystal violet OD results are 
in the same range for FGM, TNF, and DMSO, but significantly reduced for GlyH-101. That 
indirectly indicate there are less cells left adhered after treating with GlyH-101. Data are 
from 3 independent experiments (Figure 6.15). 
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Figure 6.15: HLMVECs cell count after 48 hour incubation: 
after treating the cells for 48 hour with and without exposure shear stress, treated with 
TNF-α (10 ng/ml) and GlyH-101 (20 µM) both with their controls. CFTR inhibitor 
significantly decreased cell count in both condition after 48 hour (**** p value ˂ 0.0001 
comparing GlyH-101 with DMSO, †p value ˂ 0.0001 comparing GlyH101 with TNF-α, n=3) 
data expressed as mean ± SEM, data where analysed with two way ANOVA and Tukey’s 
multiple comparison test. 
 
6.4.8 The effect of CFTR inhibition on F-actin in HLMVECs: 
To investigate the effect of GlyH-101 on F-actin content of HLMVECs, HLMVECs were 
treated with 5, 10 and 20 µM of CFTR inhibitor GlyH-101 for 16 (A), 24 (B) and 48 hour (C). 
Images in figure 6.16 shows increase in the red fluorescent dye that represents F-actin 
stress fibre stained with rhodamine phalloidin in a concentration and time-dependent 
response to the CFTR inhibitor. The vehicle control for GlyH-101 was 0.1% DMSO.  
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B: 24 h    
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Figure 6.16: HLMVECs stained for actin stress fibres: 
Cells stained with rhodamine phalloidin show a concentration-dependent increase in the 
intensity of F-actin stress fibre formation with GlyH-101. The incubation time also 
contributed to an increase in the intensity of F actin filaments. 
 
In order to quantify F-actin in response to CFTR inhibition, the effect of 16 hour 
incubation with GlyH-101 (5, 10 and 20 µM) treatment compared with vehicle control 
(DMSO 0.1%) was quantified using Image J software (Figure 6.17). 
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The raw integrated density (RawIntDen) of F-actin staining (Rhodamine Phalloidin) was 
measured, then normalised it to raw integrated density of nuclei (Hoechst stain). 
HLMVECs treated with DMSO 0.1% value RawIntDen F-actin/nuclei was 0.89 ± 0.07. CFTR 
inhibitor GlyH-101 at 5 and 10 µM concentration did not significantly change RawIntDen 
F-actin/nuclei (0.97 ± 0.04 and 1.19 ± 0.14) respectively. However, GlyH-101 at 20 µM 
significantly increase RawIntDen F-actin/nuclei to 1.48 ± 0.29. Data represent 3 
independent experiments.  
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Figure 6.17: F-actin quantification: 
HLMVECS stained for F-actin and Hoechst blue were quantified after 16 hour treatment 
with CFTR inhibitor GlyH-101 (5, 10 and 20 µM), (* p value ˂ 0.05, n=3). Data expressed by 
mean ± SEM. Data were analysed with one way ANOVA and Fisher test. 
 
6.5 Summary of results: 
• Shear stress significantly decreased endothelin release from HLMVECs, and 
increased nitric oxide production. 
• The ET-1 and NO responses to shear stress were independent of CFTR activity. 
• CFTR gene silencing increased ET-1 released from HLMVECs under static 
conditions. 
• CFTR inhibition significantly increased F-actin polymerization, and redistribution of 
F-actin filaments. 
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6.6 Discussion: 
In summary, applying shear stress on HLMVECs induced changes in two important 
vasoactive factors secreted from HLMVECs, namely a decrease in endothelin -1 and an 
increase in nitric oxide (measured indirectly as the NO metabolite nitrite (NO2-)). CFTR 
inhibition did not influence ECs response to shear stress regarding ET-1 or NO secretion. 
However, CFTR gene silencing increased ET-1 synthesis and release. 
Endothelin-1 is a potent vasoconstrictor secreted mainly from endothelial cells to 
constrict vascular smooth muscle cells. Shear stress (11.1 dyne/cm2) significantly reduced 
ET-1 production in comparison to static conditions, which agrees with previous studies of 
the effect of shear stress on endothelin-1 production from endothelial cells, in which low 
shear stress (1.8 dyne/cm2) increased ET-1 release from HUVECs, while higher (6-25 
dyne/cm2) decreased ET-1. The decrease in ET-1 with shear stress was suggested due to 
increase in nitric oxide production or increase in cGMP or both (Kuchan & Frangos, 1993).  
Under static condition, ET-1 release increased from 8 to 24 hour, but between 24 and 48 
hours there was no significant difference between concentrations, indicating regulation 
of endothelin release from endothelial cells, which could be attributed to the expression 
of ETb receptor by endothelial cells (Kelland et al., 2010), which is responsible for the 
clearance of ET-1.  
CFTR channel inhibition with GlyH-101 did not affect release of ET-1, and did not 
influence ECs response to shear stress contrary to expectations, because it was previously 
reported that IL-8 induces ET-1 production in HUVECs (Cheng et al., 2008), and it the 
current study CFTR inhibition significantly increased IL-8 production (Chapter-4), it was 
expected that increased IL-8 from HLMVECs increases ET-1 production.  
CFTR gene silencing significantly increased ET-1 production, indicating that absence of 
CFTR gene affected ET-1 expression. This has not previously been reported. In other 
words, CFTR limits ET-1 normally, and silencing of CFTR results in increase of ET-1. These 
results explain the increase in ET-1 in CF patients, where ET-1 and NF-kB caused end stage 
CF pulmonary vascular dysfunction (Henno P et al., 2009). 
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Under normal conditions, vascular ECs in the lung regulate vascular tone through 
paracrine secretion of ET-1 (vasoconstrictor) and nitric oxide (vasodilator). These two 
vasoactive molecules binds vascular smooth muscles (VSM) specific receptors, and 
constrict (ET-1) or relaxes (NO) VSM. Applying shear stress by orbital shaker mimics the 
normal conditions of fluid movement on endothelial cell surface lining blood vessels. 
Shear stress increased production of nitrite from HLMVECs, confirming results of earlier 
studies (Kolluru et al., 2010, Sriram et al., 2016).  
In airway diseases such as asthma (Alving et al., 1993) and bronchiectasis (Kharitonov et 
al., 1995) nitric oxide is elevated due to the inducing effect of TNF-α and IL-1β which 
increase nitric oxide production in airway epithelial cells (Asano et al., 1994). It could be 
expected that nitric oxide is elevated in cystic fibrosis, but researchers (Elphick et al., 
2000) (Balfour-Lynn et al., 1996) showed that nitric oxide in exhaled breath from cystic 
fibrosis patients was found lower than normal. 
In the current study, CFTR inhibitor GlyH-101 did not interfere with ECs response to shear 
stress regarding NO production, which increased significantly with applying shear stress. 
These findings further support the results of previous studies (Balfour-Lynn et al., 1996) 
(Elphick et al., 2001), that CFTR is not interfering with NO production from EC, and a 
deficit in NO could be due to either accelerated metabolism or decrease production of 
NO. In addition, Morrissey et al. (2002) found that the NO metabolites (NO2−/NO3−) in 
serum of CF patients is higher than normal, indicating that in CF patients reduced exhaled 
NO is not due to reduction in production of NO. 
Shear stress significantly increased nitrite concentration, which may indicate that the 
increase in NO metabolite is due to increase in production, which was reported previously 
by Woodman et al. (1985) that shear stress increases mRNA levels of eNOS.  
Shear stress also induced morphological changes in endothelial cells. The morphological 
changes included alignment of endothelial cells with the direction of flow, in addition to 
elongation of endothelial cells. The mechanism behind these changes, as mentioned in 
the introduction (Section 6.1.2), is due to changes in F-actin assembly and redistribution 
of focal adhesions.  
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Another important finding from the shear stress experiment was that HLMVECs alignment 
with fluid movement was inhibited when the cells were treated with the CFTR inhibitor 
GlyH-101 (Figure 6.14 A) in comparison to vehicle control (DMSO 0.1% v/v). These results 
support previous research by Brown et al. (2014). In which rat lung microvascular 
endothelial cells treated with the CFTR inhibitors, CFTR(inh)-172 and GlyH-101, resulted in 
increase in stress fibres, in addition to redistribution of actin stress fibres from cell 
periphery towards the center of the cells. In this study, treating HLMVECs with GlyH-101 
resulted in redistribution of actin from subcortical into cytoplasmic, in addition, F-actin 
polymerization increased significantly.  
In the current study, treating HLMVECs with CFTR inhibitor, while they were on the orbital 
shaker resulted in decrease in the number of cells. Extraction of crystal violet shows that 
cells numbers significantly decreased when CFTR was inhibited with GlyH-101 at 48 hours. 
These results might indicates that inhibition of CFTR channels on ECs influenced cell-
matrix adhesion either via effects on F-actin or expression of other molecules. 
Furthermore, the reduction of adherent ECs numbers after treating with GlyH-101 at 20 
µM concentrations for 48 hour explains the MTT assay results (Chapter 3 section 3.5.4), 
indicating that these results were due to decease number of cells left adherent in the dish 
at 48 hour. 
The reduced number of adherent HLMVECs incubated on orbital shaker for 48 hours. At 
48 hours there was a further increase in F-actin that in the presence of GlyH-101, resulted 
in detachment of cells both under static and flow conditions. These results led to the 
investigation of the effect of GlyH-101 on stress fibre formation. The significant increase 
in stress fibres formation, and redistribution of actin filaments from periphery to 
perinuclear with GlyH-101 20 µM concentration for 16 hour incubation. These results 
confirm the previous results in shear stress experiment, where ECs alignment with the 
direction of flow was inhibited when the cells were treated with CFTR inhibitor (Figure 
6.14 A), since it was indicated by Borisy & Svitkina (2000) that ECs morphological changes 
requires assembly of F-actin at the periphery of cells to form protrusion to change the 
shape of ECs in respond to shear stress. In this study GlyH-101 induced the assembly of F-
actin filaments perinuclear and in the cytoplasm as shown in images (Figure 6.16), which 
presumably contribute to the non-alignment of cells with the flow. 
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Chapter Seven 
General discussion 
 
Perturbation of endothelial function in patients with cystic fibrosis has previously been 
reported (Romano et al., 2001, Solic et al., 2005, Poore et al., 2013, Rodriguez-Miguelez 
et  al., 2016). In cell culture models using HUVEC, HPAEC (Totani et al. 2017) and HLMVEC 
(Brown et al., 2014) normal CFTR was previously shown to regulate the endothelial 
barrier function and CFTR inhibition increased endothelial permeability.  The data 
reported in this thesis therefore supports the hypothesis that defects in endothelial 
function, beyond the barrier function, are associated with loss of endothelial CFTR 
function.   
Endothelial expression of CFTR has previously been demonstrated in HUVEC (Tousson et 
al., 1998) (Totani et al., 2017), HLMVEC (Tousson et al., 1998) and HPAEC (Plebani et al., 
2017, Totani et al., 2017). Expression of the mature CFTR 180 kDa CFTR band C in PAEC 
was similar to that in human bronchial epithelial cells and more evident than in HUVECs 
(Totani et al., 2017).  In the current study, HLMVECs were found to have low levels of 
mature CFTR protein expressed in all cells.  However, this appeared to be sufficient for 
the normal anti-inflammatory status of the microvascular endothelium. Concentration-
dependent inhibition of CFTR function changed the endothelial cells to a pro-
inflammatory, pro-angiogenic phenotype similar to that seen in CF.   
GlyH101 is a water-soluble glycine hydrazide reported to bind to CFTR externally in the 
channel pore and rapidly inhibit CFTR chloride channel activity by 100% at 10 µM in 
human airway epithelial cells (Muanprasat et al., 2004).  Other reports indicated that 
GlyH-101 at 20 µM completely inhibited cAMP-stimulated CFTR activity in murine cell 
lines, without effect on cell cytotoxicity over 24 hours (Melis et al., 2014), as also 
described in this thesis. Melis et al. (2014) reported that GlyH101 inhibited the other 
chloride ion channels, volume-sensitive outwardly rectifying Cl(-) conductance (VSORC) 
and the calcium dependent Cl(-) conductance (CaCC) which in endothelial cells is 
predominantly TMEM16A. However, TMEM16A is a positive regulator of endothelial ROS 
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(Ma et al., 2017), and its inhibition would lead to decreased ROS in endothelial cells, and 
not the increase reported in the current study, supporting the involvement of CFTR in the 
observed responses to GlyH101.  Totani et al. (2017) demonstrated concentration-
dependent inhibition of CFTR activity in HUVEC and PAEC with the CFTR inhibitor 
CFTRinh172.  However, the concentration-dependent response of CFTR channel activity in 
HLMVECs to GlyH101 is still to be demonstrated. A simple and rapid membrane potential 
assay to monitor CFTR activity and inhibition is proposed (Maitra et al., 2013). 
Inhibition of CFTR activity with the pharmacological tool GlyH101, although potentially a 
model for the CF endothelium in which CFTR is present but inactive (Class III mutation) or 
relatively inactive (Class IV and V mutations), does not recapitulate the scenario whereby 
plasma membrane CFTR is absent (Class I and II mutations) (Griesenbach et al., 2015).  
There is evidence that the responses of cells lacking CFTR are different to those in which 
CFTR is present but inactive (Bodas & Vij, 2010).  Future work therefore includes a study 
of cells isolated from the lung tissue of CF patients lacking CFTR expression, including the 
common DF508 Class II mutation.  
Many of the findings in the current study parallel those previously demonstrated for CFTR 
inhibition in airway epithelial cells, notably the increased release of IL-8 following CFTR 
inhibition (Perez et al., 2007). However, endothelial and epithelial responses also differ in 
a number of ways, including the signalling pathway leading to increased IL-8 expression, 
NF-κB in airway epithelial cells (Perez et al., 2007), but activation of AP-1 signalling with 
increased p-c-jun in HLMVECs.  IL-8 expression in response to TNF-α was increased via the 
NF-κB pathway in both cell types.  Further, the effect of GlyH101 plus TNF-α on the 
endothelium appeared additive, emphasising the important role of the endothelium in 
sustained neutrophil chemoattraction and pulmonary inflammation in CF.   
To date there are limited options for anti-inflammatory therapy for CF (Cantin et al., 
2015).  Inhaled corticosteroids lack efficacy, and the side effects and adverse events, 
including increased risk of pulmonary infection, have limited oral corticosteroid 
prescribing in CF. The lack of efficacy of systemic steroids may relate to the observed 
increase in AP-1 expression and activation, since AP-1 interacts with and prevents the 
glucocorticoid receptor binding to DNA (Adcock et al., 1995). Similarly, despite its efficacy, 
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the known side effects of ibuprofen have limited its use in CF.  Many other approaches 
are under consideration or in clinical trial (Cantin et al., 2015). 
Nrf2 expression is central to limiting oxidative stress and inflammation (Chen et al., 2008). 
The reduced expression of nrf2 in airway epithelium (Chen et al., 2008), and now 
demonstrated in pulmonary endothelial cells, strongly indicate nrf2 may be a target to 
limit airway inflammation, by increasing its expression and activation in CF. Such an 
approach has been demonstrated using the synthetic triterpenoid CDDO (2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oic acid) in airway epithelial cell and animal models of CF 
(Nichols et al., 2009).  The effects of pre-treatment with CDDO include the ability to 
reduce NF-κB activation while increasing the activity of nuclear factor erythroid-related 
factor 2 (nrf2). As these two signalling pathways appear to be pivotal in regulating the net 
inflammatory response in the CF airway, it was suggested that these compounds may 
represent a promising anti-inflammatory therapy for CF lung disease. Other nrf2 
activators include natural products such as curcumin (Balogun et al., 2003) and 
sulforaphane, an isothiocyanate enriched in broccoli sprouts, which has been proposed as 
a dietary supplement to activate nrf2 (reviewed in Galli et al., 2012). However, the results 
of a small clinical trial in CF in which patients consumed 100 g raw broccoli sprouts over 5 
days (https://clinicaltrials.gov/ct2/show/NCT01315665) were not convincing.  Activation 
of nrf2 without an increase in expression is unlikely to be as effective as approaches that 
restore normal expression levels of nrf2 in CF cells, together with its activation.  
Dimethyl fumarate (DMF) is an orally bioavailable methyl ester of fumaric acid with anti-
oxidant and anti-inflammatory functions approved for the treatment of multiple sclerosis 
(Hammer et al., 2018) and for psoriasis (Lee et al., 2017). DMF increases nrf2 expression, 
at the mRNA and protein level, by binding to cysteine residues in Keap-1, releasing nrf2, 
and inducing the nrf2 antioxidant transcriptional machinery. Thus repurposing DMF as an 
approach to increase nrf2 expression in CF is proposed.  Additional anti-inflammatory and 
immune-modulating effects of DMF including decreased IL-17 producing T-cells and 
induction of M2 anti-inflammatory monocytes (Schulze-Topphoff et al., 2016) and 
inflammasome inhibition (Garstkiewicz et al., 2017), independent of induction of nrf2, 
have also been reported.  Future work therefore includes testing the hypothesis that DMF 
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increases the expression and activation of nrf2 in endothelial cells with important anti-
oxidant and anti-inflammatory consequences for treating lung disease in CF. 
Increased VEGF expression and peribronchial angiogenesis is a feature of the CF airway 
(Martin et al., 2013). VEGF promotes angiogenesis and increased vascular permeability, 
enhancing inflammatory cell recruitment and plasma exudation in the airway. Epithelial 
VEGF expression is negatively regulated by CFTR activity. Inhibition of epithelial CFTR 
increased VEGF expression while pre-treatment with the EGFR inhibitor AG-1478 
prevented the increase seen following CFTR inhibition. Thus it was suggested that EGFR 
tyrosine kinase inhibitors, such as AG-1478, might be useful in the treatment of CF. 
However, the findings in the current study clearly indicate that such an approach would 
further enhance VEGF synthesis by airway endothelial cells, and in this respect 
endothelial cells differ from epithelial cells.  Conversely, EGFR inhibition reduced IL-8 
expression in CFTR-inhibited epithelial cells (Kim et al., 2013) and, as demonstrated in the 
current study, in endothelial cells, suggesting that EGFR antagonists might be an effective 
anti-inflammatory approach. However, anti-inflammatory therapies targeting inhibition of 
EGFR are likely to increase VEGF expression in endothelial cells, indicating that other 
approaches such as those that target oxidative stress (Kim et al., 2014) are needed.  
An increase in intracellular oxidative stress in HLMVECs was demonstrated in response to 
CFTR inhibition in the current study. Chen et al. (2008) previously reported an increase in 
intracellular hydrogen peroxide following 72 hours of CFTR inhibition in bronchial 
epithelial cells. The difference lies in the rapid response in endothelial cells, in which 
intracellular ROS were significantly induced, in the form of hydrogen peroxide, over 5 to 
30 minutes following CFTR inhibition.  Since the NOX/Duox inhibitor, 
diphenyleneiodonium (DPI) at 10 µM, failed to inhibit hydrogen peroxide formation, then 
fully coupled mitochondrial activity appears to be the main source of ROS. This is 
supported by the live cell imaging data, with punctate staining for ROS, but would need to 
be confirmed in future work.  
Mitochondrial defects and increased production of ROS, although controversial 
(Schwarzer et al., 2007), are widely reported in lung (Atlante et al., 2016, Valdivieso et al., 
2013) and gut (Kleme et al., 2018) epithelial cells from patients with CF.   In intestinal 
166 
 
epithelial cells the effect of CFTR inhibition was to significantly increase mitochondrial 
levels of hydrogen peroxide and to decrease levels of nrf2 in the mitochondria. Further 
work is needed to demonstrate the subcellular organelle distribution of nrf2 and 
hydrogen peroxide in response to CFTR inhibition in HLMVECs.  
A deficiency in extracellular and intracellular GSH is reported in CF (Galli et al., 2018). In 
the current study, two preliminary experiments showed a highly oxidative environment 
following CFTR inhibition in HLMVECs and a reduced GSH/GSSG ratio after 30 minutes. 
This ratio (40-100 at baseline) was reduced (4-10), with high levels of GSSG following both 
CFTR inhibition and, unexpectedly, further decreased following exposure of the cells to N-
acetyl cysteine (0.4-1.0).   The increase in the amount of GSSG, indicative of oxidative 
stress, might indicate reduced activity of glutathione reductase, a key enzyme in 
determining the rate of hydrogen peroxide removal from endothelial cells and 
regeneration of GSH (Sasaki et al., 1998).  Interestingly, decreased glutathione 
reductase (GR) activity, that was not dependent on a decrease in the level of GR protein 
level, was reported in CF epithelial cells (de Bari et al., 2018).  These authors also showed 
that intracellular GSH was significantly decreased within 10 minutes of CFTR inhibition in 
cells expressing wild-type CFTR.  Others have demonstrated a biphasic effect of NAC in 
endothelial cells (Mukherjee et al., 2007), with pro-oxidant effects at high (30 mM) NAC 
indicating that only low concentrations of NAC are likely to have beneficial effects on the 
endothelium. Alternatively, since DMF induces glutathione recycling by upregulation of 
glutathione reductase in neuronal cells,  (Hoffmann et al., 2017), DMF may have a positive 
effect on oxidative stress in HLMVECs through this GR-dependent mechanism, in addition 
to the positive effects of DMF on nrf2 activity (described above). It remains to be seen if 
DMF induces GR in HLMVECs. 
The rapid induction of ROS might, in part, be due to autocrine effects of VEGF released in 
response to CFTR inhibition, as Nox4-derived H2O2 in part activates Nox2 to increase 
mtROS enhancing VEGFR2 signaling and angiogenesis in ECs (Kim et al., 2017), although 
DPI is expected to inhibit NOX isoenzymes at the concentration tested (Lu et al., 2017). 
Functional CFTR attenuated high glucose-induced endothelial cell oxidative stress and 
inflammation in HUVECs through inactivation of NF-κB and MAPK signalling, indicating 
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that elevation of CFTR expression may be a novel strategy in preventing oxidative stress 
and endothelial dysfunction in diabetes (Fei Y et al., 2018). 
Exocrine pancreatic insufficiency is found in 85–95% of patients with CF, and 30–50% of 
CF patients have endocrine pancreatic insufficiency (Lavelle et al., 2015). This contributes 
to a systemic deficiency in fat-soluble anti-oxidants (vitamin E, carotenoids, coenzyme 
Q10, polyunsaturated fatty acids) and elements such as Se, Cu, Zn required for 
antioxidant enzyme activity, that  lead to sub-optimal anti-oxidant defences (Galli et al., 
2012). Dietary vitamin supplements and inhaled N-acetyl cysteine in the form of 
Mucomyst are commonly used, but not FDA approved.  Therapeutic strategies to limit 
oxidative stress have so far had limited success and further trials of new and improved 
agents, such as those that up-regulate nrf2 expression and activity, are needed (Galli et 
al., 2012). 
Systemic inflammation has been proposed to contribute to increased vessel stiffness and 
haemodynamic alterations in CF, whereas anti-inflammatory therapy favourably 
modulates vascular changes (Giacchi et al., 2015). Thus far, there is limited evidence that 
endothelial CFTR is involved in these changes. 
In endothelial GM7373 cells, polyphenol-induced activation of CFTR induced hydration 
and swelling of the endothelial glycocalyx which masked adhesion molecules, potentially 
limiting inflammation, and was proposed to be associated with depolymerisation of 
cortical F-actin (Peters et al., 2015).  Conversely, inhibition of CFTR with both CFTRinh172 
and GlyH101 was associated with an increase in F-actin polymerisation and the formation 
of stress fibres throughout the cell in rat lung microvascular endothelial cells (Brown et 
al., 2014).  In the current study, inhibition of CFTR activity with GlyH101 was accompanied 
by increased F-actin polymerisation throughout HLMVECs. Such changes may be 
important for the regulation of NO-production, since cortical actin polymerisation limits 
the activity of eNOS, while actin depolymerisation increases G-actin concentration in the 
cell cortex and G-actin binds to eNOS and stimulates its activity (Fels et al., 2012).  The 
effect of shear stress, alone, was to increase NO production and in the presence of 
GlyH101 there was no further increase in nitrite production.  Previous reports indicate 
that shear stress reduces actin polymerisation, allowing alignment with flow (Osborn et 
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al., 2006), indicating such a response could be responsible for the increased NO 
production in response to shear stress reported in this thesis.  However the effect of 
shear stress alone, on F-actin polymerisation was not studied in the experiments 
described in this thesis.   Following CFTR inhibition in HLMVECs, total F-actin increased 
and cortical F-actin appeared to be maintained, potentially limiting eNOS activation and 
NO production. Similarly, others have shown, in HUVEC and HPAEC, that inhibition of 
CFTR suppressed insulin-induced eNOS activity (Totani et al., 2017), contributing to the 
development of insulin resistance in CF-related diabetes.  
In addition to inherited defects in CFTR in patients with CF, cigarette smoke has been 
shown to inhibit bronchial epithelial cell CFTR function (Dransfield et al., 2013) (Sloane et 
al., 2012) (Cantin et al., 2006) (Kreindler et al., 2005) (Savitski et al., 2009) (Shi et al., 
2018), while inhibition of CFTR on endothelial cells increased the loss of barrier function 
induced by exposure of EC to cigarette smoke (Brown et al., 2014).  Raju et al. (2013) 
showed that smoking causes systemic CFTR dysfunction and that acrolein present in 
cigarette smoke mediates CFTR defects in extrapulmonary tissues in smokers.  Endothelial 
dysfunction is associated with loss of lung function, severity of disease and reduced 
exercise capacity in COPD (Green et al., 2017).  Together, these findings further indicate 
that acquired loss of endothelial CFTR function in response to cigarette smoking may be 
relevant to the development of vascular disease and other co-morbidities in COPD. 
Therapeutic strategies to restore endothelial function in CF include correction of CFTR. 
Correction of CFTR expression in the bronchial epithelium by gene transfer in 10 - 25% of 
cells in a population was sufficient to restore normal chloride conductance and epithelial 
function (Johnson et al., 1992) (Zhang et al., 2009).  However, it is currently unclear 
whether low-level expression in many cells (eg 10% of residual CFTR expression) or a low 
number of cells expressing high levels of CFTR are required to restore normal function 
and achieve clinical benefit after gene therapy (Griesenbach et al., 2015). Recent revised 
estimates of the number of endothelial cells in the human body indicate a total of 6X1011 
cells (Sender et al., 2016), and low level of expression of CFTR in all of them may be 
sufficient to maintain normal barrier, anti-inflammatory and anti-oxidant endothelial 
function. 
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Summary 
In summary, the experiments described in this thesis; 
• Demonstrate the low level of expression of stable mature, functional, CFTR in 
human lung microvascular endothelial cells in cell culture. 
• Demonstrate negative regulation of CFTR expression by functional CFTR. 
• Demonstrate the normal anti-inflammatory function of endothelial CFTR including 
suppression of c-jun activation and IL-8 expression.    
• Demonstrate the normal anti-oxidant function of endothelial CFTR, including up-
regulation of nrf-2 and suppression of intracellular ROS. 
• Demonstrate the effect of the anti-oxidant NAC in down-regulating ROS and IL-8 
expression when CFTR function is inhibited. 
• Demonstrate down-regulation of VEGF expression by both normal endothelial 
CFTR and EGFR function. 
• Demonstrate a role for functional endothelial CFTR in limiting F-actin 
polymerisation and shear stress responses. 
• Demonstrate a role for functional neutrophil CFTR in limiting neutrophil elastase 
activation on the cell surface. 
 
Endothelial expression of defective CFTR may explain the derangements in endothelial 
function, systemic inflammation and oxidative stress in CF patients (Reverri, 2014), and 
contribute to the risk of cardiovascular disease in children and adults with CF (Giacci et 
al., 2015).  Targeting endothelial CFTR for correction and/or potentiation would seem to 
be a logical therapeutic approach, as small molecule correctors and potentiators are 
already in development to restore epithelial CFTR function. It was surprising that 6 
months treatment with ivacaftor in CF patients with the G551D mutation improved lung 
function, and reduced sweat chloride, indicating an effect on CFTR function, without an 
effect on pulmonary inflammation (Rowe et al., 2014).  Systemic inflammation was not 
measured in the study, so it is not possible to appreciate the effect of the oral drug, 
ivacaftor, on endothelial function. The combination of lumacaftor with ivacaftor 
(Orkambi) for delF508 patients was approved in 2015, but as yet no studies have reported 
effects on systemic inflammation (Kuk and Taylor-Cousar, 2015). 
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Future Work  
CFTR expression and function has been extensively studied in airway epithelial cells. To 
date, relatively little research has focussed on the role of CFTR in airway endothelial cells, 
yet these cells form the barrier between blood and pulmonary tissue and are the portal 
for the neutrophilic inflammatory response that characterises pulmonary disease in both 
CF and COPD.  
The studies reported in this thesis rely largely on the pharmacological tool GlyH101 to 
inhibit CFTR function with results on IL-8 expression confirmed using the siRNA technique 
for transient gene knockdown.  It had been planned to use an endothelial cell line 
generated by immortalisation of ECs isolated following collagenase digestion of 
pulmonary arteries dissected from CF and non-CF lung tissue (Plebani et al., 2017).  
However, these did not become available during the course of the project, but will form 
the basis of future work.  Since genetic manipulation of cells can alter cell function, 
alternative approaches based on primary pulmonary microvascular cells isolated from 
resected CF lung tissue using magnetic beads (Mackay et al., 2013) would provide further 
useful information. This technique has been used to isolate pulmonary microvascular cells 
from resected lung tissue from patients with COPD and severe emphysema (Mackay et 
al., 2013), providing a source of cells for the comparison of the functional effects of 
inherited and acquired deficiencies in endothelial CFTR in CF and COPD respectively.  
Normal HLMVECs are commercially available and when exposed to cigarette smoke 
extract will provide a model of the effect of smoking in subjects without COPD.  
Pharmacological inhibition of CFTR in normal HLMVECs with GlyH101 will provide a 
control. 
These primary cells and cell lines would be used to investigate the protein networks 
regulating the stability and function of CFTR in normal, CF and COPD endothelial cells.  
Immunoprecipitation of CFTR and examination of binding partners by Western blotting 
would examine the role of NHERF-1 and/or NHERF-2 in plasma membrane localisation of 
CFTR (Farinha et al., 2013). Further since up to 50% of surface CFTR in epithelial cells is 
immobilised tethered to F-actin (Haggie et al., 2006), the association of CFTR with F-actin 
will be investigated, both at baseline and following CFTR inhibition and activation, which 
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are known to affect the polymerisation of actin.  The association of CFTR with potential 
transactivating receptors such as adenosine, histamine and beta2 receptors will be 
examined using assays of CFTR function based on using a voltage sensitive fluorescent 
probe (Plebani et al., 2017), following activation with the receptor agonists adenosine, 
histamine and adrenaline. It has been suggested that the long-acting beta2 agonist 
salmeterol stabilises CFTR in epithelial cell membrane macromolecular complexes with 
the beta2 receptor (Collawn et al., 2009) and it will be of interest to investigate the effect 
of salmeterol on endothelial CFTR stability and function.  
Beyond these molecular interactions, the role of endothelial CFTR in endothelial cell 
physiology would be further investigated.  Since IL-8 and VEGF are increased in the 
circulation in both CF and COPD, the effect of dysfunctional endothelial CFTR on IL-8 and 
VEGF synthesis will be investigated at the protein level by ELISA of endothelial cell culture 
supernatants and mRNA level by RT-PCR.  The adhesion and endothelial transmigration of 
normal neutrophils stained with Cell Tracker Red will determine the effect of endothelial 
CFTR function on pulmonary inflammation in a relevant model. 
Inflammation and oxidative stress are associated with the development of CF-related 
diabetes and type 2 diabetes mellitus (T2DM) in COPD and endothelial dysfunction may 
precede the development of T2DM.  A further hypothesis to be tested is that reduced 
CFTR activity reduces insulin-induced NO generation by EC.  Western blotting would be 
used to examine the expression and activation (phosphorylation) of endothelial nitric 
oxide synthase (eNOS) under basal conditions and following EC activation by insulin. Flow-
mediated dilation of blood vessels is limited in CF and COPD. Therefore, using a model of 
flow-induced shear stress that I have shown to induce NO release, the effect of 
dysfunctional CFTR on NO release and actin stress fibre formation will be investigated in 
parallel.  NO will be measured in cell culture supernatants using sensitive intracellular 
fluorescent indicators, DAN or DAF-2, and actin stress fibres within EC stained with 
phalloidin. 
My PhD data indicates that the mitochondria are a major source of ROS in EC. In 
collaboration with Dorota Dymkowska at the Nencki Institute in Warsaw, Poland, we have 
found CFTR associated with mitochondria in normal epithelial cells. Therefore 
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dysfunctional mitochondrial CFTR may contribute to oxidative stress. The objective will be 
to use Western blotting to examine CFTR expression in mitochondria isolated from 
normal, CF and COPD EC.  The effect of mitochondrial-targeted antioxidants such as 
mitoQ and GSH monoethyl ester on ROS production by EC in the absence and presence of 
the pharmacological CFTR inhibitor GlyH101 will be tested.   
Finally, the models will be used to investigate the effect of DMF and the effect of CFTR 
correctors and potentiators on endothelial function in the absence and presence of active 
plasma membrane CFTR. 
Overall, the data will provide an insight into the possibility of targeting CFTR in the 
endothelium to improve outcomes in patients with CF and COPD. 
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